


30.03.05



INVESTOR IN PEOPLE


The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated 8 February 2005

**PRIORITY
DOCUMENT**


SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Patents Form 1/77

Patents Act 1977
(Rule 16)



08APR04 ES87376-1 001298
P01/7700 0.00-0407946.3 NONE



The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

1. Your reference

PC25571

2. Patent application number

(The Patent Office will fill in this part)

07 APR 2004

0407946.3

3. Full name, address and postcode of the or of each applicant (underline all surnames)

PFIZER LIMITED
Ramsgate Road,
Sandwich,
Kent, CT13 9NJ

06892673001

Patents ADP number (*if you know it*)

United Kingdom

If the applicant is a corporate body, give the country/state of its incorporation

4. Title of the invention

NOVEL PHARMACEUTICALS

5. Name of your agent (*if you have one*)

Dr. D.A. Kendrick

"Address for service" in the United Kingdom to which all correspondence should be sent (*including the postcode*)

European Pharma Patent Department
Pfizer Limited,
Ramsgate Road,
Sandwich, Kent,
CT13 9NJ
United Kingdom

Patents ADP number (*if you know it*)

08835548001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (*if you know it*) the or each application number

Country

Priority application number
(*if you know it*)

Date of filing
(*day / month / year*)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(*day / month / year*)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (*Answer 'Yes' if:*

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 120

Claim(s) 22

Abstract 1

Drawing(s) 0

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination (*Patents Form 10/77*)

Any other documents
(please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature

D.A. Kendrick

Date

7 April 2004

12. Name and daytime telephone number of person to contact in the United Kingdom Dr. D.A. Kendrick 01304.646010

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

Novel Pharmaceuticals

The present invention relates to a series of novel 5,7-diaminopyrazolo[4,3-d]pyrimidines, which are cyclic guanylate monophosphate (cGMP)-specific phosphodiesterase type 5 inhibitors (hereinafter referred to as PDE-5 inhibitors) that are useful in the treatment of hypertension and other disorders, to processes for their preparation, intermediates used in their preparation, to compositions containing them and the uses of said compounds and compositions.

i) Hypertension

Blood pressure (BP) is defined by a number of haemodynamic parameters taken either in isolation or in combination. Systolic blood pressure (SBP) is the peak arterial pressure attained as the heart contracts. Diastolic blood pressure is the minimum arterial pressure attained as the heart relaxes. The difference between the SBP and the DBP is defined as the pulse pressure (PP).

Hypertension, or elevated BP, has been defined as a SBP of at least 140mmHg and/or a DBP of at least 90mmHg. By this definition, the prevalence of hypertension in developed countries is about 20% of the adult population, rising to about 60-70% of those aged 60 or more, although a significant fraction of these hypertensive subjects have normal BP when this is measured in a non-clinical setting. Some 60% of this older hypertensive population have isolated systolic hypertension (ISH), i.e. they have an elevated SBP and a normal DBP. Hypertension is associated with an increased risk of stroke, myocardial infarction, atrial fibrillation, heart failure, peripheral vascular disease and renal impairment (Fagard, RH; Am. J. Geriatric Cardiology 11(1), 23-28, 2002; Brown, MJ and Haycock, S; Drugs 59(Suppl 2), 1-12, 2000).

The pathophysiology of hypertension is the subject of continuing debate. While it is generally agreed that hypertension is the result of an imbalance between cardiac output and peripheral vascular resistance, and that most hypertensive subjects have abnormal cardiac output and increased peripheral resistance

there is uncertainty which parameter changes first (Beevers, G et al.; BMJ 322, 912-916, 2001).

5 Despite the large number of drugs available in various pharmacological categories, including diuretics, alpha-adrenergic antagonists, beta-adrenergic antagonists, calcium channel blockers, angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor antagonists, the need for an effective treatment of hypertension is still not satisfied.

10 ii) PDE5 inhibitors

Vascular endothelial cells secrete nitric oxide (NO). This acts on vascular smooth muscle cells and leads to the activation of guanylate cyclase and the accumulation of cyclic guanosine monophosphate (cGMP). The accumulation of cGMP causes the muscles to relax and the blood vessels to dilate. This
15 dilation reduces vascular resistance and so leads to a reduction in blood pressure.

The cGMP is inactivated by hydrolysis to guanosine 5'-monophosphate (GMP) by a cGMP-specific phosphodiesterase. One important phosphodiesterase has
20 been identified as Phosphodiesterase type 5 (PDE5). Inhibitors of PDE5 decrease the rate of hydrolysis of cGMP and so potentiate the actions of nitric oxide.


Inhibitors of PDE5 have been reported in several chemical classes, including:
25 pyrazolo[4,3-d]pyrimidin-7-ones (e.g. published international patent applications WO 93/06104, WO 98/49166, WO 99/54333, WO 00/24745, WO 01/27112 and WO 01/27113); pyrazolo[3,4-d]pyrimidin-4-ones (e.g. published international patent application WO 93/07149); pyrazolo[4,3-d]pyrimidines (e.g. published international patent application WO 01/18004); quinazolin-4-ones (e.g. published
30 international patent application WO 93/12095); pyrido[3,2-d]pyrimidin-4-ones (e.g. published international patent application WO 94/05661); purin-6-ones (e.g. published international patent application WO 94/00453); hexahydro-pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-diones (e.g. published international

application WO 95/19978) and imidazo[5,1-f][1,2,4]triazin-ones (e.g. published international application WO 99/24433).

Although they have been suggested as agents for the treatment of related conditions such as angina, PDE5 inhibitors have not yet been adopted as agents for the treatment of hypertension. PDE5 inhibitors are known for the treatment of male erectile dysfunction, e.g. sildenafil, tadalafil and vardenafil. There remains a demand for new PDE5 inhibitors, particularly with improved pharmacokinetic and pharmacodynamic properties. The compounds provided herein are potent inhibitors of PDE5 that have improved selectivity *in vitro* and/or an extended half-life *in vivo*.

WO 02/00660 and WO 01/18004 disclose pyrazolo[4,3-d]pyrimidines with a PDE-5 inhibiting effect, which can be used for treating disorders of the cardiovascular system.

According to a first aspect, the present invention provides compounds of formula (I)



wherein

R¹ is a cyclic group selected from R^A, R^B, R^C and R^D, each of which is optionally substituted with one or more R⁷ groups;

R² is hydrogen or C₁-C₂ alkyl;

R³ and R⁴ are each independently C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl or C₃-C₁₀ cycloalkyl, each of which is optionally substituted with one or more R⁸

groups, or R^E , which is optionally substituted with one or more R^9 groups, or hydrogen;

or $-NR^3R^4$ forms R^F , which is optionally substituted with one or more R^{10} groups;

5

R^5 is $-Y-NR^{15}R^{16}$;

R^6 , which may be attached at N^1 or N^2 , is C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl or C_2 - C_6 alkynyl, each of which is optionally substituted by C_1 - C_6 alkoxy, (10) $(C_3$ - C_6 cycloalkyl)methoxy, C_1 - C_6 haloalkoxy or a cyclic group selected from R^J , R^K , R^L and R^M , or R^6 is R^N , C_3 - C_7 cycloalkyl or C_3 - C_7 halocycloalkyl, each of which is optionally substituted by C_1 - C_6 alkoxy or C_1 - C_6 haloalkoxy, or R^6 is hydrogen;

15 R^7 is halo, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_3 - C_{10} cycloalkyl, C_3 - C_{10} halocycloalkyl, phenyl, OR^{12} , $OC(O)R^{12}$, NO_2 , $NR^{12}R^{13}$, $NR^{12}C(O)R^{13}$, $NR^{12}CO_2R^{14}$, $C(O)R^{12}$, CO_2R^{12} , $CONR^{12}R^{13}$ or CN ;

R^8 is halo, phenyl, C_1 - C_6 alkoxyphenyl, OR^{12} , $OC(O)R^{12}$, NO_2 , $NR^{12}R^{13}$, 20 $NR^{12}C(O)R^{13}$, $NR^{12}CO_2R^{14}$, $C(O)R^{12}$, CO_2R^{12} , $CONR^{12}R^{13}$, CN , C_3 - C_6 cycloalkyl, R^G or R^H , the last two of which are optionally substituted with one or more R^9 groups;

R^9 is C_1 - C_6 alkyl, C_1 - C_6 haloalkyl or CO_2R^{12} ;

25

R^{10} is halo, C_3 - C_{10} cycloalkyl, C_3 - C_{10} halocycloalkyl, phenyl, OR^{12} , $OC(O)R^{12}$, NO_2 , $NR^{12}R^{13}$, $NR^{12}C(O)R^{13}$, $NR^{12}CO_2R^{14}$, $C(O)R^{12}$, CO_2R^{13} , $CONR^{12}R^{13}$, CN , 30 oxo, C_1 - C_6 alkyl or C_1 - C_6 haloalkyl, the last two of which are optionally substituted by R^{11} ;

30

R^{11} is phenyl, $NR^{12}R^{13}$ or $NR^{12}CO_2R^{14}$;

R^{12} and R^{13} are each independently hydrogen, C_1 - C_6 alkyl or C_1 - C_6 haloalkyl;

R^{14} is C_1 - C_6 alkyl or C_1 - C_6 haloalkyl;

R^{15} is selected from R^{17} , $R^{17}C(O)$ and $R^{18}SO_2$, and

- 5 R^{16} is selected from hydrogen, C_1 - C_6 alkyl optionally substituted with one or more R^{19} groups, C_1 - C_6 haloalkyl and C_3 - C_{10} cycloalkyl optionally substituted with one or more R^{20} groups,

- 10 or $-NR^{15}R^{16}$ constitutes a 3- to 8-membered saturated ring which may optionally include one or more further heteroatoms selected from nitrogen, oxygen and sulphur, and which may optionally be substituted with one or more groups selected from R^{21} , R^{22} and $(C_1$ - C_6 alkoxy) C_1 - C_6 alkyl;

- 15 R^{17} is hydrogen or R^{18} ;

R^{18} is selected from C_1 - C_6 alkyl optionally substituted with one or more R^{19} groups, C_1 - C_6 haloalkyl and C_3 - C_{10} cycloalkyl optionally substituted with one or more R^{20} groups;

- 20 R^{19} is selected from R^{21} , $-NR^{23}R^{24}$, $-CO_2R^{25}$, $-CONR^{26}R^{27}$, R^{28} and phenyl optionally substituted by R^{29} ;

R^{20} is selected from R^{21} , R^{22} and oxo;

- 25 R^{21} is hydroxy, C_1 - C_6 alkoxy, C_1 - C_6 (haloalkyl)oxy or C_3 - C_7 cycloalkyloxy;

R^{22} is C_1 - C_6 alkyl or C_1 - C_6 haloalkyl;

- 30 R^{23} and R^{24} are each independently selected from hydrogen and C_1 - C_6 alkyl;

or $-NR^{23}R^{24}$ constitutes an azetidine, pyrrolidine, piperidine or morpholine ring;

R^{25} is hydrogen or C_1 - C_6 alkyl;

R^{26} and R^{27} are each independently selected from hydrogen and C_1 - C_6 alkyl;

or $-NR^{26}R^{27}$ constitutes an azetidine, pyrrolidine, piperidine or morpholine ring;

- 5 R^{28} is a saturated, unsaturated or aromatic heterocycle with up to 10 ring atoms, at least one of which is selected from nitrogen, oxygen and sulphur;

R^{29} is selected from halo, R^{21} and R^{22} ,

- 10 R^A and R^J are each independently a C_3 - C_{10} cycloalkyl or C_3 - C_{10} cycloalkenyl group, each of which may be either monocyclic or, when there are an appropriate number of ring atoms, polycyclic and which may be fused to either
- (a) a monocyclic-aromatic ring selected from a benzene ring and a 5- or 6-membered heteroaromatic ring containing up to three heteroatoms selected
- 15 from nitrogen, oxygen and sulphur, or
- (b) a 5-, 6- or 7-membered heteroalicyclic ring containing up to three heteroatoms selected from nitrogen, oxygen and sulphur;

- R^B and R^K are each independently a phenyl or naphthyl group, each of which
- 20 may be fused to
- (a) a C_5 - C_7 cycloalkyl or C_5 - C_7 cycloalkenyl ring,
- (b) a 5-, 6- or 7-membered heteroalicyclic ring containing up to three heteroatoms selected from nitrogen, oxygen and sulphur, or
- (c) a 5- or 6-membered heteroaromatic ring containing up to three
- 25 heteroatoms selected from nitrogen, oxygen and sulphur;

- R^C , R^L and R^N are each independently a monocyclic or, when there are an appropriate number of ring atoms, polycyclic saturated or partly unsaturated ring system containing between 3 and 10 ring atoms, of which at least one is a
- 30 heteroatom selected from nitrogen, oxygen and sulphur, which ring may be fused to a C_5 - C_7 cycloalkyl or C_5 - C_7 cycloalkenyl group or a monocyclic aromatic ring selected from a benzene ring and a 5- or 6-membered heteroaromatic ring containing up to three heteroatoms selected from nitrogen, oxygen and sulphur;

R^D and R^M are each independently a 5- or 6-membered heteroaromatic ring containing up to three heteroatoms independently selected from nitrogen, oxygen and sulphur, which ring may further be fused to

- (a) a second 5- or 6-membered heteroaromatic ring containing up to three heteroatoms selected from nitrogen, oxygen and sulphur;
- (b) C_5 - C_7 cycloalkyl or C_5 - C_7 cycloalkenyl ring;
- (c) a 5-, 6- or 7-membered heteroalicyclic ring containing up to three heteroatoms selected from nitrogen, oxygen and sulphur; or
- (d) a benzene ring;

R^E , R^F and R^G are each independently a monocyclic or, when there are an appropriate number of ring atoms, polycyclic saturated ring system containing between 3 and 10 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur;

R^H is a 5- or 6-membered heteroaromatic ring containing up to three heteroatoms independently selected from nitrogen, oxygen and sulphur; and

Y is a covalent bond, C_1 - C_6 alkylenyl or C_3 - C_7 cycloalkylenyl;

a tautomer thereof or a pharmaceutically acceptable salt, solvate or polymorph of said compound or tautomer.

As used herein, alkylenyl indicates an alkyl- m,n -diyl unit where m and n are the same or different, such as methylene ($-\text{CH}_2-$), ethylene ($-\text{CH}_2\text{CH}_2-$) and propane-1,2-diyl ($-\text{CH}(\text{CH}_3)\text{CH}_2-$).

As used herein, cycloalkylenyl indicates a cycloalkyl- m,n -diyl unit where m and n are the same or different, such as cyclopropane-1,1-diyl and cyclohexane-1,4-diyl.

Unless otherwise indicated, an alkyl or alkoxy group may be straight or branched and contain 1 to 8 carbon atoms, preferably 1 to 6 and particularly 1 to 4 carbon atoms. Examples of alkyl include methyl, ethyl, n-propyl, isopropyl, n-butyl,

isobutyl, sec-butyl, pentyl and hexyl. Examples of alkoxy include methoxy, ethoxy, isopropoxy and n-butoxy.

5 Unless otherwise indicated, an alkenyl or alkynyl group may be straight or branched and contain 2 to 8 carbon atoms, preferably 2 to 6 and particularly 2 to 4 carbon atoms and may contain up to 3 double or triple bonds which may be conjugated. Examples of alkenyl and alkynyl include vinyl, allyl, butadienyl and propargyl.

10 Unless otherwise indicated, a cycloalkyl or cycloalkoxy group may contain 3 to 10 ring-atoms, may be either monocyclic or, when there are an appropriate number of ring atoms, polycyclic. Examples of cycloalkyl groups are cyclopropyl, cyclopentyl, cyclohexyl and adamantyl.

15 Unless otherwise indicated, a cycloalkenyl group may contain 3 to 10 ring-atoms, may be either monocyclic or, when there are an appropriate number of ring atoms, polycyclic and may contain up to 3 double bonds. Examples of cycloalkenyl groups are cyclopentenyl and cyclohexenyl.

20 Aryl includes phenyl, naphthyl, anthracenyl and phenanthrenyl.

Unless otherwise indicated, a heteroalicycyl group contains 3 to 10 ring-atoms up to 4 of which may be hetero-atoms such as nitrogen, oxygen and sulfur, and may be saturated or partially unsaturated. Examples of heteroalicycyl groups
25 are oxiranyl, azetidiny, tetrahydrofuranyl, thiolanyl, pyrrolidiny, pyrroliny, imidazolidiny, imidazoliny, sulfolanyl, dioxolanyl, dihydropyranyl, tetrahydropyranyl, piperidiny, pyrazoliny, pyrazolidiny, dioxanyl, morpholiny, dithianyl, thiomorpholiny, piperaziny, azepiny, oxazepiny, thiazepiny, thiazoliny and diazapanyl.

30

Unless otherwise indicated, a heteroaryl group contains 3 to 10 ring-atoms up to 4 of which may be hetero-atoms such as nitrogen, oxygen and sulfur. Examples of heteroaryl groups are furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridyl,

pyrimidinyl, pyrazinyl, pyridazinyl, tetrazolyl, triazinyl. In addition, the term heteroaryl includes fused heteroaryl groups, for example benzimidazolyl, benzoxazolyl, imidazopyridinyl, benzoxazinyl, benzothiazinyl, oxazolopyridinyl, benzofuranyl, quinolinyl, quinazolinyl, quinoxalinyl, benzothiazolyl, phthalimido, 5 benzofuranyl, benzodiazepinyl, indolyl and isoindolyl.

Halo means fluoro, chloro, bromo or iodo.

10 Haloalkyl includes monohaloalkyl, polyhaloalkyl and perhaloalkyl, such as 2-bromoethyl, 2,2,2-trifluoroethyl, chlorodifluoromethyl and trichloromethyl. Haloalkoxy includes monohaloalkoxy, polyhaloalkoxy and perhaloalkoxy, such as 2-bromoethoxy, 2,2,2-trifluoroethoxy, chlorodifluoromethoxy and trichloromethoxy. Halocycloalkyl includes monohalocycloalkyl, polyhalocycloalkyl and perhalocycloalkyl.

15

Unless otherwise indicated, the term substituted means substituted by one or more defined groups. In the case where groups may be selected from a number of alternative groups, the selected groups may be the same or different.

20 In one preferred embodiment, R^1 is R^A , which is optionally substituted with one or more R^7 groups; and

R^A is a C_3 - C_{10} cycloalkyl group, which may be either monocyclic or, when there are an appropriate number of ring atoms, polycyclic, which may be fused to either

25 (a) a monocyclic aromatic ring selected from a benzene ring and a 5- or 6-membered heteroaromatic ring containing up to three heteroatoms selected from nitrogen, oxygen and sulphur, or

(b) a 5-, 6- or 7-membered heteroalicyclic ring containing up to three heteroatoms selected from nitrogen, oxygen and sulphur.

30

Preferably, R^A is a monocyclic C_3 - C_8 cycloalkyl group.

More preferably, R^A is a monocyclic C_5 - C_7 cycloalkyl group.

Most preferably, R^A is cyclopentyl or cyclohexyl.

In another preferred embodiment, R^1 is R^B , which is optionally substituted with one or more R^7 groups.

5

Preferably, R^B is phenyl.

In another preferred embodiment, R^1 is R^C , which is optionally substituted with one or more R^7 groups.

10

Preferably, R^C is a monocyclic saturated or partly unsaturated ring system containing between 3 and 8 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur.

15 More preferably, R^C is a monocyclic saturated or partly unsaturated ring system containing between 5 and 7 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur.

20 Most preferably, R^C is a monocyclic saturated ring system containing between 5 and 7 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur.

In another preferred embodiment, R^1 is R^D , which is optionally substituted with one or more R^7 groups.

25

Preferably, R^D is a 5- or 6-membered heteroaromatic ring containing up to three heteroatoms independently selected from nitrogen, oxygen and sulphur.

30 More preferably, R^D is a 5-membered heteroaromatic ring containing a heteroatom selected from nitrogen, oxygen and sulphur and optionally up to two further nitrogen atoms in the ring, or a 6-membered heteroaromatic ring including 1, 2 or 3 nitrogen atoms.

More preferably R^D is furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isothiazolyl, thiazolyl, oxadiazolyl, pyridyl, pyridazinyl, pyrimidyl or pyrazinyl.

- 5 Most preferably, R^D is pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, oxadiazolyl, pyridyl, pyridazinyl, pyrimidyl or pyrazinyl.

Preferably, R^7 is halo, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, OR^{12} or $CONR^{12}R^{13}$.

- 10 More preferably, R^7 is halo, C_1 - C_3 alkyl, C_1 - C_3 alkoxy, hydroxy or $CONH(C_1$ - C_3 alkyl).

Most preferably, R^7 is fluoro, methyl, ethyl, hydroxy, methoxy, propoxy or $CONHMe$.

15

Preferably, R^2 is hydrogen or methyl.

More preferably, R^2 is hydrogen.

- 20 Preferably, R^3 is hydrogen, C_1 - C_6 alkyl, which is optionally substituted with one or more R^8 groups, or R^E , which is optionally substituted with one or more R^9 groups; and wherein R^E is a monocyclic or, when there are an appropriate number of ring atoms, polycyclic saturated ring system containing between 3 and 7 ring atoms, of which at least one is a heteroatom selected from nitrogen,
25 oxygen and sulphur.

- More preferably, R^3 is hydrogen, C_1 - C_4 alkyl, which is optionally substituted with one or more R^8 groups, or R^E , which is optionally substituted with one or more R^9 groups; and wherein R^E is a monocyclic saturated ring system containing
30 between 3 and 7 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur.

In one preferred embodiment, R^3 is R^E , which is optionally substituted with one or more R^9 groups and wherein R^E is a monocyclic saturated ring system containing between 3 and 7 ring atoms containing one nitrogen atom.

5 More preferably, R^E is azetidiny, pyrrolidinyl or piperidinyl.

In another preferred embodiment, R^3 is C_1 - C_4 alkyl, which is optionally substituted with one or more R^8 groups and wherein R^8 is halo, phenyl, C_1 - C_6 alkoxyphenyl, OR^{12} , $NR^{12}R^{13}$, $NR^{12}CO_2R^{14}$, CO_2R^{12} , $CONR^{12}R^{13}$, R^G or R^H , the
10 last two of which are optionally substituted with one or more R^9 groups.

More preferably, R^8 is hydroxy, methoxy, methoxyphenyl, NH_2 , $NHMe$, NMe_2 , $NHCO_2^tBu$, $NMeCO_2^tBu$, CO_2H , $CONHMe$, R^G or R^H , the last two of which are optionally substituted with one or more R^9 groups.

15

In one preferred embodiment, R^8 is R^G , which is optionally substituted with one or more R^9 groups and wherein R^G is a monocyclic saturated ring system containing between 3 and 7 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur.

20

More preferably, R^G is a monocyclic saturated ring system containing between 3 and 7 ring atoms containing one nitrogen atom and optionally one oxygen atom.

Most preferably, R^G is pyrrolidinyl, piperidinyl or morpholinyl.

25

In another preferred embodiment, R^8 is R^H , which is optionally substituted with one or more R^9 groups and wherein R^H is a 5- or 6-membered heteroaromatic ring containing up to two nitrogen atoms.

30 More preferably, R^H is pyrazolyl.

Preferably, R^9 is methyl or CO_2^tBu .

In another preferred embodiment, R^3 is hydrogen or C_1 - C_4 alkyl, which is optionally substituted with one or more R^8 groups, or R^3 is azetidiny, pyrrolidiny or piperidiny, each of which is optionally substituted with one or more R^9 groups, wherein

- 5 R^8 is hydroxy, methoxy, methoxyphenyl, NH_2 , $NHMe$, NMe_2 , $NHCO_2^tBu$, $NMeCO_2^tBu$, CO_2H , $CONHMe$, pyrrolidiny, piperidiny, morpholiny or pyrazolyl, the last four of which are optionally substituted with one or more R^9 groups and wherein R^9 is methyl or CO_2^tBu .

10

In one preferred embodiment, R^4 is hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl or C_2 - C_6 alkynyl.

More preferably, R^4 is hydrogen, C_1 - C_6 alkyl or C_1 - C_6 haloalkyl.

15

Most preferably, R^4 is hydrogen, methyl or ethyl.

- In another preferred embodiment, $-NR^3R^4$ forms R^F , which is optionally substituted with one or more R^{10} groups and wherein R^F is a monocyclic or, when there are an appropriate number of ring atoms, polycyclic saturated ring system containing between 3 and 10 ring atoms containing at least one nitrogen atom and optionally one other atom selected from oxygen and sulphur.

- 20 More preferably, R^F is a monocyclic or, when there are an appropriate number of ring atoms, polycyclic saturated ring system containing between 3 and 10 ring atoms containing one or two nitrogen atoms and optionally one other atom selected from oxygen and sulphur.

- 30 Most preferably, R^F is selected from azetidiny, pyrrolidiny, piperidiny, piperaziny, morpholiny, 3-azabicyclo[3.1.0]hex-3-yl, homopiperaziny, 2,5-diazabicyclo[4.3.0]non-2-yl, 3,8-diazabicyclo[3.2.1]oct-3-yl, 3,8-diazabicyclo[3.2.1]oct-8-yl, 2,5-diazabicyclo[2.2.1]hept-2-yl, 1,4-diazabicyclo[4.3.0]non-4-yl and 1,4-diazabicyclo[3.2.2]non-4-yl.

Preferably R^{10} is halo, OR^{12} , $NR^{12}R^{13}$, $NR^{12}CO_2R^{14}$, CO_2R^{13} , oxo, C_1 - C_6 alkyl or C_1 - C_6 haloalkyl, the last two of which are optionally substituted by R^{11} .

5 More preferably, R^{10} is halo, methyl, ethyl, isopropyl, hydroxy, methoxy, NH_2 , $NHMe$, NMe_2 , $NHCO_2^tBu$, CO_2H , CO_2^tBu , oxo, benzyl, $-CH_2NH_2$, $-CH_2NHMe$, CH_2NMe_2 or $-CH_2NMeCO_2^tBu$.

10 In one preferred embodiment, R^5 is $-Y-NR^{15}R^{16}$ and Y is C_1 - C_6 alkylene. More preferably, Y is methylene ($-CH_2-$).


In another preferred embodiment, R^5 is $-Y-NR^{15}R^{16}$, R^{15} is $R^{17}C(O)$ or $R^{18}SO_2-$, and R^{16} is hydrogen or C_1 - C_6 alkyl.

15 In another preferred embodiment, R^5 is $-Y-NR^{15}R^{16}$, R^{15} is R^{17} , and R^{16} is hydrogen or C_1 - C_6 alkyl.

In another preferred embodiment, R^{17} is R^{18} and R^{18} is C_1 - C_6 alkyl optionally substituted with one R^{19} group.


20 In another preferred embodiment, R^5 is $-Y-NR^{15}R^{16}$ wherein $-NR^{15}R^{16}$ constitutes a 3- to 8-membered saturated ring which may optionally include one or more further heteroatoms selected from nitrogen, oxygen and sulphur, and which may optionally be substituted with one or more groups selected from R^{21} , R^{22} and $(C_1$ - C_6 alkoxy) C_1 - C_6 alkyl. More preferably, $-NR^{15}R^{16}$ constitutes a 5- or 6-
25 membered saturated ring which may optionally include one further nitrogen atom, and which may optionally be substituted with a group selected from R^{21} , R^{22} and $(C_1$ - C_6 alkoxy) C_1 - C_6 alkyl. Preferably R^{21} is C_1 - C_6 alkoxy and R^{22} is C_1 - C_6 alkyl.

30 Preferably, R^6 is positioned on N^1 to give the compound of formula (I^A):



In an alternative embodiment of the present invention, R^6 may be positioned on N^2 to give the compound of formula (I^B):

5



- Preferably, R^6 is C_1 - C_6 alkyl or C_1 - C_6 haloalkyl, each of which is optionally substituted by C_1 - C_6 alkoxy, C_1 - C_6 haloalkoxy or a cyclic group selected from R^J , R^L and R^M , or R^6 is R^N or hydrogen;
- R^J is a C_3 - C_7 monocyclic cycloalkyl group;
- R^L and R^N are each independently a monocyclic, saturated or partly unsaturated ring system containing between 4 and 7 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur; and
- R^M is a 5- or 6-membered heteroaromatic ring containing up to three heteroatoms independently selected from nitrogen, oxygen and sulphur.

- More preferably, R^6 is C_1 - C_4 alkyl or C_1 - C_4 haloalkyl, each of which is optionally substituted by C_1 - C_4 alkoxy, C_1 - C_4 haloalkoxy or a cyclic group selected from R^J , R^L and R^M , or R^6 is R^N or hydrogen;
- R^J is cyclopropyl or cyclobutyl;
- R^L and R^N are each independently a monocyclic saturated ring system containing either 5 or 6 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur; and

R^M is a 5- or 6-membered heteroaromatic ring containing a heteroatom selected from nitrogen, oxygen and sulphur.

5 More preferably, R^6 is C_1 - C_4 alkyl or C_1 - C_4 haloalkyl, each of which is optionally substituted by C_1 - C_4 alkoxy or a cyclic group selected from R^J , R^L and R^M , or R^6 is R^N or hydrogen;

R^J is cyclopropyl or cyclobutyl;

R^L and R^N are each independently a monocyclic saturated ring system containing either 5 or 6 ring atoms containing one heteroatom selected from
10 nitrogen, oxygen and sulphur; and

R^M is a 5- or 6-membered heteroaromatic ring containing one nitrogen atom.

15 More preferably, R^6 is C_1 - C_4 alkyl or C_1 - C_4 haloalkyl, each of which is optionally substituted by C_1 - C_4 alkoxy, cyclopropyl, cyclobutyl, tetrahydrofuranyl, tetrahydropyranyl or pyridinyl, or R^6 is hydrogen or tetrahydropyranyl.

20 Most preferably, R^6 is hydrogen, methyl, ethyl, isopropyl, isobutyl, methoxyethyl, methoxypropyl, ethoxyethyl, ethoxypropyl, propoxyethyl, 2,2,2-trifluoroethyl, tetrahydrofuranylmethyl, tetrahydropyranylmethyl, tetrahydropyranyl or pyridinylmethyl.

Preferred embodiments of compounds of formula (I) are those that incorporate two or more of the foregoing preferences.

25 Preferably R^1 is a cyclic group selected from R^A , R^B , R^C and R^D , each of which is optionally substituted with one or more R^7 groups;

R^2 is hydrogen or C_1 - C_2 alkyl;

30 R^3 is hydrogen, C_1 - C_4 alkyl, which is optionally substituted with one or more R^8 groups, or R^E , which is optionally substituted with one or more R^9 groups;

R^4 is hydrogen, C_1 - C_6 alkyl or C_1 - C_6 haloalkyl;

or $-NR^3R^4$ forms R^F , which is optionally substituted with one or more R^{10} groups;

R^5 is $-Y-NR^{15}R^{16}$;

- 5 R^6 is C_1 - C_4 alkyl or C_1 - C_4 haloalkyl, each of which is optionally substituted by C_1 - C_4 alkoxy, C_1 - C_4 haloalkoxy or a cyclic group selected from R^J , R^L and R^M , or R^6 is R^N or hydrogen;

- 10 R^7 is halo, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_3 - C_{10} cycloalkyl, C_3 - C_{10} halocycloalkyl, phenyl, OR^{12} , $OC(O)R^{12}$, NO_2 , $NR^{12}R^{13}$, $NR^{12}C(O)R^{13}$, $NR^{12}CO_2R^{14}$, $C(O)R^{12}$, CO_2R^{12} , $CONR^{12}R^{13}$ or CN ;

- 15 R^8 is halo, phenyl, C_1 - C_6 alkoxyphenyl, OR^{12} , $OC(O)R^{12}$, NO_2 , $NR^{12}R^{13}$, $NR^{12}C(O)R^{13}$, $NR^{12}CO_2R^{14}$, $C(O)R^{12}$, CO_2R^{12} , $CONR^{12}R^{13}$, CN , R^G or R^H , the last two of which are optionally substituted with one or more R^9 groups;

R^9 is C_1 - C_6 alkyl, C_1 - C_6 haloalkyl or CO_2R^{12} ;

- 20 R^{10} is halo, C_3 - C_{10} cycloalkyl, C_3 - C_{10} halocycloalkyl, phenyl, OR^{12} , $OC(O)R^{12}$, NO_2 , $NR^{12}R^{13}$, $NR^{12}C(O)R^{13}$, $NR^{12}CO_2R^{14}$, $C(O)R^{12}$, CO_2R^{13} , $CONR^{12}R^{13}$, CN , oxo, C_1 - C_6 alkyl or C_1 - C_6 haloalkyl, the last two of which are optionally substituted by R^{11} ;

- 25 R^{11} is phenyl, $NR^{12}R^{13}$ or $NR^{12}CO_2R^{14}$;

R^{12} and R^{13} are each independently hydrogen, C_1 - C_6 alkyl or C_1 - C_6 haloalkyl;

R^{14} is C_1 - C_6 alkyl or C_1 - C_6 haloalkyl;

- 30 R^{15} is hydrogen or C_1 - C_3 alkyl;

R^{16} is tetrazol-5-yl, 5-trifluoromethyl-1,2,4-triazol-3-yl or 2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl;

R^A is a monocyclic C_3 - C_8 cycloalkyl group;

R^B is phenyl;

5 R^C is a monocyclic saturated or partly unsaturated ring system containing between 3 and 8 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur;

10 R^D is a 5- or 6-membered heteroaromatic ring containing up to three heteroatoms independently selected from nitrogen, oxygen and sulphur;

R^E is a monocyclic saturated ring system containing between 3 and 7 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur;

15 R^F and R^G are each independently a monocyclic or, when there are an appropriate number of ring atoms, polycyclic saturated ring system containing between 3 and 10 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur;

20 R^H is a 5- or 6-membered heteroaromatic ring containing up to three heteroatoms independently selected from nitrogen, oxygen and sulphur;

R^J is cyclopropyl or cyclobutyl;

25 R^L and R^N are each independently a monocyclic saturated ring system containing either 5 or 6 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur;

30 R^M is a 5- or 6-membered heteroaromatic ring containing a heteroatom selected from nitrogen, oxygen and sulphur; and

Y is C_1 - C_6 alkylenyl.

More preferably, R^1 is a cyclic group selected from R^A , R^B , R^C and R^D , each of which is optionally substituted with one or more R^7 groups;

R^2 is hydrogen or C_1 - C_2 alkyl;

5

R^3 is hydrogen, C_1 - C_4 alkyl, which is optionally substituted with one or more R^8 groups, or R^E , which is optionally substituted with one or more R^9 groups;

R^4 is hydrogen, C_1 - C_6 alkyl or C_1 - C_6 haloalkyl;

10

or $-NR^3R^4$ forms R^F , which is optionally substituted with one or more R^{10} groups;

R^5 is $-Y-NR^{15}R^{16}$;

15

R^6 is C_1 - C_4 alkyl or C_1 - C_4 haloalkyl, each of which is optionally substituted by C_1 - C_4 alkoxy, C_1 - C_4 haloalkoxy or a cyclic group selected from R^J , R^L and R^M , or R^6 is R^N or hydrogen;

R^7 is halo, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, OR^{12} or $CONR^{12}R^{13}$;

20

R^8 is halo, phenyl, C_1 - C_6 alkoxyphenyl, OR^{12} , $NR^{12}R^{13}$, $NR^{12}CO_2R^{14}$, CO_2R^{12} , $CONR^{12}R^{13}$, R^G or R^H , the last two of which are optionally substituted with one or more R^9 groups;

25 R^9 is C_1 - C_6 alkyl, C_1 - C_6 haloalkyl or CO_2R^{12} ;

R^{10} is halo, C_3 - C_{10} cycloalkyl, C_3 - C_{10} halocycloalkyl, phenyl, OR^{12} , $OC(O)R^{12}$, NO_2 , $NR^{12}R^{13}$, $NR^{12}C(O)R^{13}$, $NR^{12}CO_2R^{14}$, $C(O)R^{12}$, CO_2R^{13} , $CONR^{12}R^{13}$, CN, oxo, C_1 - C_6 alkyl or C_1 - C_6 haloalkyl, the last two of which are optionally substituted by R^{11} ;

30

R^{11} is phenyl, $NR^{12}R^{13}$ or $NR^{12}CO_2R^{14}$;

R^{12} and R^{13} are each independently hydrogen, C_1 - C_6 alkyl or C_1 - C_6 haloalkyl;

R^{14} is C_1 - C_6 alkyl or C_1 - C_6 haloalkyl;

R^{15} is hydrogen;

5

R^A is a monocyclic C_5 - C_7 cycloalkyl group;

R^B is phenyl;

10 R^C is a monocyclic saturated ring system containing between 5 and 7 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur;

15 R^D is a 5-membered heteroaromatic ring containing a heteroatom selected from nitrogen, oxygen and sulphur and optionally up to two further nitrogen atoms in the ring, or a 6-membered heteroaromatic ring including 1, 2 or 3 nitrogen atoms;

20 R^E is a monocyclic saturated ring system containing between 3 and 7 ring atoms containing one nitrogen atom;

25 R^F is a monocyclic or, when there are an appropriate number of ring atoms, polycyclic saturated ring system containing between 3 and 10 ring atoms containing at least one nitrogen atom and optionally one other atom selected from oxygen and sulphur;

30 R^G is a monocyclic saturated ring system containing between 3 and 7 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur;

R^H is a 5- or 6-membered heteroaromatic ring containing up to two nitrogen atoms;

R^L and R^N are each independently a monocyclic saturated ring system containing either 5 or 6 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur;

- 5 R^M is a 5- or 6-membered heteroaromatic ring containing a heteroatom selected from nitrogen, oxygen and sulphur; and

Y is methylene.

- 10 Most preferred compounds are:

2-dimethylamino-N-[5-dimethylamino-1-(2-ethoxyethyl)-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-3-ylmethyl]acetamide,

- 15 *N-[5-dimethylamino-1-(2-ethoxyethyl)-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-3-ylmethyl]methanesulfonamide,*

N-[5-dimethylamino-1-(2-ethoxyethyl)-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-3-ylmethyl]-2-hydroxyacetamide,

20

N-[5-dimethylamino-1-(2-ethoxyethyl)-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-3-ylmethyl]acetamide,

- 25 *N-[1-(2-ethoxyethyl)-5-ethylamino-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-3-ylmethyl]acetamide,*

N-[5-dimethylamino-1-(2-ethoxyethyl)-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-3-ylmethyl]propionamide,

- 30 *N-[1-(2-ethoxyethyl)-5-ethylamino-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-3-ylmethyl]propionamide,*

N-[1-(2-ethoxyethyl)-5-ethylamino-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-3-ylmethyl]-N-methylacetamide,

1-(2-ethoxyethyl)- N^5, N^5 -dimethyl-3-[(4-methylpiperazin-1-yl)methyl]- N^7 -(4-methylpyridin-2-yl)-1*H*-pyrazolo[4,3-*d*]pyrimidine-5,7-diamine,

- 5 1-(2-ethoxyethyl)- N^5, N^5 -dimethyl-3-[(4-morpholino)methyl]- N^7 -(4-methylpyridin-2-yl)-1*H*-pyrazolo[4,3-*d*]pyrimidine-5,7-diamine, and

1-(2-ethoxyethyl)-3-(ethylaminomethyl)- N^5, N^5 -dimethyl- N^7 -(4-methylpyridin-2-yl)-1*H*-pyrazolo[4,3-*d*]pyrimidine-5,7-diamine

10

and tautomers thereof and pharmaceutically acceptable salts, solvates and polymorphs of said compounds or tautomers.

- 15 Pharmaceutically acceptable salts of the compounds of formula (I) include the acid addition and base salts thereof.

Suitable acid addition salts are formed from acids which form non-toxic salts. Examples include the acetate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate, citrate, edisylate, 20 esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulphate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, 25 saccharate, stearate, succinate, tartrate, tosylate and trifluoroacetate salts.

Suitable base salts are formed from bases which form non-toxic salts. Examples include the aluminium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, 30 tromethamine and zinc salts.

For a review on suitable salts, see "Handbook of Pharmaceutical Salts: Properties, Selection, and Use" by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002).

A pharmaceutically acceptable salt of a compound of formula (I) may be readily prepared by mixing together solutions of the compound of formula (I) and the desired acid or base, as appropriate. The salt may precipitate from solution and
5 be collected by filtration or may be recovered by evaporation of the solvent. The degree of ionisation in the salt may vary from completely ionised to almost non-ionised.

The compounds of the invention may exist in both unsolvated and solvated
10 forms. The term 'solvate' is used herein to describe a molecular complex comprising the compound of the invention and one or more pharmaceutically acceptable solvent molecules, for example, ethanol. The term 'hydrate' is employed when said solvent is water.

15 Included within the scope of the invention are complexes such as clathrates, drug-host inclusion complexes wherein, in contrast to the aforementioned solvates, the drug and host are present in stoichiometric or non-stoichiometric amounts. Also included are complexes of the drug containing two or more organic and/or inorganic components which may be in stoichiometric or non-
20 stoichiometric amounts. The resulting complexes may be ionised, partially ionised, or non-ionised. For a review of such complexes, see J Pharm Sci, 64 (8), 1269-1288 by Haleblian (August 1975).

Hereinafter all references to compounds of formula (I) include references to
25 salts, solvates and complexes thereof and to solvates and complexes of salts thereof.

The compounds of the invention include compounds of formula (I) as hereinbefore defined, polymorphs, prodrugs, and isomers thereof (including
30 optical, geometric and tautomeric isomers) as hereinafter defined and isotopically-labeled compounds of formula (I).

As stated, the invention includes all polymorphs of the compounds of formula (I) as hereinbefore defined.

Also within the scope of the invention are so-called 'prodrugs' of the compounds of formula (I). Thus certain derivatives of compounds of formula (I) which may have little or no pharmacological activity themselves can, when administered into or onto the body, be converted into compounds of formula (I) having the desired activity, for example, by hydrolytic cleavage. Such derivatives are referred to as 'prodrugs'. Further information on the use of prodrugs may be found in 'Prodrugs as Novel Delivery Systems, Vol. 14, ACS Symposium Series (T Higuchi and W Stella) and 'Bioreversible Carriers in Drug Design', Pergamon Press, 1987 (ed. E B Roche, American Pharmaceutical Association).

Prodrugs in accordance with the invention can, for example, be produced by replacing appropriate functionalities present in the compounds of formula (I) with certain moieties known to those skilled in the art as 'pro-moieties' as described, for example, in "Design of Prodrugs" by H Bundgaard (Elsevier, 1985).

Some examples of prodrugs in accordance with the invention include:

(i) where the compound of formula (I) contains a carboxylic acid functionality (-COOH), an ester thereof, for example, replacement of the hydrogen with (C₁-C₈)alkyl;

(ii) where the compound of formula (I) contains an alcohol functionality (-OH), an ether thereof, for example, replacement of the hydrogen with (C₁-C₆)alkanoyloxymethyl; and

(iii) where the compound of formula (I) contains a primary or secondary amino functionality (-NH₂ or -NHR where R ≠ H), an amide thereof, for example, replacement of one or both hydrogens with (C₁-C₁₀)alkanoyl.

Further examples of replacement groups in accordance with the foregoing examples and examples of other prodrug types may be found in the aforementioned references.

Finally, certain compounds of formula (I) may themselves act as prodrugs of other compounds of formula (I).

Compounds of formula (I) containing one or more asymmetric carbon atoms can exist as two or more stereoisomers. Where a compound of formula (I) contains an alkenyl or alkenylene group, geometric *cis/trans* (or *Z/E*) isomers are possible. Where the compound contains, for example, a keto or oxime group or an aromatic moiety, tautomeric isomerism ('tautomerism') can occur. It follows that a single compound may exhibit more than one type of isomerism.

Included within the scope of the present invention are all stereoisomers, geometric isomers and tautomeric forms of the compounds of formula (I), including compounds exhibiting more than one type of isomerism, and mixtures of one or more thereof. Also included are acid addition or base salts wherein the counterion is optically active, for example, D-lactate or L-lysine, or racemic, for example, DL-tartrate or DL-arginine.

Cis/trans isomers may be separated by conventional techniques well known to those skilled in the art, for example, chromatography and fractional crystallisation.

Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC).

Alternatively, the racemate (or a racemic precursor) may be reacted with a suitable optically active compound, for example, an alcohol, or, in the case where the compound of formula (I) contains an acidic or basic moiety, an acid or base such as tartaric acid or 1-phenylethylamine. The resulting diastereomeric mixture may be separated by chromatography and/or fractional crystallization and one or both of the diastereoisomers converted to the corresponding pure enantiomer(s) by means well known to a skilled person.

Chiral compounds of the invention (and chiral precursors thereof) may be obtained in enantiomerically-enriched form using chromatography, typically HPLC, on an asymmetric resin with a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing from 0 to 50% isopropanol, typically from 2 to 20%, and from 0 to 5% of an alkylamine, typically 0.1% diethylamine. Concentration of the eluate affords the enriched mixture.

Stereoisomeric conglomerates may be separated by conventional techniques known to those skilled in the art - see, for example, "Stereochemistry of Organic Compounds" by E L Eliel (Wiley, New York, 1994).

The present invention includes all pharmaceutically acceptable isotopically-labelled compounds of formula (I) wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature.

Examples of isotopes suitable for inclusion in the compounds of the invention include isotopes of hydrogen, such as ^2H and ^3H , carbon, such as ^{11}C , ^{13}C and ^{14}C , chlorine, such as ^{36}Cl , fluorine, such as ^{18}F , iodine, such as ^{123}I and ^{125}I , nitrogen, such as ^{13}N and ^{15}N , oxygen, such as ^{15}O , ^{17}O and ^{18}O , phosphorus, such as ^{32}P , and sulphur, such as ^{35}S .

Certain isotopically-labelled compounds of formula (I), for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies. The radioactive isotopes tritium, *i.e.* ^3H , and carbon-14, *i.e.* ^{14}C , are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.

Substitution with heavier isotopes such as deuterium, *i.e.* ^2H , may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased *in vivo* half-life or reduced dosage requirements, and hence may be preferred in some circumstances.

Substitution with positron emitting isotopes, such as ^{11}C , ^{18}F , ^{15}O and ^{13}N , can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy.

- 5 Isotopically-labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled reagents in place of the non-labeled reagent previously employed.

10

Pharmaceutically acceptable solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, *e.g.* D_2O , d_6 -acetone, d_6 -DMSO.

- 15 Compounds of the invention intended for pharmaceutical use may be administered as crystalline or amorphous products. They may be obtained, for example, as solid plugs, powders, or films by methods such as precipitation, crystallization, freeze drying, spray drying, or evaporative drying. Microwave or radio frequency drying may be used for this purpose.

20

The compounds of formula (I) are inhibitors of PDE5. Accordingly, in a further aspect the present invention provides for the use of a compound of formula (I), or a tautomer, salt or solvate thereof, as a pharmaceutical agent, and particularly as a therapeutic agent for the treatment of a condition where inhibition of PDE5

25 is known, or can be shown, to produce a beneficial effect.

The term "treatment" includes palliative, curative and prophylactic treatment.

- 30 Conditions suitable for treatment with the compounds of the invention include hypertension (including essential hypertension, pulmonary hypertension, secondary hypertension, isolated systolic hypertension, hypertension associated with diabetes, hypertension associated with atherosclerosis, and renovascular hypertension), congestive heart failure, angina (including stable, unstable and variant (Prinzmetal) angina), stroke, coronary artery disease, congestive heart

failure, conditions of reduced blood vessel patency (such as post-percutaneous coronary angioplasty), peripheral vascular disease, atherosclerosis, nitrate-induced tolerance, nitrate tolerance, diabetes, impaired glucose tolerance, metabolic syndrome, obesity, sexual dysfunction (including male erectile disorder, impotence, female sexual arousal disorder, clitoral dysfunction, female hypoactive sexual desire disorder, female sexual pain disorder, female sexual orgasmic dysfunction and sexual dysfunction due to spinal cord injury), premature labour, pre-eclampsia, dysmenorrhea, polycystic ovary syndrome, benign prostatic hyperplasia, bladder outlet obstruction, incontinence, chronic obstructive pulmonary disease, acute respiratory failure, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, gut motility disorders (including irritable bowel syndrome), Kawasaki's syndrome, multiple sclerosis, Alzheimer's disease, psoriasis, skin necrosis, scarring, fibrosis, pain (particularly neuropathic pain), cancer, metastasis, baldness, nutcracker oesophagus, anal fissure and haemorrhoids.

In a further aspect, the present invention provides for the use of a compound of formula (I), or a tautomer, salt or solvate thereof, for the manufacture of a medicament for the treatment of such a condition.

20

The compounds of the present invention may be used alone or in combination with other therapeutic agents. When used in combination with another therapeutic agent the administration of the two agents may be simultaneous or sequential. Simultaneous administration includes the administration of a single dosage form that comprises both agents and the administration of the two agents in separate dosage forms at substantially the same time. Sequential administration includes the administration of the two agents according to different schedules provided that there is an overlap in the periods during which the treatment is provided. Suitable agents with which the compounds of formula (I) can be co-administered include aspirin, angiotensin II receptor antagonists (such as losartan, candesartan, telmisartan, valsartan, irbesartan and eprosartan), calcium channel blockers (such as amlodipine), beta-blockers (i.e. beta-adrenergic receptor antagonists such as sotalol, propranolol, timolol, atenolol, carvedilol and metoprolol), C11027, CCR5 receptor antagonists,

30

imidazolines, sGCa's (soluble guanylate cyclase activators) antihypertensive agents, diuretics (such as hydrochlorothiazide, torsemide, chlorothiazide, chlorthalidone and amiloride), alpha adrenergic antagonists (such as doxazosin), ACE (angiotensin converting enzyme) inhibitors (such as quinapril, enalapril, ramipril and lisinopril), aldosterone receptor antagonists (such as eplerenone and spironolactone), neutral endopeptidase inhibitors, antidiabetic agents (such as insulin, sulfonylureas (such as glyburide, glipizide and glimepiride), glitazones (such as rosiglitazone and pioglitazone) and metformin), cholesterol lowering agents (such as atorvastatin, pravastatin, lovastatin, simvastatin, clofibrate and rosuvastatin), and alpha-2-delta ligands (such as gabapentin, pregabalin, [(1R,5R,6S)-6-(aminomethyl)bicyclo[3.2.0]hept-6-yl]acetic acid, 3-(1-aminomethyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one, C-[1-(1H-tetrazol-5-ylmethyl)-cycloheptyl]-methylamine, (3S,4S)-(1-aminomethyl-3,4-dimethyl-cyclopentyl)-acetic acid, (1 α ,3 α ,5 α)-(3-amino-methyl-bicyclo[3.2.0]hept-3-yl)-acetic acid, (3S,5R)-3-aminomethyl-5-methyl-octanoic acid, (3S,5R)-3-amino-5-methyl-heptanoic acid, (3S,5R)-3-amino-5-methyl-nonanoic acid and (3S,5R)-3-amino-5-methyl-octanoic acid).

The compounds of formula (I) may be administered alone or in combination with one or more other compounds of the invention or in combination with one or more other drugs (or as any combination thereof). Generally, they will be administered as a formulation in association with one or more pharmaceutically acceptable excipients. The term "excipient" is used herein to describe any ingredient other than the compound(s) of the invention. The choice of excipient will to a large extent depend on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form.

Pharmaceutical compositions suitable for the delivery of compounds of the present invention and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation may be found, for example, in 'Remington's Pharmaceutical Sciences', 19th Edition (Mack Publishing Company, 1995).

The compounds of the invention may be administered orally. Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, or buccal or sublingual administration may be employed by which the compound enters the blood stream directly from the mouth.

5

Formulations suitable for oral administration include solid formulations such as tablets, capsules containing particulates, liquids, or powders, lozenges (including liquid-filled), chews, multi- and nano-particulates, gels, solid solution, liposome, films (including muco-adhesive), ovules, sprays and liquid formulations.

10

Liquid formulations include suspensions, solutions, syrups and elixirs. Such formulations may be employed as fillers in soft or hard capsules and typically comprise a carrier, for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents. Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet.

15

The compounds of the invention may also be used in fast-dissolving, fast-disintegrating dosage forms such as those described in Expert Opinion in Therapeutic Patents, 11 (6), 981-986 by Liang and Chen (2001).

20

For tablet dosage forms, depending on dose, the drug may make up from 1 wt% to 80 wt% of the dosage form, more typically from 5 wt% to 60 wt% of the dosage form. In addition to the drug, tablets generally contain a disintegrant. Examples of disintegrants include sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, methyl cellulose, microcrystalline cellulose, lower alkyl-substituted hydroxypropyl cellulose, starch, pregelatinised starch and sodium alginate. Generally, the disintegrant will comprise from 1 wt% to 25 wt%, preferably from 5 wt% to 20 wt% of the dosage form.

25

30

Binders are generally used to impart cohesive qualities to a tablet formulation. Suitable binders include microcrystalline cellulose, gelatin, sugars, polyethylene glycol, natural and synthetic gums, polyvinylpyrrolidone, pregelatinised starch,

hydroxypropyl cellulose and hydroxypropyl methylcellulose. Tablets may also contain diluents, such as lactose (monohydrate, spray-dried monohydrate, anhydrous and the like), mannitol, xylitol, dextrose, sucrose, sorbitol, microcrystalline cellulose, starch and dibasic calcium phosphate dihydrate.

5

Tablets may also optionally comprise surface active agents, such as sodium lauryl sulfate and polysorbate 80, and glidants such as silicon dioxide and talc. When present, surface active agents may comprise from 0.2 wt% to 5 wt% of the tablet, and glidants may comprise from 0.2 wt% to 1 wt% of the tablet.

10

Tablets also generally contain lubricants such as magnesium stearate, calcium stearate, zinc stearate, sodium stearyl fumarate, and mixtures of magnesium stearate with sodium lauryl sulphate. Lubricants generally comprise from 0.25 wt% to 10 wt%, preferably from 0.5 wt% to 3 wt% of the tablet.

15

Other possible ingredients include anti-oxidants, colourants, flavouring agents, preservatives and taste-masking agents.

20

Exemplary tablets contain up to about 80% drug, from about 10 wt% to about 90 wt% binder, from about 0 wt% to about 85 wt% diluent, from about 2 wt% to about 10 wt% disintegrant, and from about 0.25 wt% to about 10 wt% lubricant.

25

Tablet blends may be compressed directly or by roller to form tablets. Tablet blends or portions of blends may alternatively be wet-, dry-, or melt-granulated, melt congealed, or extruded before tableting. The final formulation may comprise one or more layers and may be coated or uncoated; it may even be encapsulated.

30

The formulation of tablets is discussed in "Pharmaceutical Dosage Forms: Tablets, Vol. 1", by H. Lieberman and L. Lachman, Marcel Dekker, N.Y., N.Y., 1980 (ISBN 0-8247-6918-X).

Solid formulations for oral administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.

- 5 Suitable modified release formulations for the purposes of the invention are described in US Patent No. 6,106,864. Details of other suitable release technologies such as high energy dispersions and osmotic and coated particles are to be found in Verma *et al*, Pharmaceutical Technology On-line, 25(2), 1-14 (2001). The use of chewing gum to achieve controlled release is described in
10 WO 00/35298.

The compounds of the invention may also be administered directly into the blood stream, into muscle, or into an internal organ. Suitable means for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal,
15 intraventricular, intraurethral, intrasternal, intracranial, intramuscular and subcutaneous. Suitable devices for parenteral administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques.

Parenteral formulations are typically aqueous solutions which may contain
20 excipients such as salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water.

- 25 The preparation of parenteral formulations under sterile conditions, for example, by lyophilisation, may readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art.

The solubility of compounds of formula (I) used in the preparation of parenteral
30 solutions may be increased by the use of appropriate formulation techniques, such as the incorporation of solubility-enhancing agents.

Formulations for parenteral administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-,

sustained-, pulsed-, controlled-, targeted and programmed release. Thus compounds of the invention may be formulated as a solid, semi-solid, or thixotropic liquid for administration as an implanted depot providing modified release of the active compound. Examples of such formulations include drug-coated stents and PGLA microspheres.

The compounds of the invention may also be administered topically to the skin or mucosa, that is, dermally or transdermally. Typical formulations for this purpose include gels, hydrogels, lotions, solutions, creams, ointments, dusting powders, dressings, foams, films, skin patches, wafers, implants, sponges, fibres, bandages and microemulsions. Liposomes may also be used. Typical carriers include alcohol, water, mineral oil, liquid petrolatum, white petrolatum, glycerin, polyethylene glycol and propylene glycol. Penetration enhancers may be incorporated - see, for example, J Pharm Sci, 88 (10), 955-958 by Finnin and Morgan (October 1999).

Other means of topical administration include delivery by electroporation, iontophoresis, phonophoresis, sonophoresis and microneedle or needle-free (e.g. Powderject™, Bioject™, etc.) injection.

Formulations for topical administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.

The compounds of the invention can also be administered intranasally or by inhalation, typically in the form of a dry powder (either alone, as a mixture, for example, in a dry blend with lactose, or as a mixed component particle, for example, mixed with phospholipids, such as phosphatidylcholine) from a dry powder inhaler or as an aerosol spray from a pressurised container, pump, spray, atomiser (preferably an atomiser using electrohydrodynamics to produce a fine mist), or nebuliser, with or without the use of a suitable propellant, such as 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane. For intranasal use, the powder may comprise a bioadhesive agent, for example, chitosan or cyclodextrin.

The pressurised container, pump, spray, atomizer, or nebuliser contains a solution or suspension of the compound(s) of the invention comprising, for example, ethanol, aqueous ethanol, or a suitable alternative agent for dispersing, solubilising, or extending release of the active, a propellant(s) as solvent and an optional surfactant, such as sorbitan trioleate, oleic acid, or an oligolactic acid.

Prior to use in a dry powder or suspension formulation, the drug product is micronised to a size suitable for delivery by inhalation (typically less than 5 microns). This may be achieved by any appropriate comminuting method, such as spiral jet milling, fluid bed jet milling, supercritical fluid processing to form nanoparticles, high pressure homogenisation, or spray drying.

Capsules (made, for example, from gelatin or HPMC), blisters and cartridges for use in an inhaler or insufflator may be formulated to contain a powder mix of the compound of the invention, a suitable powder base such as lactose or starch and a performance modifier such as *l*-leucine, mannitol, or magnesium stearate. The lactose may be anhydrous or in the form of the monohydrate, preferably the latter. Other suitable excipients include dextran, glucose, maltose, sorbitol, xylitol, fructose, sucrose and trehalose.

A suitable solution formulation for use in an atomiser using electrohydrodynamics to produce a fine mist may contain from 1µg to 10mg of the compound of the invention per actuation and the actuation volume may vary from 1µl to 100µl. A typical formulation may comprise a compound of formula (I), propylene glycol, sterile water, ethanol and sodium chloride. Alternative solvents which may be used instead of propylene glycol include glycerol and polyethylene glycol.

Suitable flavours, such as menthol and levomenthol, or sweeteners, such as saccharin or saccharin sodium, may be added to those formulations of the invention intended for inhaled/intranasal administration.

Formulations for inhaled/intranasal administration may be formulated to be immediate and/or modified release using, for example, poly(DL-lactic-coglycolic acid (PGLA). Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.

5

In the case of dry powder inhalers and aerosols, the dosage unit is determined by means of a valve which delivers a metered amount. Units in accordance with the invention are typically arranged to administer a metered dose or "puff" containing from 1µg to 20mg of the compound of formula (I). The overall daily
10 dose will typically be in the range 1µg to 80mg which may be administered in a single dose or, more usually, as divided doses throughout the day.

The compounds of the invention may be administered rectally or vaginally, for example, in the form of a suppository, pessary, or enema. Cocoa butter is a
15 traditional suppository base, but various alternatives may be used as appropriate.

Formulations for rectal/vaginal administration may be formulated to be immediate and/or modified release. Modified release formulations include
20 delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.

The compounds of the invention may also be administered directly to the eye or ear, typically in the form of drops of a micronised suspension or solution in isotonic, pH-adjusted, sterile saline. Other formulations suitable for ocular and
25 aural administration include ointments, biodegradable (*e.g.* absorbable gel sponges, collagen) and non-biodegradable (*e.g.* silicone) implants, wafers, lenses and particulate or vesicular systems, such as niosomes or liposomes. A polymer such as crossed-linked polyacrylic acid, polyvinylalcohol, hyaluronic acid, a cellulosic polymer, for example, hydroxypropylmethylcellulose,
30 hydroxyethylcellulose, or methyl cellulose, or a heteropolysaccharide polymer, for example, gelan gum, may be incorporated together with a preservative, such as benzalkonium chloride. Such formulations may also be delivered by iontophoresis.

Formulations for ocular/aural administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted, or programmed release.

- 5 The compounds of the invention may be combined with soluble macromolecular entities, such as cyclodextrin and suitable derivatives thereof or polyethylene glycol-containing polymers, in order to improve their solubility, dissolution rate, taste-masking, bioavailability and/or stability for use in any of the aforementioned modes of administration.

10

Drug-cyclodextrin complexes, for example, are found to be generally useful for most dosage forms and administration routes. Both inclusion and non-inclusion complexes may be used. As an alternative to direct complexation with the drug, the cyclodextrin may be used as an auxiliary additive, *i.e.* as a carrier, diluent, or
15 solubiliser. Most commonly used for these purposes are alpha-, beta- and gamma-cyclodextrins, examples of which may be found in International Patent Applications Nos. WO 91/11172, WO 94/02518 and WO 98/55148.

Inasmuch as it may be desirable to administer a combination of active compounds,
20 for example, for the purpose of treating a particular disease or condition, it is within the scope of the present invention that two or more pharmaceutical compositions, at least one of which contains a compound in accordance with the invention, may conveniently be combined in the form of a kit suitable for
coadministration of the compositions.

25

Thus the kit of the invention comprises two or more separate pharmaceutical compositions, at least one of which contains a compound of formula ... in accordance with the invention, and means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet. An
30 example of such a kit is the familiar blister pack used for the packaging of tablets, capsules and the like.

The kit of the invention is particularly suitable for administering different dosage forms, for example, oral and parenteral, for administering the separate

compositions at different dosage intervals, or for titrating the separate compositions against one another. To assist compliance, the kit typically comprises directions for administration and may be provided with a so-called memory aid.

5


For administration to human patients, the total daily dose of the compounds of the invention is typically in the range 0.1mg to 500 mg depending, of course, on the mode of administration. For example, oral administration may require a total daily dose of from 0.1 mg to 500 mg, while an intravenous dose may only require
10 from 0.01mg to 50mg. The total daily dose may be administered in single or divided doses.

These dosages are based on an average human subject having a weight of about 65kg to 70kg. The physician will readily be able to determine doses for
15 subjects whose weight falls outside this range, such as infants and the elderly.

Compounds of the invention may be prepared, in known manner in a variety of ways. In the following reaction schemes and hereafter, unless otherwise stated R^1 to R^{18} are as defined in the first aspect. These processes form further aspects of
20 the invention.

a) Compounds of formula (I^C), i.e. compounds of formula (I) wherein R^{15} is $R^{17}C(O)$ can be prepared by acylation of the corresponding compounds of formula (I^D), i.e. compounds of formula (I) wherein R^{15} is hydrogen, as illustrated
25 in Scheme 1.


Scheme 1



- The compound of formula (I^D) is treated with 1-2 equivalents of an acylating agent such as an acyl chloride $R^{17}C(O)Cl$ or an anhydride $(R^{17}C(O))_2O$ in a suitable solvent in the presence of a tertiary amine base such as triethylamine, N-ethyldiisopropylamine or pyridine. Suitable solvents include dichloromethane and dimethylformamide. Preferably, the compound of formula (I^D) is treated with about 1.3 equivalents of acyl chloride and about 1.3 equivalents of triethylamine in dichloromethane for 18 hours.
- Alternatively, a mixture of the compound of formula (I^D) and an acid $R^{17}COOH$ in a suitable solvent is treated with a condensing agent, optionally in the presence of 1-hydroxybenzotriazole (HOBT) (or 1-hydroxy-7-azabenzotriazole (HOAT)) and a tertiary amine base such as triethylamine, N-ethyldiisopropylamine or 4-(dimethylamino)pyridine, at a temperature of between $0^\circ C$ and the boiling point of the solvent. Suitable solvents include acetonitrile, dichloromethane, dimethylformamide, ethyl acetate, N-methylpyrrolidinone, tetrahydrofuran and mixtures thereof. Suitable condensing agents include: 1,1'-carbonyldiimidazole, carbodiimides such as dicyclohexylcarbodiimide (DCC) and 1-(3-dimethylaminopropyl)-1-ethylcarbodiimide (WSCDI); uronium salts such as O-(benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) and O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU); phosphonium salts such as 1-benzotriazolyloxytris(dimethylamino)-phosphonium hexafluorophosphate (BOP) and 1-benzotriazolyloxy-tris(pyrrolidino)phosphonium hexafluorophosphate (PyBOP); diphenylphosphinic chloride (Dpp-Cl) and bis(2-oxo-3-oxazolidinyl)phosphinic chloride (BOP-Cl). Preferably, an equimolar solution of the compound of formula (I^D) and the acid in dichloromethane is treated with about 1.1 equivalents of HATU and about 1.5 equivalents of N-ethyldiisopropylamine at room temperature for 18 hours.
- It will be appreciated that any functional groups in R^1 , R^3 , R^4 , R^{16} and R^{17} , and particularly any primary or secondary amine groups, may need to be protected in order to allow this reaction to proceed successfully. In such a case a subsequent deprotection step will be necessary.

b) Compounds of formula (I^E), i.e. compounds of formula (I) wherein R¹⁵ is R¹⁸SO₂ can be prepared by sulfonylation of the corresponding compounds of formula (I^D), as illustrated in Scheme 2.


5 Scheme 2



The compound of formula (I^D) is treated with 1-2 equivalents of a sulfonyl chloride R¹⁸SO₂Cl in a suitable solvent in the presence of a tertiary amine base such as triethylamine, N-ethyldiisopropylamine or pyridine. Suitable solvents include dichloromethane and dimethylformamide. Preferably, the compound of formula (I^D) is treated with about 1.1 equivalents of sulfonyl chloride and about 1.5 equivalents of N-ethyldiisopropylamine in dichloromethane for 18 hours.

15 Again, any functional groups in R¹, R³, R⁴, R¹⁶ and R¹⁷, and particularly any primary or secondary amine groups, may need to be protected.

c) Compounds of formula (I^F), i.e. compounds of formula (I) wherein R¹⁵ is R¹⁷, may be prepared by elaboration of the C³-substituent R^{5A} of a precursor of formula (II) as illustrated in Scheme 3.

Scheme 3

- Where at least one of R^{16} and R^{17} is hydrogen, such that the amine function of R^5 is a primary or secondary amine, the group R^{5A} may be the same as R^5 with the amine protected by protecting group such as a *tert*-butoxycarbonyl (BOC), fluorenylmethoxycarbonyl (Fmoc) or benzyloxycarbonyl (Z, sometimes referred to as Cbz) group. In such cases the transformation of Scheme 1 is a deprotection step appropriate for the protecting group used, such as treatment with acid (e.g. HCl in dioxan or trifluoroacetic acid in dichloromethane) for the removal of a BOC group, treatment with a base (such as piperidine) for the removal of an Fmoc group, or catalytic hydrogenolysis for the removal of a Z group. Other protected functional groups may be deprotected in the same step or, if orthogonal protecting groups are chosen, deprotection may be stepwise.
- Where neither of R^{16} and R^{17} is hydrogen, such that the amine function of R^5 is a tertiary amine, no protecting group can be used.


Scheme 3 also provides for the elaboration of the amine group of R^5 in one or more steps from a functional group that is more amenable to the reaction conditions needed for the preparation of the compounds of formula (II). Examples of such reactions, which include substitution reactions, imine reduction reactions and rearrangement reactions, are illustrated in Schemes 3A to 3J, in which R^a , R^b , R^c and R^d are hydrogen, alkyl, cycloalkyl or aryl groups.

25 Substitution reactions

Primary, secondary and tertiary amines may be prepared by the reaction of an alkylating agent with ammonia, a primary or a secondary amine respectively, as illustrated in scheme 3A, wherein LG is a halogen atom such as a chlorine,

bromine or iodine atom, or a sulphonate group such as a methanesulphonate, toluenesulphonate to trifluoromethanesulphonate group.


Scheme 3A



5

A variation of this reaction is illustrated in Scheme 3B. In this case the alkylating agent is an epoxide.


10 Scheme 3B



The utility of these reactions is sometimes limited by the propensity of the product amine to react with the alkylating agent, resulting in a complex mixture.

15 This problem can be overcome by the use of an amine equivalent that gives a product that is incapable of further reaction. Scheme 3C illustrates the use of an alkali metal azide or phthalimide as an amine equivalent.


Scheme 3C




20

Imine reduction reactions


Compounds containing a carbon-nitrogen double bond are susceptible to reduction to give the corresponding amine. Scheme 3D illustrates the reductive amination of an aldehyde or ketone, in which an iminium species is generated as a reactive intermediate.

Scheme 3D

This method is generally applicable to the synthesis of secondary and tertiary amines. It is less well suited to the synthesis of primary amines (i.e. when R^a and R^b are both hydrogen). In this case the use of hydroxylamine provides a more practicable route, as illustrated in scheme 3E.


15 Scheme 3E

The carbon-nitrogen triple bond of nitriles is also amenable to reduction to provide primary amines, as illustrated in scheme 3F. The nitrile may be obtained by the reaction of an alkyl halide with an appropriate alkylating agent.

Scheme 3F

Amide reduction reactions


Compounds containing an amide functional group can be reduced to the corresponding amines using reagents such as lithium aluminiumhydride, as illustrated in scheme 3G. The amides can generally be prepared from the corresponding acids and amines.

Scheme 3G

- 10 Carbamate esters are reduced in an analogous manner to the corresponding N-methyl amines.


Rearrangement reactions

- 15 A number of well known reactions involving rearrangement reactions are useful for the preparation of amines. One example, illustrated in Scheme 3H, is the Curtius reaction, in which a carboxylic acid is converted to the corresponding acyl azide and then to an acyl nitrene that rearranges to an isocyanate. Hydrolysis gives the amine.

20 Scheme 3H


- 25 The Lossen rearrangement provides an equivalent process in which the acyl nitrene is generated from a hydroxamic acid. The Schmidt reaction and the Hofmann reaction are other equivalent processes.


The Beckmann rearrangement, illustrated in Scheme 3J, provides secondary amines from oximes.

Scheme 3J

- The intermediate nitrilium ion can be reduced *in situ* to provide the amine directly, or quenched with water to provide an amide that can be reduced to the amine in a separate step.

- Preferred methods of introducing the group $-\text{NR}^{16}\text{R}^{17}$ are the displacement reaction of Scheme 3A and the reductive amination of Scheme 3D. The particularly preferred variants are illustrated in Schemes 3K and 3L (where $-\text{W}-$ is a covalent bond or an alkylene group such that $-\text{W}-\text{CH}_2-$ forms $-\text{Y}-$).

Scheme 3K

Scheme 3L

- 5 In the light of the foregoing discussion, it will be appreciated that R^{5A} may be, for example, -W-CO₂H, -Y-CO₂H, -W-CO₂R^A, -Y-CO₂R^A, -W-CHO, -W-CN, -Y-OH, -Y-LG or -Y-NHPG, where -W- is a covalent bond or an alkylene group such that -W-CH₂- forms -Y-, R^A is a methyl, ethyl, *tert*-butyl or benzyl group, LG is a leaving group as defined above, PG is an amine protecting group and Y is as
- 10 defined for general formula (I). Of these, the less reactive groups such as -W-CO₂R^A, -Y-CO₂R^A, -W-CN, -Y-OH and -Y-NHPG are more likely to be compatible with the conditions required in the overall synthetic sequence. The groups -Y-Cl and -W-CHO present in the compounds of formulae (II^A) and (II^B) are unlikely to be compatible with the conditions required to elaborate the
- 15 compounds. Both groups are, however, readily prepared from the more robust groups such as -W-CO₂R^A. These transformations are described in more detail in parts o) to z) below.


It will further be appreciated that the elaboration of the amine group of R⁵ does

20 not necessarily need to be the last step of the synthetic route, but may be carried out at any point during the route provided that the amine (optionally in protected form) is compatible with the subsequent chemical transformations. In particular, it has been found that it can be advantageous to elaborate R⁵ before introducing the -NR³R⁴ group as described in part d) below. When the amine group of R⁵ is

25 elaborated early in the synthesis it may be necessary to use a suitable protecting group in order to carry it through the subsequent manipulations.

d) Compounds of formula (II) can be prepared from the corresponding monochlorides of formula (III) by reaction with HNR^3R^4 as illustrated in Scheme 4.

5 Scheme 4




A solution of the monochloride (III) and the amine HNR^3R^4 in a suitable dipolar aprotic solvent are stirred at elevated temperature for between 1 and 24 hours. Suitable solvents include dimethylsulfoxide, dimethylformamide and N-methylpyrrolidinone. An excess of a tertiary amine such as N-ethyl-diisopropylamine, N-methylmorpholine or triethylamine may optionally be included. It is sometimes necessary to perform the reaction at elevated pressure in a closed vessel, particularly when the amine HNR^3R^4 or the solvent is volatile.

Preferably, the monochloride is treated with 1-5 equivalents of the amine HNR^3R^4 and optionally 3-5 equivalents of N-ethyl-diisopropylamine in dimethylsulfoxide or N-methylpyrrolidinone at 100-125°C for 12-18 hours, in a sealed vessel.

It will be appreciated that any functional groups in HNR^3R^4 , and particularly any primary or secondary amine groups, may need to be protected in order to allow this reaction to proceed successfully. In such a case a subsequent deprotection step such as is described in part c) will be necessary. The protecting group can be selected such that it can be removed at the same as the protecting group of the amine in R^5 (where such a protecting group is present). Alternatively it may be preferable to provide for sequential removal of the protecting groups.

e) Compounds of formula (III) can be prepared from the corresponding dichlorides of formula (IV) by reaction with HNR^1R^2 as illustrated in Scheme 5.

Scheme 5



5 A solution of the dichloride (IV), the amine HNR^1R^2 and an excess of a tertiary amine such as N-ethyldiisopropylamine, N-methylmorpholine or triethylamine in a suitable dipolar aprotic solvent are stirred at ambient or elevated temperature for between 1 and 24 hours. Suitable solvents include dimethylsulfoxide, dimethylformamide and N-methylpyrrolidinone. It will be appreciated that any functional groups in HNR^1R^2 , and particularly any primary or secondary amine groups, may need to be protected in order to allow this reaction to proceed successfully. Preferably, the monochloride is treated with 2-5 equivalents of the amine HNR^1R^2 and optionally 2-5 equivalents of N-ethyldiisopropylamine in 10 dimethylsulfoxide or a mixture of dimethylsulfoxide and N-methylpyrrolidinone at 15 30-90°C for 1-18 hours.

Alternatively, a solution of the amine HNR^1R^2 in a suitable solvent is treated with butyllithium or sodium hexamethyldisilazide at low temperature, and the 20 dichloride is added to the resulting solution. Suitable solvents include tetrahydrofuran and dioxan.

As discussed in part d), reactive functional groups in HNR^1R^2 may need to be protected for this reaction to give a satisfactory result.


25

When R^{5A} is an ester group such as $-\text{CO}_2\text{CH}_3$ directly attached to the pyrazolopyrimidine nucleus, the reaction of compounds of formula (IV) with less

reactive amines HNR^1R^2 can be low-yielding. In such cases it is sometimes advantageous to use an alternative strategy, as discussed in part z) below.

- f) Compounds of formula (IV) can be prepared from the corresponding
5 pyrazolopyrimidinediones formula (V) as illustrated in Scheme 6.


Scheme 6



The dione is treated with a large excess of a suitable chlorinating reagent such
10 as phosphorus oxychloride (POCl_3) or phenylphosphonyl dichloride ($\text{PhP}(\text{O})\text{Cl}_2$)
in the presence of a tertiary amine such as N-ethyldiisopropylamine, N-
methylmorpholine, triethylamine or N,N-dimethylaniline or tetraethylammonium
chloride at elevated temperature for 8-48 hours. Dimethylformamide can
optionally be added as a catalyst. The reaction may be performed in the
15 absence of a solvent. When a solvent is used then suitable solvents include
acetonitrile and propionitrile. Preferably, the dione is treated with 10-30
equivalents of POCl_3 and 3 equivalents of N-ethyldiisopropylamine or 3-5
equivalents of tetraethylammonium chloride in acetonitrile or propionitrile at
reflux for 18 hours.


20

- g) Compounds of formula (V) can be prepared from the corresponding
aminoamides of formula (VI) as illustrated in Scheme 7.

Scheme 7

A solution of the pyrazolecarboxamide (VI) and phosgene or an equivalent thereof, such as carbonyl diimidazole, trichloromethyl chloroformate or bis(trichloromethyl) carbonate, in a dipolar aprotic solvent is stirred at a temperature of between ambient temperature and the boiling point of the solvent, optionally at elevated pressure, for between 2 and 18 hours. Preferably, a solution of the dione and 1-2 equivalent of carbonyl diimidazole in dimethylformamide is stirred at 70°C to 90°C for 18 hours.

h) Compounds of formula (VI) can be prepared from the corresponding nitroamides of formula (VII) as illustrated in Scheme 8.

Scheme 8

Reduction of the nitro group can be achieved by, for example, transfer or catalytic hydrogenation, or by a dissolving metal reduction.

For transfer hydrogenation, the nitro compound is reacted with a suitable hydrogen donor, such as ammonium formate or cyclohexene, in a polar solvent, such as tetrahydrofuran, methanol or ethanol, in the presence of a transition metal or transition metal salt catalyst, such as palladium or palladium(II) hydroxide, optionally at elevated temperature and pressure.


For catalytic hydrogenation, a solution of the nitro compound in a polar solvent, such as tetrahydrofuran, methanol or ethanol, is stirred under a hydrogen atmosphere in the presence of a transition metal or transition metal salt catalyst, such as palladium or palladium(II) hydroxide, optionally at elevated pressure.

- 5 The catalyst may be in solution (homogeneous catalysis) or in suspension (heterogeneous catalysis).

For dissolving metal reduction, the nitro compound is treated with a suitable reactive metal, such as zinc or tin, in the presence of an acid such as acetic acid or hydrochloric acid. Other reducing agents, such as tin(II) chloride, may also be used.


- 15 i) Compounds of formula (VII) can be prepared from the corresponding nitroacids of formula (VIII) as illustrated in Scheme 9.

Scheme 9




The acid (VIII) is converted to the corresponding acid chloride (IX) by treatment with oxalyl chloride and dimethylformamide in a suitable solvent such as dichloromethane, or with thionyl chloride. A solution of the acid chloride in a suitable solvent such as dichloromethane, tetrahydrofuran or dioxan is then treated with gaseous ammonia or aqueous ammonia to provide the amide of formula (VII).

- 25 j) Compounds of formula (VIII) can be prepared from the corresponding acids of formula (X) as illustrated in Scheme 10.

Scheme 10


The nitration of pyrazoles is well known. The compounds of formula (X) are treated with nitric acid or a mixture of nitric acid and sulphuric acid to provide the compounds of formula (VIII).

k) Certain compounds of formula (X) are commercially available. Compounds of formula (X) that are not items of commerce can be prepared via the corresponding methyl esters (XI) as illustrated in Schemes 11 to 13.

Scheme 11


The method illustrated in Scheme 9 is the Knorr pyrazole synthesis. A 1,3-diketone of formula (XII) is reacted with hydrazine to give a pyrazole of formula (XI^A), or with a substituted hydrazine R^{6A}-NHNH₂, wherein R^{6A} is any group according to R⁶ except hydrogen, to give a pyrazole of formula (XI^B).

- Pyrazoles of formula (XI^B) may also be obtained by N-alkylation of the corresponding pyrazoles of formula (XI^A). The pyrazole of formula (XI^A) is treated with a base such as an alkaline metal carbonate or bicarbonate, for example potassium carbonate or caesium carbonate, or a tertiary amine, for example triethylamine, diisopropylethylamine or pyridine, and the appropriate chloride (R^{6A}-Cl), bromide (R^{6A}-Br), iodide (R^{6A}-I), mesylate (R^{6A}-OSO₂CH₃) or tosylate (R^{6A}-OSO₂Tol) in a suitable solvent at a temperature of between -70°C and 100°C. Suitable solvents include alcohols such as methanol, ethanol, isopropanol and butanol, ethers such as tetrahydrofuran and dioxan, dimethylformamide and acetonitrile. When the reaction gives a mixture of the N¹- and N²-alkylated products, these can be separated using standard techniques.
- The methyl esters of formula (XI^A) and (XI^B) are hydrolysed to provide the corresponding acids of formula (X^A) and (X^B) by treatment with an alkali metal hydroxide, such as lithium hydroxide, sodium hydroxide or potassium hydroxide, in a suitable solvent. Suitable solvents include lower alcohols, such as methanol and ethanol, and mixtures of water and dioxan or tetrahydrofuran.
- Compounds of formula (XII) can be prepared from the corresponding methyl ketones of formula (XIII) using a crossed Claisen condensation as illustrated in Scheme 12.

25 Scheme 12

A methyl ketone of formula (XIII) is reacted with dimethyl oxalate in a suitable solvent in the presence of a suitable base. Suitable solvents include ethers, such as tetrahydrofuran. Suitable bases include sodium hydride, potassium t-butoxide and lithium diisopropylamide. Alternatively, unless R^{5A} includes a reactive functional group, sodium methoxide may be used as the base and methanol as the solvent.

Scheme 13




10

15

The method illustrated in Scheme 13 is the Pechmann pyrazole synthesis. A diazo compound and an acetylene are combined to produce a pyrazole of formula (XI^A). When R^{5A} is other than -COOCH₃ two variants of the method can be considered. An acetylene of formula (XIV) can be combined with methyl diazoacetate, or a diazo compound of formula (XV) can be combined with methyl propiolate. The initial reaction product (XI^A) may be N-alkylated as described above to give the pyrazoles of formula (XI^B).

l) A particularly useful series of compounds are those wherein R^{5A} is $-\text{CO}_2\text{CH}_3$. Their elaboration is illustrated in Scheme 14.

Scheme 14



5


Dimethyl 4-nitropyrazole-3,5-dicarboxylate is readily prepared according to the method described in published international patent application WO00/24745 (see preparation 2, page 48), and can be N-alkylated according to the methods described in part k) above. Because the two nitrogen atoms of the pyrazole are equivalent, a single alkylation product is obtained. Selective hydrolysis of the diester with one equivalent of alkali metal hydroxide according to the method of Chambers *et al.* (J. Org. Chem. 50, 4736-4738, 1985) cleaves the ester adjacent to the substituted nitrogen, providing the monoacids of formula (VIII^A), i.e. compounds of formula (VIII) wherein R^{5A} is $-\text{CO}_2\text{CH}_3$ and R^{6A} is attached at the nitrogen atom adjacent to the free carboxylic acid group.

15

m) In some embodiments of the compounds of formula (I), the group R^6 may not be compatible with the synthetic methods described above. An alternative in these circumstances is to introduce the R^6 group at a late stage, as illustrated in Scheme 15.

20

Scheme 15




A compound of formula (II^C), i.e. a compound of formula (II) wherein R⁶ is hydrogen, can be alkylated using the methods described in part k) above. The reaction will generally give a mixture of the N¹-alkylated compound (II^D) and the N²-isomer (II^E). These can be separated and purified by conventional methods. The use of more reactive alkylating agents tends to promote alkylation at the N² position.

It will be appreciated that the alkylation reaction to introduce R^{6A} might also be carried out at other stages in the synthetic sequence.

n) Compounds of formula (I^F) wherein Y is a covalent bond can be prepared by the methods described in parts c) to f) above, starting from compounds of formula (V^A), i.e. compounds of formula (V) wherein R^{5A} is -NR¹⁶R¹⁷, provided that any incompatible functional groups are suitably protected. The requisite compounds of formula (V^A) can be prepared from the corresponding compounds of formula (V^B), i.e. compounds of formula (V) wherein R^{5A} is hydrogen, following the method illustrated in Scheme 16.

Scheme 16



The pyrazolopyrimidinedione of formula (V^B) can be brominated by treatment with bromine. Treatment with an amine HNR¹⁵R¹⁶ leads to the introduction of the amino group at the C³-position. The compound of formula (V^B) may be treated with chlorine to give the 3-chloropyrazolopyrimidinedione which reacts in an analogous manner to provide the compound of formula (V^A).


The compounds of formula (V^B) can be prepared from methyl pyrazole-3-carboxylate by N-alkylation (when R⁶ is other than hydrogen) as described in part k) above, followed by elaboration as described in parts j), i), h) and g).

As previously noted in part c), compounds of formula (II) and (III) in which R^{5A} is -W-CO₂H, -Y-CO₂H, -W-CO₂R^A, -Y-CO₂R^A, -W-CHO, -W-CN, -Y-OH or -Y-LG are particularly useful precursors to compounds wherein the amine group in R⁵ has been elaborated. It may be necessary or convenient to introduce some of these groups by manipulating a more accessible starting material.

Interconversions of these common functional groups are well known in the art. Some representative manipulations are described below. It will be appreciated that the synthetic transformations discussed may also be used in the elaboration of precursor compounds such as the pyrazoles of formula (XI).

o) Esters of formula (III^A), in which -V- represents either -W- or -Y-, i.e. compounds of formula (III) wherein R^{5A} is -V-CO₂R^A, and the corresponding acids of formula (III^B), i.e. compounds of formula (III) wherein R^{5A} is -V-CO₂H, may be interconverted as illustrated in Schemes *17A and *17B.


Scheme 17A



When R^A is methyl or ethyl the conversion may conveniently be accomplished by treating the compound of formula (III^A) with an alkaline metal hydroxide such as lithium hydroxide, sodium hydroxide or potassium hydroxide in a suitable solvent at a temperature of between about 10°C and the boiling point of the solvent.

Suitable solvents include water, methanol, ethanol and mixtures of water with methanol, ethanol, tetrahydrofuran and dioxan. When R^A is *tert*-butyl the conversion may be accomplished by treating the compound of formula (III^A) with an acid such as hydrogen chloride or trifluoroacetic acid in a suitable solvent at a temperature of between 0°C and ambient temperature. Suitable solvents include dioxan and dichloromethane. When R^A is benzyl the conversion may conveniently be accomplished by treating the compound of formula (III^A) with an alkaline metal hydroxide as discussed above, or by hydrogenolysis using molecular hydrogen or a suitable hydrogen donor such as ammonium formate in the presence of a transition metal or transition metal salt catalyst such as palladium-on-carbon, in a suitable solvent, such as methanol.

Scheme 17B




The conversion may conveniently be accomplished by treating a mixture of the acid of formula (III^B) and an alcohol R^A-OH in a suitable solvent with a condensing agent such as a carbodiimide, e.g. dicyclohexylcarbodiimide or N-(3-

dimethylaminopropyl)-N'-ethylcarbodiimide, optionally in the presence of 4-dimethylaminopyridine, at a temperature of between 0°C and the boiling point of the solvent. Suitable solvents include dichloromethane and dimethylformamide.

Alternatively, the acid of formula (III^B) may be converted to the corresponding acid chloride using thionyl chloride or oxalyl chloride and then treated with the alcohol R^A-OH.

p) Compounds of formula (III^C), i.e. compounds of formula (III^A) wherein V is CH₂, may be prepared from the corresponding compounds of formula (III^D), i.e. compounds of formula (III^B) wherein V is a covalent bond, by a one-carbon homologation method such as the Arndt-Eistert reaction illustrated in Scheme 18.

Scheme 18




15

The carboxylic acid is converted to a reactive intermediate such as the acid chloride (by reaction with oxalyl chloride) or a mixed anhydride (by reaction with isobutyl chloroformate). The intermediate is reacted with diazomethane to provide an α -diazoketone. This is treated with silver oxide in the presence of R^A-OH to give the homologated ester of formula (III^C).

20


q) Compounds of formula (III^E), i.e. compounds of formula (III^B) wherein V is CH₂, may be prepared from the corresponding nitriles of formula III^F by the method illustrated in Scheme 19.

25

Scheme 19


5 The nitrile group can be hydrolysed, e.g. by treatment with aqueous mineral acids, such as hydrochloric acid.

r) Compounds of formula (III^F) can be prepared from the corresponding chlorides of formula (III^G) by the method illustrated in Scheme 20.

10 Scheme 20


15 The chloride is treated with a metal cyanide, such as sodium cyanide or potassium cyanide in a suitable solvent, such as dimethylsulfoxide, dimethylformamide or ethanol.

s) Compounds of formula (III^G) can be prepared from the corresponding alcohols of formula (III^H) by the method illustrated in Scheme 21.

Scheme 21

The alcohol is treated with a mixture of triphenylphosphine and N-chlorosuccinimide or tetrachloromethane, or with thionyl chloride.

- t) Compounds of formula (III^H) can be prepared from the corresponding esters of formula (III^J), i.e. compounds according to formula (III^A) wherein V is a covalent bond, or from the corresponding acids of formula (III^D) by the method illustrated in Scheme 22.

Scheme 22


- 15 The acids of formula (III^D) and the esters of formula (III^J) can be reduced to the alcohols of formula (III^H) by treatment with lithium aluminium hydride in a suitable

solvent at a temperature of between 0° and the boiling point of the solvent.

Suitable solvents include ethers such as tetrahydrofuran. The acids can also be reduced by treatment with isobutyl chloroformate and a tertiary amine base to provide a mixed anhydride, followed by reaction with sodium borohydride. The esters can also be reduced by treatment with disobutylaluminium hydride or lithium borohydride.

u) Compounds of formula (III^K), i.e. compounds of formula (III^A) wherein V is CH₂CH₂ can be prepared from the corresponding acrylate ester of formula (III^L) by the method illustrated in Scheme 23.

Scheme 23




The reduction of the carbon-carbon double bond of (III^L) to give the compounds of formula (III^K) can be accomplished by catalytic hydrogenation using molecular hydrogen in the presence of a transition metal catalyst such as palladium, platinum or nickel. When R^A is benzyl the conditions can be chosen such that only the double bond is reduced or reduction is accompanied by hydrogenolytic cleavage of the ester to give the carboxylic acid.

The acrylates of formula (III^L) can also be treated with alkylcopper reagents to give analogues of the compounds of formula (III^K) in which an alkyl substituent is introduced on the carbon atom adjacent to the pyrazolopyrimidine ring system, or with a sulphonium ylid or a carbene equivalent to give a 2-(pyrazolopyrimidinyl)-cyclopropane-1-carboxylate derivative.

v) Compounds of formula (III^L) can be prepared from the corresponding aldehydes of formula (III^M) by the method illustrated in Scheme 24.

Scheme 24




The aldehyde of formula (III^M) can be converted to the acrylate ester of formula (III^L) by reaction with a phosphorus reagent following the protocols of the Wittig, Horner or Wadsworth-Horner-Emmons reactions. The reagent is prepared by treating a triphenylphosphonium salt Ph₃P⁺CH₂CO₂R^A.X⁻ (Wittig), a phosphine oxide Ph₂P(O)CH₂CO₂R^A (Horner), or a phosphonate (EtO)₂P(O)CH₂CO₂R^A (Wadsworth-Horner-Emmons), with a base such as butyllithium, a lithium dialkylamide or an alkaline metal alkoxide, in a suitable solvent such as tetrahydrofuran.

The method is not limited to the preparation of α-unsubstituted acrylate esters. The use of an alkyl-substituted phosphorus reagent such as Ph₃P⁺CH(R)CO₂R^A.X⁻ or the equivalent phosphine oxide or phosphonate, wherein R is alkyl, gives access to the corresponding α-alkyl acrylate derivative.

The conversion of the aldehydes of formula (III^M) to acrylate esters of formula (III^L) can also be achieved by reaction with a malonate derivative following the method of the Knoevenagel condensation.

w) Compounds of formula (III^M) can be prepared from the esters of formula (III^J) or more preferably from the corresponding alcohols of formula (III^H) by the methods illustrated in Scheme 25.


Scheme 25



- The reduction of the esters of formula (III^J) can be achieved using
- 5 diisobutylaluminium hydride (DIBAL) in a suitable solvent at a temperature of less than 0°C, preferably less than -60°C. Suitable solvents include hydrocarbons such as pentane, hexane and toluene, ethers such as tetrahydrofuran, and mixtures thereof.
 - 10 The oxidation of the alcohols of formula (III^H) can be achieved using a chromium(VI) reagent such as pyridinium chlorochromate, a hypervalent iodine reagent such as the Dess-Martin periodinane, or a combination of tetra-n-propylammonium perruthenate and N-methylmorpholine-N-oxide in a suitable solvent at a temperature of between 0°C and ambient temperature. Suitable
 - 15 solvents include dichloromethane.

x) The aldehydes of formula (III^M) may be converted to esters of formula (III^C) as illustrated in Scheme 26


Scheme 26



- The aldehyde is treated with methyl methylmercaptomethyl sulfoxide (CH₃SCH₂S(O)CH₃) and triton B in tetrahydrofuran to give intermediate (III^N) which is treated with the appropriate alcohol R^AOH and acetyl chloride to provide the ester of formula (III^C). This method is particularly useful when R^A is methyl.

y) Compounds of formula (III^K) can also be prepared from the corresponding chlorides of formula (III^G) by the method illustrated in Scheme 27.

Scheme 27



The chloride of formula (III^G) is reacted with a dialkyl malonate $(R^A O_2C)_2CH_2$ and a base in a suitable solvent. Typically, the base is an alkaline metal alkoxide such as sodium ethoxide or potassium *tert*-butoxide, and the solvent is an alcohol such as ethanol or an ether such as tetrahydrofuran. Preferably the base and the solvent are chosen such as to minimise transesterification with the malonate reagent and the intermediate (III^O) . For example, when the reagent is diethyl malonate the base is preferably sodium ethoxide and the solvent is ethanol. The intermediate (III^O) is then decarboxylated to give the product (III^K) .


This can be achieved by selective hydrolysis using one equivalent of an alkaline metal hydroxide, such as sodium hydroxide, followed by acidification, or by any other method known in the art.

The method is not limited to symmetrical malonates. For example, the use of *tert*-butyl methyl malonate would give an intermediate (III^O) in which one R^A is methyl and the other is *tert*-butyl. By choosing the appropriate conditions, decarboxylation could then be controlled to give a product (III^K) in which R^A was either *tert*-butyl or methyl.

The method can be extended to substituted malonates $(R^A O_2 C)_2 CHR$, where R is an alkyl group. This gives access to compounds analogous to (III^K) in which the group R is a substituent on the carbon atom adjacent to the $R^A O_2 C$ group. These compounds can also be prepared by alkylating the intermediate (III^O) with
 5 R-Br or R-I in the presence of an alkaline metal alkoxide base.


z) As mentioned in part e) above, the reaction of compounds of formula (IV^A) , i.e. compounds of formula (IV) wherein R^{5A} is $-CO_2 R^A$, with weakly nucleophilic amines $HNR^1 R^2$ is sometimes not high yielding. An alternative
 10 route is illustrated in Schemes 28A and 28B.

Scheme 28A



15 The esters of formula (IV^A) can be reduced to the alcohols of formula (IV^B) according to the methods described in part t) above. A preferred method is reduction with diisobutylaluminium hydride at a temperature of between $-20^\circ C$ and $0^\circ C$. The primary alcohol is then protected to give compounds of formula (IV^C) , wherein PG is an alcohol protecting group. A preferred protecting group
 20 is a trialkylsilyl group, particularly a *tert*-butyldimethylsilyl group. The compounds of formula (IV^C) are then reacted with an amine $HNR^1 R^2$ according to the methods described in part e) above to give compounds of formula (III^P) .

Scheme 28B




- The compounds of formula (III^P) are deprotected to provide the primary alcohols of formula (III^H) using appropriate conditions. When PG is a trialkylsilyl group it may be removed by treatment with a fluoride salt, such as tetrabutylammonium fluoride, or with hydrochloric acid. The alcohols of formula (III^H) may then be further modified as discussed above. For example, the $\text{-NR}^3\text{R}^4$ group may be introduced according to the methods described in part d) above to provide compounds of formula (II^F). The primary alcohol may then be oxidised as described in part w) above to provide the aldehydes of formula (II^G). A preferred oxidising agent is the Dess-Martin periodinane. Finally, if the carboxylic acids are desired, the aldehydes of formula (II^G) may be oxidised to provide the acids of formula (II^H). Suitable oxidising agents include potassium permanganate,

Jones' reagent and sodium chlorite. A preferred method is to treat the aldehydes with sodium chlorite, sodium dihydrogenphosphate and 2-methyl-2-butene in *tert*-butanol at room temperature for about 1 hour.

- 5 The following compounds form further aspects of the present invention:


A compound of formula (II^A)



(II^A)

- 10 wherein R¹, R², R³, R⁴, R⁶ and Y are as defined above. Preferably, R⁶ is attached at N¹. Preferably, Y is -CH₂-.


A compound of formula (II^B)



(II^B)

- 15 wherein R¹, R², R³, R⁴, R⁶ and W are as defined above. Preferably, R⁶ is attached at N¹. Preferably, W is a covalent bond.

A compound of formula (XVI)



(XVI)

wherein R^1 , R^2 , R^5 and R^6 are as defined above. Preferably, R^6 is attached at N^1 .

- 5 The invention is further illustrated by the following, non-limiting examples. Melting points were determined on a Gallenkamp melting point apparatus using glass capillary tubes and are uncorrected. Unless otherwise indicated all reactions were carried out under a nitrogen atmosphere, using commercially available anhydrous solvents. '0.88 Ammonia' refers to commercially-available aqueous ammonia solution of about 0.88 specific gravity. Thin-layer chromatography was performed on glass-backed pre-coated Merck silica gel (60 F254) plates, and silica gel column chromatography was carried out using 40-63 μ m silica gel (Merck silica gel 60). Ion exchange chromatography was performed using with the specified ion exchange resin which had been pre-washed with deionised water. Proton NMR spectra were measured on a Varian Inova 300, Varian Inova 400, or Varian Mercury 400 spectrometer in the solvents specified. In the NMR spectra, only non-exchangeable protons which appeared distinct from the solvent peaks are reported. Low resolution mass spectra were recorded on either a Fisons Trio 1000, using thermospray positive ionisation, or a Finnigan Navigator, using electrospray positive or negative ionisation. High resolution mass spectra were recorded on a Bruker Apex II FT-MS using electrospray positive ionisation. Combustion analyses were conducted by Exeter Analytical UK. Ltd., Uxbridge, Middlesex. Optical rotations were determined at 25°C using a Perkin Elmer 341 polarimeter using the solvents and concentrations specified. Example compounds designated as (+) or (-) optical isomers are assigned based on the sign of optical rotation when determined in a suitable solvent.
- 10
- 15
- 20
- 25

Abbreviations, Definitions and Glossary

AcOH	acetic acid
Amberlyst® 15	Ion exchange resin, available from Aldrich Chemical Company
APCI	Atmospheric Pressure Chemical Ionisation
Arbocel™	Filtration agent, from J. Rettenmaier & Sohne, Germany
atm	Pressure in atmospheres (1 atm = 760 Torr = 101.3 kPa)
Biotage™	Chromatography performed using Flash 75 silica gel cartridge, from Biotage, UK
BOC	<i>tert</i> -butoxycarbonyl
br	Broad
<i>c</i>	Concentration used for optical rotation measurements in g per 100 ml (1 mg/ml is <i>c</i> 0.10)
cat	Catalytic
CBz	benzyloxycarbonyl
CDI	N,N'-carbonyldiimidazole
d	Doublet
DCC	N,N'-dicyclohexylcarbodiimide
DCM	dichloromethane
dd	Doublet of doublets
DEAD	diethyl azodicarboxylate
Degussa® 101	10 wt% palladium on activated carbon, Degussa type E101 available from Aldrich Chemical Company
Dess-Martin periodinane	1,1,1-triacetoxy-1,1-dihydro-1,2-benziodoxol-3(1H)-one
Develosil	Supplied by Phenomenex - manufactured by Nomura Chemical Co. Composed of spherical silica particles (size 3 µm or 5 µm) which have a chemically bonded surface of C30 chains. These particles are packed into stainless steel columns of dimensions 2 cm internal diameter and 25 cm long.
Combi-RP C ₃₀ hplc column	
DIAD	diisopropyl azodicarboxylate
DIBAL	diisobutylaluminium hydride
DMAP	4-dimethylaminopyridine
DMF	N,N-dimethylformamide
DMSO	dimethyl sulphoxide

Dowex®	Ion exchange resin, from Aldrich Chemical Company
ee	Enantiomeric excess
Et ₃ N	triethylamine
EtOAc	ethyl acetate
EtOH	ethanol
HOAT	1-hydroxy-7-azabenzotriazole
HOBT	1-hydroxybenzotriazole hydrate
HRMS	High Resolution Mass Spectroscopy (electrospray ionisation positive scan)
Hünig's base	N-ethyldiisopropylamine
Hyflo™	Hyflo supercel®, from Aldrich Chemical Company
KHMDS	potassium bis(trimethylsilyl)amide
liq	Liquid
LRMS	Low Resolution Mass Spectroscopy (electrospray or thermospray ionisation positive scan)
LRMS (ES ⁻)	Low Resolution Mass Spectroscopy (electrospray ionisation negative scan)
m	Multiplet
m/z	Mass spectrum peak
MCI™ gel	High porous polymer, CHP20P 75-150µm, from Mitsubishi Chemical Corporation
MeOH	methanol
Mukaiyama's reagent	2-chloro-1-methylpyridinium iodide
NaHMDS	sodium bis(trimethylsilyl)amide
NMM	N-methylmorpholine
NMO	4-methylmorpholine <i>N</i> -oxide
NMP	1-methyl-2-pyrrolidinone
Phenomenex	Supplied by Phenomenex. Composed of spherical silica particles
Luna C18 hplc column	(size 5 µm or 10 µm) which have a chemically bonded surface of C18 chains. These particles are packed into a stainless steel column of dimensions 2.1cm internal diameter and 25 cm long.
psi	Pounds per square inch (1 psi = 6.9 kPa)
PyBOP®	Benzotriazol-1-yloxytris(pyrrolidino)phosphonium


	hexafluorophosphate
PyBrOP®	bromo-tris-pyrrolidino-phosphonium hexafluorophosphate
q	Quartet
R _f	Retention factor on TLC
s	Singlet
Sep-Pak®	Reverse phase C ₁₈ silica gel cartridge, Waters Corporation
t	Triplet
TBDMS-Cl	<i>tert</i> -butyldimethylchlorosilane
TFA	trifluoroacetic acid
THF	tetrahydrofuran
TLC	Thin Layer Chromatography
TMS-Cl	chlorotrimethylsilane
WSCDI	1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
δ	Chemical shift

The following Examples illustrate the preparation of the compounds of the formula (I):-

5

Preparation 1

Dimethyl 1-(2-ethoxyethyl)-4-nitro-1H-pyrazole-3,5-dicarboxylate



Potassium carbonate (1.32g, 9.57mmol) and 2-ethoxyethyl bromide (1.18mL, 9.57mmol) were added to a solution of dimethyl 4-nitro-1H-pyrazole-3,5-dicarboxylate (EP 1241170, pg. 50, preparation 10) (2g, 9.57mmol) in N,N-dimethylformamide (35mL) and the reaction mixture was stirred at room temperature for 18 hours. The reaction mixture was concentrated *in vacuo* and the residue was partitioned between ethyl acetate (200mL) and water (100mL). The organic phase was dried over magnesium sulphate and concentrated *in*


15

vacuo. The crude product was purified by column chromatography on silica gel eluting with pentane:ethyl acetate 100:0 to 70:30 in 10% increments to yield the title product, 1.63g.

¹H NMR (CDCl₃, 400MHz) δ: 1.07 (t, 3H), 3.41 (m, 2H), 3.73 (t, 2H), 3.89 (s, 3H),
5 3.94 (s, 3H), 4.76 (t, 2H). MS APCI+ m/z 302 [MH]⁺

Preparation 2

1-(2-Ethoxyethyl)-4-nitro-1H-pyrazole-3,5-dicarboxylic acid 3-methyl ester




10 The di-ester of preparation 1 (1.63g, 5.4mmol) was added to a solution of potassium hydroxide (300mg, 5.9mmol) in methanol (20mL) and the reaction mixture stirred at room temperature for 18 hours. The reaction mixture was concentrated *in vacuo* and the residue dissolved in water (100mL) and washed with ether. The aqueous phase was acidified with 2M hydrochloric acid and
15 extracted with dichloromethane (3x100mL). The organic phases were combined, dried over magnesium sulphate and concentrated *in vacuo* to yield the title product, 1.34g.

¹H NMR (CD₃OD, 400MHz) δ: 1.07 (t, 3H), 3.47 (m, 2H), 3.80 (t, 2H), 3.88 (s, 3H), 4.77 (t, 2H). MS APCI+ m/z 288 [MH]⁺

20

Preparation 3

Methyl 5-carbamoyl-1-(2-ethoxyethyl)-4-nitro-1H-pyrazole-3-carboxylate




Oxalyl chloride (15.7mL, 190mmol) was added steadily to a solution of the
25 carboxylic acid of preparation 2 (17.1g, 59.5mmol) in dichloromethane (300mL).

N,N-Dimethylformamide (46 μ L, 6mmol) was then added and the reaction mixture stirred for 2 hours. The reaction mixture was concentrated *in vacuo* and the residue azeotrope with dichloromethane (3x200mL). The product was dissolved in tetrahydrofuran (300mL), the solution cooled in ice, treated with 0.88 ammonia (200mL) and stirred for 18 hours at room temperature. The reaction mixture was concentrated *in vacuo* and the residue partitioned between water (200mL) and ethyl acetate. The organics were dried over magnesium sulphate and concentrated *in vacuo* to yield the crude product which was triturated from ether to yield the title product, 8.2g.

^1H NMR (DMSO- D_6 , 400MHz) δ : 1.03 (t, 3H), 3.38 (m, 2H), 3.70 (t, 2H), 3.86 (s, 3H), 4.36 (t, 2H), 8.30 (m, 1H), 8.46 (m, 1H). MS APCI+ m/z 287 $[\text{MH}]^+$


Preparation 4

Methyl 4-amino-5-carbamoyl-1-(2-ethoxyethyl)-1H-pyrazole-3-carboxylate



Palladium(II) hydroxide on carbon (1g) was added to a solution of the nitro compound of preparation 3 (8.2g, 28.6mmol) in methanol (300mL). Ammonium formate (8.8g, 0.14mol) was added portionwise to the reaction mixture over 20 minutes and the reaction mixture then stirred at reflux for 2 hours. The reaction was cooled to room temperature and filtered to remove catalyst. The filtrate was concentrated *in vacuo* and azeotrope with toluene to yield the title product, 7.3g.


^1H NMR (DMSO- D_6 , 400MHz) δ : 1.04 (t, 3H), 3.32 (m, 2H), 3.66 (t, 2H), 3.78 (s, 3H), 4.49 (t, 2H), 5.12 (m, 2H), 7.50 (m, 2H). MS APCI+ m/z 257 $[\text{MH}]^+$

Preparation 5Methyl 1-(2-ethoxyethyl)-5,7-dioxo-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-d]pyrimidine-3-carboxylate

- 5 N,N'-Carbonyldiimidazole (5.54g, 34.2mmol) was added to a solution of the amide of preparation 4 (7.3g, 28.5mmol) in N,N-dimethylformamide (250mL) and the reaction mixture stirred at room temperature for 1 hour and then at 90°C for 18 hours. The reaction mixture was allowed to cool to room temperature and concentrated *in vacuo*. The residue was sonicated in acetone (200mL), the
- 10 resulting solid filtered off and dried *in vacuo* to yield the title product, 5.3g. ¹H NMR (DMSO-D₆, 400MHz) δ: 0.99 (t, 3H), 3.37 (m, 2H), 3.77 (t, 2H), 3.82 (s, 3H), 4.64 (t, 2H). MS ES- m/z 281 [M-H]⁻

Preparation 6

15 Methyl 5,7-dichloro-1-(2-ethoxyethyl)-1H-pyrazolo[4,3-d]pyrimidine-3-carboxylate



- Phosphorous oxychloride (6.5mL, 70mmol) and tetraethylammonium chloride (3.47g, 21mmol) were added to a solution of the dione of preparation 5 (1.97g, 7mmol) in propionitrile (28mL) and the reaction mixture heated under reflux for 4
- 20 hours. Additional phosphorous oxychloride (2.5mL, 26.9mmol) was added and the reaction mixture was then stirred under reflux for 18 hours. The reaction mixture was then concentrated *in vacuo* and the residue partitioned between dichloromethane (300mL) and water (50mL). The organics were separated, dried over magnesium sulphate and concentrated *in vacuo*. The crude product


was purified by column chromatography on silica gel, eluting with ethyl acetate:pentane 0:100 to 25:75 to yield the title product, 1.98g.

^1H NMR (CDCl_3 , 400MHz) δ : 1.03 (t, 3H), 3.40 (m, 2H), 3.87 (t, 2H), 4.06 (s, 3H), 4.98 (t, 2H). MS APCI+ m/z 319 $[\text{MH}]^+$

5

Preparation 7

Methyl 5-chloro-1-(2-ethoxyethyl)-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-
d]pyrimidine-3-carboxylate




10 2-Amino-4-methylpyridine (1.34g, 12.4mmol) was added to a solution of the dichloro compound of preparation 6 (1.98g, 6.2mmol) in dimethyl sulphoxide (10mL) and the reaction stirred at 35°C for 5 hours. The reaction mixture was partitioned between dichloromethane (300mL) and water (500mL). The organics were separated, washed with water (3x100mL), dried over magnesium sulphate
15 and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel, eluting with dichloromethane:acetonitrile 98:2. Appropriate fractions were concentrated *in vacuo*, triturated with ether (50mL), filtered and the solid dried to yield the title product, 1.2g.

^1H NMR (CDCl_3 , 400MHz) δ : 1.06 (t, 3H), 2.49 (s, 3H), 3.62 (m, 2H), 4.00 (t, 2H),
20 4.06 (s, 3H), 5.05 (m, 2H), 6.98 (m, 1H), 8.16 (m, 1H), 8.50 (m, 1H). MS APCI+ m/z 391 $[\text{MH}]^+$

Preparation 8

Methyl 5-chloro-1-(2-ethoxyethyl)-7-(5-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-
d]pyrimidine-3-carboxylate

25




The title product was prepared by a method similar to that described for preparation 7 using the dichloro compound of preparation 6 and 2-amino-5-methylpyridine.

- 5 ^1H NMR (DMSO- D_6 , 400MHz) δ : 1.01 (t, 3H), 2.26 (s, 3H), 3.52 (m, 2H), 3.88 (m, 5H), 4.96 (m, 2H), 7.76 (m, 1H), 8.03 (m, 1H), 8.20 (m, 1H).

MS APCI+ m/z 391 $[\text{MH}]^+$


Preparation 9

- 10 [5,7-Dichloro-1-(2-ethoxyethyl)-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methanol



- The dichloro compound of preparation 6 (2.4g, 7.52mmol) was dissolved in tetrahydrofuran (60mL) and the reaction mixture cooled to -78°C . A 1M solution of diisobutylaluminium hydride in tetrahydrofuran (37.6mL, 37.6mmol) was added dropwise over 10 minutes and the reaction mixture stirred at -78°C for 10 minutes and then at -10°C for 1 hour. The reaction mixture was cooled to -78°C , quenched with ammonium chloride solution (25mL) and allowed to return to room temperature. The reaction mixture was diluted with dichloromethane (200mL) and water (100mL) and the solution filtered through Arbocel®, washing thorough with dichloromethane (3x100mL). The organic phase was separated, dried over magnesium sulphate and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel eluting with dichloromethane:methanol 99:1 to yield the title product, 1.67g.


- 25 ^1H NMR (CDCl_3 , 400MHz) δ : 1.08 (t, 3H), 3.42 (m, 2H), 3.80 (m, 2H), 4.90 (m, 2H), 5.10 (s, 2H). MS APCI+ m/z 291 $[\text{MH}]^+$

Preparation 103-(*tert*-Butyldimethylsilyloxymethyl)-5,7-dichloro-1-(2-ethoxyethyl)-1*H*-pyrazolo[4,3-*d*]pyrimidine

5

The alcohol of preparation 9 (1.32g, 4.53mmol) was dissolved in dichloromethane (25mL) and the solution treated with imidazole (339mg, 4.98mmol) and then *tert*-butyldimethylsilyl chloride (750mg, 4.98mmol). The reaction mixture was stirred at room temperature for 18 hours, diluted with dichloromethane (200mL) and washed with 10% potassium carbonate solution (100mL). The organic phase was dried over sodium sulphate and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel eluting with dichloromethane:methanol 99:1 to yield the title product, 1.56g. ¹H NMR (CDCl₃, 400MHz) δ: 0.00 (s, 6H), 0.78 (s, 9H), 0.93 (t, 3H), 3.29 (q, 2H), 3.71 (t, 2H), 4.72 (m, 2H), 4.94 (s, 2H). MS APCI+ *m/z* 405[MH]⁺

15

Preparation 11*N*-[3-(*tert*-Butyldimethylsilyloxymethyl)-5-chloro-1-(2-ethoxyethyl)-1*H*-pyrazolo[4,3-*d*]pyrimidin-7-yl]pyrimidin-4-ylamine

20

Pyrimidin-4-ylamine (1.10g, 11.55mmol) was dissolved in tetrahydrofuran (30mL) and the solution treated with sodium hexamethyldisilazide (2.12g, 11.55mmol) and stirred at room temperature for 20 minutes. The solution was treated with a solution of the dichloro compound of preparation 10 (1.56g, 3.85mmol) in tetrahydrofuran (10mL) and the reaction mixture stirred for 90 minutes at room

25

temperature. The reaction mixture was quenched with ammonium chloride solution (100mL) and extracted with dichloromethane (200mL). The organic phase was separated, dried over magnesium sulphate and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel

5 eluting with dichloromethane:methanol 97:3 to yield the title product, 830mg.


^1H NMR (CDCl_3 , 400MHz) δ : 0.00 (s, 6H), 0.77 (s, 9H), 1.08 (t, 3H), 3.54 (q, 2H), 3.80 (m, 2H), 4.63 (m, 2H), 4.90 (s, 2H), 8.33 (d, 1H), 8.51 (d, 1H), 8.77 (s, 1H).

MS APCI+ m/z 464 $[\text{MH}]^+$

10

Preparation 12

N-[3-(*tert*-Butyldimethylsilyloxymethyl)-5-chloro-1-(2-ethoxyethyl)-1*H*-pyrazolo[4,3-*d*]pyrimidin-7-yl]pyrazin-2-ylamine



15


The title compound was prepared by a method similar to that described for preparation 11 using the dichloro compound of preparation 10 and aminopyrazine.

^1H NMR (CDCl_3 , 400MHz) δ : 0.18 (s, 6H), 0.93 (s, 9H), 1.21 (t, 3H), 3.65 (m, 2H), 3.97 (m, 2H), 4.80 (m, 2H), 5.06 (m, 2H), 8.30 (m, 2H), 9.77 (m, 1H), 10.17 (m, 1H)

20

Preparation 13

[5-Chloro-1-(2-ethoxyethyl)-7-(pyrimidin-4-ylamino)-1*H*-pyrazolo[4,3-*d*]pyrimidin-3-yl]methanol




The protected alcohol of preparation 11 (2.0g, 1.76mmol) was dissolved in tetrahydrofuran (40mL) and the solution treated with a 1M solution of tetrabutylammonium fluoride in tetrahydrofuran (8.63mL, 8.63mmol). The reaction mixture was stirred for 90 minutes at room temperature and was then treated with additional tetrabutylammonium fluoride solution in tetrahydrofuran (4.32mL, 4.32mmol) and stirred for another hour. The reaction mixture was diluted with water (50mL) and the aqueous extracted with ethyl acetate (3x50mL). The combined organics were dried over magnesium sulphate and concentrated *in vacuo*. The crude product was purified by column chromatography on silica gel eluting with dichloromethane:methanol 99:1 to 95:5 to yield the title product, 1.25g.

^1H NMR (CDCl_3 , 400MHz) δ : 1.26 (t, 3H), 3.70 (q, 2H), 3.97 (m, 2H), 4.76 (m, 2H), 5.10 (s, 2H), 8.51 (d, 1H), 8.72 (d, 1H), 8.99 (s, 1H).

MS APCI+ m/z 350 $[\text{MH}]^+$

Preparation 14

[5-Chloro-1-(2-ethoxyethyl)-7-(pyrazin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methanol




The title compound was prepared by a method similar to that described for preparation 13 using the protected alcohol of preparation 12.

^1H NMR (CDCl_3 , 400MHz) δ : 1.22 (t, 3H), 3.66 (m, 2H) 3.98 (m, 2H), 4.80 (m, 2H), 5.08 (s, 2H), 8.34 (m, 2H), 9.80 (m, 1H), 10.22 (m, 1H)

Preparation 15

[5-Chloro-1-(2-ethoxyethyl)-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methanol




- 5 The ester of preparation 7 (1.89g, 4.84mmol) was suspended in tetrahydrofuran (450mL) and the reaction mixture cooled to -78°C. Diisobutylaluminium hydride (39mL, 1M solution in toluene, 39mmol) was added and the reaction mixture allowed to warm to -5°C. The reaction mixture was stirred at -5°C for 15 minutes before being re-cooled to -78°C and being quenched with aqueous ammonium chloride solution (10mL). The reaction mixture was allowed to warm to room temperature and partitioned between dichloromethane (200mL) and water (200mL). The mixture was filtered through Arbocel® and the organic layer separated, dried over magnesium sulphate and concentrated *in vacuo*. The crude product was triturated with ethyl acetate and the solid filtered off to yield
- 10 the title product.
- 15

¹H NMR (CDCl₃, 400MHz) δ: 1.11 (t, 3H), 2.46 (s, 3H), 3.61 (m, 2H), 3.94 (m, 2H), 4.86 (m, 2H), 5.07 (m, 2H), 6.96 (m, 1H), 8.19 (m, 1H), 8.48 (m, 1H)

MS APCI+ m/z 363 [MH]⁺

Preparation 16

[5-Chloro-1-(2-ethoxyethyl)-7-(5-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methanol




- 5 The title compound was prepared by a method similar to that described for preparation 15 using the ester of preparation 8.

¹H NMR (CD₃OD, 400MHz) δ: 1.12 (t, 3H), 2.34 (s, 3H), 3.61 (q, 2H), 3.89 (m, 2H), 4.69 (m, 2H), 4.77 (s, 2H), 7.63 (d, 1H), 8.15 (s, 1H), 8.36 (d, 1H)

10

Preparation 17

5-Chloro-1-(2-ethoxyethyl)-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbaldehyde



- 15 The alcohol of preparation 15 (90mg, 0.25mmol) was dissolved in dichloromethane (15.5mL) and the solution cooled to 0°C and treated with 1,1,1-triacetoxy-1,1-dihydro-1,2-benziodoxol-3(1H)-one (112mg, 0.93mmol). The reaction mixture was stirred at room temperature for 2 hours and was then treated with saturated sodium thiosulphate solution (13mL), sodium hydrogencarbonate solution (13mL) and ether (13mL). The mixture was allowed to stand for 15 minutes before being extracted into dichloromethane (3x100mL). The organics were combined, dried over magnesium sulphate and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel
- 20


eluting with dichloromethane:methanol 100:0 to 98:2 to yield the title product, 53mg.

^1H NMR (CDCl_3 , 400MHz) δ : 1.10 (m, 3H), 2.40 (s, 3H), 3.62 (m, 2H), 3.99 (t, 2H), 4.85 (m, 2H), 6.90 (d, 1H), 8.20 (d, 1H), 8.40 (m, 1H), 10.35 (m, 1H)

5

Preparation 18


N-[5-Chloro-1-(2-ethoxyethyl)-3-methylaminomethyl-1*H*-pyrazolo[4,3-*d*]pyrimidin-7-yl]-4-methylpyridin-2-ylamine



- 10 The aldehyde of preparation 17 (53mg, 0.15mmol) was dissolved in dichloromethane (2mL) and the solution treated with methylamine hydrochloride (11mg, 0.17mmol) and triethylamine (22 μ L, 0.17mmol). The mixture was stirred at room temperature for 30 minutes and was then treated with additional methylamine hydrochloride (11mg, 0.17mmol) and triethylamine (22 μ L,
- 15 0.17mmol) and stirred for a further 30 minutes. Sodium triacetoxyborohydride (48mg, 0.22mmol) was added to the mixture and the reaction mixture stirred for 18 hours at room temperature. The reaction mixture was concentrated *in vacuo* and the residue partitioned between sodium hydrogencarbonate solution (100mL) and dichloromethane (100mL). The aqueous was extracted with
- 20 dichloromethane (3x10mL) and the organics combined, dried over magnesium sulphate and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:0.88 ammonia 95:5:0 to 90:10:1 to yield the title product, 19mg.

^1H NMR (CDCl_3 , 400MHz) δ : 1.10 (t, 3H), 2.37 (s, 3H), 2.72 (s, 3H), 3.58 (q, 2H), 3.90 (t, 2H), 4.38 (s, 2H), 4.85 (t, 2H), 6.81 (s, 1H), 8.10 (d, 1H), 8.30 (d, 1H)


25 MS APCI+ m/z 376 $[\text{MH}]^+$

Preparation 19*N*-[3-Bromomethyl-5-chloro-1-(2-ethoxyethyl)-1*H*-pyrazolo[4,3-*d*]pyrimidin-7-yl]-4-methylpyridin-2-ylamine

- 5 The alcohol of preparation 15 (560mg, 1.54mmol) was dissolved in dichloromethane (15mL) and the solution treated with tetrabromomethane (614mg, 1.85mmol) and cooled to 0°C in an ice bath. The mixture was treated dropwise with a solution of triphenylphosphine (567mg, 2.16mmol) in dichloromethane (5mL) and the reaction stirred at room temperature for 18
- 10 hours. The reaction mixture was concentrated *in vacuo* and the residue purified by column chromatography on silica gel eluting with dichloromethane:methanol 100:0 to 98:2 to yield the title product, 457mg.

¹H NMR (CDCl₃, 400MHz) δ: 1.13 (t, 3H), 2.49 (s, 3H), 3.63 (q, 2H), 3.94 (t, 2H), 4.81 (s, 2H), 4.98 (t, 2H), 6.95 (s, 1H), 8.18 (d, 1H), 8.50 (d, 1H).

- 15 MS ES+ *m/z* 425 [MH]⁺

Preparation 20*N*-[3-Bromomethyl-5-chloro-1-(2-ethoxyethyl)-1*H*-pyrazolo[4,3-*d*]pyrimidin-7-yl]pyrazin-2-ylamine


20

The title compound was prepared by a method similar to that described for preparation 19 using the alcohol of preparation 14.

^1H NMR (CDCl_3 , 400MHz) δ : 1.12 (t, 3H), 3.64 (q, 2H), 3.94 (t, 2H), 4.81 (s, 2H), 4.98 (t, 2H), 6.95 (s, 1H), 8.16 (d, 1H), 8.46 (d, 1H)

Preparation 21

5 *N*-[5-Chloro-3-(diethylaminomethyl)-1-(2-ethoxyethyl)-1*H*-pyrazolo[4,3-*d*]pyrimidin-7-yl]pyrimidin-4-ylamine




The alcohol of preparation 13 (446mg, 1.28mmol) was dissolved in dichloromethane (30mL) and the solution treated with tetrabromomethane (507mg, 1.53mmol) and triphenylphosphine (401mg, 1.53mmol). The reaction mixture was stirred at room temperature for 2 hours, additional tetrabromomethane (85mg, 0.26mmol) and triphenylphosphine (67mg, 0.26mmol) were added and the reaction mixture stirred for a further 2 hours. The reaction mixture was concentrated *in vacuo* and the residue purified by column chromatography on silica gel eluting with pentane:ethyl acetate 80:20. The crude product was further purified by column chromatography on silica gel once more, eluting with toluene:diethylamine 95:5 to yield the title product, 196mg.

^1H NMR (CDCl_3 , 400MHz) δ : 1.19 (t, 3H), 1.14 (t, 6H), 2.99 (m, 4H), 3.67 (q, 2H), 3.96 (t, 2H), 4.57 (s, 2H), 4.79 (t, 2H), 8.41 (d, 1H), 8.67 (d, 1H), 8.99 (s, 1H)

20 MS ES+ m/z 405 $[\text{MH}]^+$

Preparation 22

N-[5-Chloro-3-chloromethyl-1-(2-ethoxyethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-methylpyridin-2-ylamine



- 5 The alcohol of preparation 15 (1.80g, 5.00mmol) was dissolved in dichloromethane (15mL) and the solution treated with thionyl chloride (1.50mL, 17mmol). The reaction mixture was stirred at room temperature for 18 hours and concentrated *in vacuo*, the residue was azeotroped with toluene and then dried *in vacuo*. The crude product was purified by column chromatography on silica
- 10 gel eluting with dichloromethane:methanol 100:0 to 95:5 to yield the title product, 980mg.


^1H NMR (CDCl_3 , 400MHz) δ : 0.92 (t, 3H), 2.63 (s, 3H), 3.58 (m, 2H), 3.91 (m, 2H), 4.81 (s, 2H), 5.20 (m, 2H), 7.14 (m, 1H), 8.16 (m, 1H), 8.97 (m, 1H)

MS APCI+ m/z 381 $[\text{MH}]^+$

15

Preparation 23

N-[3-Azidomethyl-5-chloro-1-(2-ethoxyethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]-4-methylpyridin-2-ylamine



- 20 The chloro compound of preparation 22 (700mg, 1.80mmol) was dissolved in N,N-dimethylformamide (10mL) and the solution treated with sodium azide (129mg, 1.98mmol). The reaction mixture was stirred at room temperature for 1


hour and then allowed to stand at room temperature for a further 18 hours. The reaction mixture was concentrated *in vacuo* and the residue taken up in water (100mL) and washed with ether (4x20mL). The ether washings were combined, washed with water (20mL), dried over magnesium sulphate and concentrated *in vacuo* to yield the title product, 600mg.

^1H NMR (CDCl_3 , 400MHz) δ : 1.20 (t, 3H), 2.40 (s, 3H), 3.60 (q, 2H), 3.95 (t, 2H), 4.70 (s, 2H), 4.80 (m, 2H), 6.90 (s, 1H), 8.20 (s, 1H), 8.30 (s, 1H), 10.00 (s, 1H)

MS APCI+ m/z 388 $[\text{MH}]^+$

Preparation 24

N-[3-Aminomethyl-5-chloro-1-(2-ethoxyethyl)-1*H*-pyrazolo[4,3-*d*]pyrimidin-7-yl]-4-methylpyridin-2-ylamine




The azide of preparation 23 (130mg, 0.34mmol) was dissolved in tetrahydrofuran (5mL) and the solution treated with triphenylphosphine (92mg, 0.35mmol). The reaction mixture was stirred at room temperature for 2 hours, diluted with water (5mL), and stirred for a further 18 hours. The reaction mixture was concentrated *in vacuo* and the residue taken up in brine and extracted with dichloromethane. The dichloromethane phase was dried over magnesium sulphate and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:ammonium hydroxide 95:5:0.5 to yield the title product, 70mg.

^1H NMR (CDCl_3 , 400MHz) δ : 1.23 (t, 3H), 2.45 (s, 3H), 3.65 (q, 2H), 3.95 (t, 2H), 4.20 (s, 2H), 4.78 (t, 2H), 6.82 (s, 1H), 8.18 (m, 1H), 8.30 (m, 1H). MS APCI+

m/z 362 $[\text{MH}]^+$

Preparation 25

N-[5-Chloro-1-(2-ethoxyethyl)-7-(4-methylpyridin-2-ylamino)-1*H*-pyrazolo[4,3-*d*]pyrimidin-3-ylmethyl]methanesulfonamide




- 5 The amine of preparation 24 (150mg, 0.40mmol) was dissolved in dichloromethane (5mL) and the solution treated with *N*-ethyldiisopropylamine (108μL, 0.62mmol) and methanesulfonyl chloride (34μL, 0.44mmol). The reaction mixture was stirred at room temperature for 18 hours before being concentrated *in vacuo*. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol 100:0 to 98:2 to yield the title product, 110mg.

¹H NMR (CD₃OD, 400MHz) δ: 1.10 (t, 3H), 2.40 (s, 3H), 3.00 (s, 3H), 3.60 (q, 2H), 3.90 (t, 2H), 4.50 (s, 2H), 4.70 (t, 2H), 6.90 (d, 1H), 8.15 (d, 1H), 8.40 (s, 1H).

- 15 MS APCI+ *m/z* 438 [M-H]⁺

Preparation 26

N-[5-Chloro-1-(2-ethoxyethyl)-7-(4-methylpyridin-2-ylamino)-1*H*-pyrazolo[4,3-*d*]pyrimidin-3-ylmethyl]-2-hydroxyacetamide




The amine of preparation 24 (50mg, 0.14mmol) was dissolved in dichloromethane (5mL) and the solution treated with glycolic acid (11mg, 0.14mmol), N-ethyldiisopropylamine (36 μ L, 0.21mmol) and O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (57mg, 0.15mmol). The reaction mixture was then stirred at room temperature for 18 hours. The reaction mixture was diluted with dichloromethane (20mL), washed with water (10mL), dried over magnesium sulphate and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol 98:2 to yield the title product, 50mg.

^1H NMR (CDCl_3 , 400MHz) δ : 1.20 (t, 3H), 2.40 (s, 3H), 3.60 (m, 2H), 3.90 (t, 2H), 4.20 (s, 2H), 4.75 (m, 2H), 4.80 (d, 2H), 6.85 (m, 1H), 7.60 (m, 1H), 8.20 (m, 1H), 8.30 (m, 1H), 10.10 (m, 1H). MS APCI+ m/z 420 $[\text{MH}]^+$

Preparation 27

N-[5-Chloro-1-(2-ethoxyethyl)-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-3-ylmethyl]-2-(dimethylamino)acetamide




The title product was prepared by a method similar to that described for preparation 26 using N,N-dimethylaminoacetic acid and the amine of preparation 24. The crude product was purified by column chromatography on silica gel eluting with dichloromethane:methanol:ammonium hydroxide 98:2:0.5.

^1H NMR (CDCl_3 , 400MHz) δ : 1.20 (t, 3H), 2.39 (s, 6H), 2.40 (s, 3H), 3.10 (s, 2H), 3.60 (q, 2H), 3.90 (t, 2H), 4.75 (m, 2H), 4.80 (d, 2H), 6.85 (m, 1H), 7.90 (m, 1H), 8.20 (m, 1H), 8.35 (m, 1H), 10.00 (m, 1H). MS APCI+ m/z 447 $[\text{MH}]^+$

Preparation 28

N-[5-Chloro-1-(2-ethoxyethyl)-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-3-ylmethyl]acetamide




- 5 The amine of preparation 24 (70mg, 0.19mmol) was dissolved in dichloromethane (5mL) and the solution treated with acetyl chloride (16μL, 0.23mmol) and N-ethyldiisopropylamine (40μL, 0.23mmol). The reaction mixture was stirred at room temperature for 1 hour and then concentrated *in vacuo*. The residue was taken up in methanol and treated dropwise with dichloromethane
- 10 until all solid was in solution. The solution was treated with 2M sodium hydroxide solution (500μL) and then stirred at room temperature for 30 minutes. The solution was concentrated *in vacuo* and the residue taken up in water (5mL) and washed with dichloromethane (3x10mL). The organics were combined, dried over magnesium sulphate and concentrated *in vacuo*. The residue was purified
- 15 by column chromatography on silica gel eluting with dichloromethane:methanol 98:2 to yield the title product, 50mg.

¹H NMR (CDCl₃, 400MHz) δ: 1.18 (t, 3H), 2.20 (s, 3H), 2.40 (s, 3H), 3.65 (q, 2H), 3.95 (t, 2H), 4.75 (m, 2H), 4.80 (t, 2H), 6.50 (m, 1H), 6.85 (m, 1H), 8.20 (m, 1H), 8.30 (s, 1H), 10.00 (s, 1H). MS APCI+ m/z 404 [MH]⁺

Preparation 29

N-[5-Chloro-1-(2-ethoxyethyl)-7-(4-methylpyridin-2-ylamino)-1*H*-pyrazolo[4,3-*d*]pyrimidin-3-ylmethyl]propionamide




- 5 The title product was prepared by a method similar to that described for preparation 28 using propionyl chloride and the amine of preparation 24. ¹H NMR (CDCl₃, 400MHz) δ: 1.20 (t, 6H), 2.30 (m, 2H), 2.40 (s, 3H), 3.60 (q, 2H), 3.90 (t, 2H), 4.75 (t, 2H), 4.80 (d, 2H), 6.60 (m, 1H), 6.90 (d, 1H), 8.20 (d, 1H), 8.30 (s, 1H), 10.10 (s, 1H). MS ES+ m/z 418 [MH]⁺

10

Preparation 30

N-[5-Chloro-1-(2-ethoxyethyl)-7-(4-methylpyridin-2-ylamino)-1*H*-pyrazolo[4,3-*d*]pyrimidin-3-ylmethyl]-*N*-methylacetamide




15

The title product was prepared by a method similar to that described for preparation 28 using the amine of preparation 18 and acetyl chloride.

- ¹H NMR (CDCl₃, 400MHz) δ: Rotamers 1.20 (t, 3H), 2.15 (m, 1H), 2.40 (s, 2H), 2.45 (s, 3H), 3.05, 3.15 (2xs, 3H), 3.65 (q, 2H), 4.70 (t, 2H), 4.80 (m, 3H), 4.90 (s, 1H), 6.85 (t, 1H), 8.20 (m, 1H), 8.30 (s, 1H), 10.00 (s, 1H).

20

MS ES+ m/z 418 [MH]⁺

Preparation 31N-[5-Chloro-3-chloromethyl-1-(2-ethoxyethyl)-1H-pyrazolo[4,3-d]pyrimidin-7-yl]pyrimidin-4-ylamine

5


The alcohol of preparation 13 (1.35g, 3.86mmol) was dissolved in dichloromethane (10mL) and the solution treated dropwise with thionyl chloride (1.13mL, 15.44mmol). The reaction mixture was stirred at room temperature for 18 hours and then concentrated *in vacuo*. The residue was azeotroped with

10 toluene to yield the title product, 1.44g.

¹H NMR (CD₃OD, 400MHz) δ : 1.24 (t, 3H), 3.72 (q, 2H), 4.00 (t, 2H), 4.90 (t, 2H), 4.99 (s, 2H), 8.68 (m, 1H), 8.86 (m, 1H), 9.22 (m, 1H). MS APCI+ m/z 368 [MH]⁺

Preparation 32

15 N-[5-Chloro-1-(2-ethoxyethyl)-3-methylaminomethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl]pyrimidin-4-ylamine




20 The chloro compound of preparation 31 (770mg, 2.09mmol) and N-ethyl-diisopropylamine (400 μ L, 2.30mmol) were dissolved in N,N-dimethylformamide (10mL) and the solution treated with a 33% solution of methylamine in ethanol (6mL, 42.0mmol). The reaction mixture was stirred at room temperature for 3 hours and then concentrated *in vacuo*. The residue was

purified by column chromatography on silica gel eluting with dichloromethane:methanol:0.88 ammonia 95:5:0 to 95:5:0.5 to 90:10:1 to yield the title product, 560mg.

^1H NMR (CD_3OD , 400MHz) δ : 1.17 (t, 3H), 2.52 (s, 3H), 3.65 (q, 2H), 3.95 (t, 2H), 4.13 (s, 2H), 4.87 (m, 2H), 8.36 (dd, 1H), 8.65 (d, 1H), 8.84 (s, 1H)
MS APCI+ m/z 363 $[\text{MH}]^+$

Preparation 33

N-[5-Chloro-1-(2-ethoxyethyl)-3-methylaminomethyl-1*H*-pyrazolo[4,3-*d*]pyrimidin-7-yl]pyrazin-2-ylamine




The bromo compound of preparation 20 (109mg, 0.26mmol) and a 33% solution of methylamine in ethanol (490 μL , 5.2mmol) were added to 1-methyl-2-pyrrolidinone (1mL) and the reaction mixture heated to 35°C for 1 hour. The reaction mixture was concentrated *in vacuo* to yield the title product.

MS APCI+ m/z 363 $[\text{MH}]^+$

Preparation 34

N-[5-Chloro-1-(2-ethoxyethyl)-7-(pyrimidin-4-ylamino)-1*H*-pyrazolo[4,3-*d*]pyrimidin-3-ylmethyl]-*N*-methylacetamide




The amine of preparation 32 (530mg, 1.45mmol) and N-ethyldiisopropylamine (280 μ L, 1.59mmol) were dissolved in dichloromethane (15mL) and the solution treated with acetyl chloride (114 μ L, 1.59mmol). The reaction mixture was stirred at room temperature for 45 minutes and then concentrated *in vacuo*. The residue was dissolved in methanol (15mL), treated with 2M sodium hydroxide solution (5mL) and allowed to stand at room temperature for 1 hour. The mixture was concentrated *in vacuo* and the residue purified by column chromatography on silica gel eluting with dichloromethane:methanol 100:0 to 96:4 to yield the title product, 495mg.

¹H NMR (CD₃OD, 400MHz) δ : Rotamers 1.20 (t, 3H), 2.16, 2.38 (2xs, 3H), 2.99, 3.18 (2xs, 3H), 3.67 (m, 2H), 3.95 (q, 2H), 4.75-4.91 (m, 4H), 8.43 (d, 1H), 8.67 (dd, 1H), 8.86 (s, 1H). MS APCI+ m/z 405 [MH]⁺

Preparation 35

tert-Butyl N-[5-chloro-1-(2-ethoxyethyl)-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-3-ylmethyl]-N-methylcarbamate




The amine of preparation 18 (157mg, 0.42mmol) was dissolved in dichloromethane (10mL) and the solution treated with di-*tert*-butyldicarbonate (129mg, 0.59mmol). The reaction mixture stirred at room temperature for 1 hour and concentrated *in vacuo* to yield the title product, 200mg.

¹H NMR (CD₃OD, 400MHz) δ : 1.10 (t, 3H), 1.52 (s, 9H), 2.42 (s, 3H), 2.96 (s, 3H), 3.60 (q, 2H), 3.94 (t, 2H), 4.75 (s, 2H), 4.82 (t, 2H), 7.00 (d, 1H), 8.18 (m, 1H), 8.36 (m, 1H). MS APCI+ m/z 476 [MH]⁺

Preparation 36


[5-Dimethylamino-1-(2-ethoxyethyl)-7-(4-methylpyridin-2-ylamino)-1*H*-pyrazolo[4,3-*d*]pyrimidin-3-yl]methanol



- 5 The chloro compound of preparation 15 (780mg, 2.15mmol) and N-ethyl-diisopropylamine (1.125mL, 6.46mmol) were dissolved in dimethyl sulphoxide (6mL) and the mixture treated with a 5.6M solution of dimethylamine in ethanol (1.15mL, 6.46mmol) and heated to 120°C for 18 hours in a sealed vessel. The reaction mixture was partitioned between dichloromethane (100mL) and water (100mL) and the organic phase separated and washed with water (3x200mL). The organic phase was dried over magnesium sulphate and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol 100:0 to 98:2. The product was triturated with ether to yield the title product, 230mg.
- 10
- 15 ¹H NMR (CD₃OD, 400MHz) δ: 1.07 (t, 3H), 2.38 (s, 3H), 3.20 (s, 6H), 3.60 (q, 2H), 3.85 (t, 2H), 4.65 (t, 2H), 4.80 (s, 2H), 6.90 (d, 1H), 8.12 (d, 1H), 8.39 (s, 1H)
- MS APCI+ m/z 372 [MH]⁺

Preparation 37

[5-Dimethylamino-1-(2-ethoxyethyl)-7-(5-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methanol




- 5 The title product was prepared by a method similar to that described for preparation 36 using the chloro compound of preparation 16.

^1H NMR (CD_3OD , 400MHz) δ : 1.12 (t, 3H), 2.33 (s, 3H), 3.20 (s, 6H), 3.59 (q, 2H), 3.85 (m, 2H), 4.71 (m, 2H), 4.81 (s, 2H), 7.62 (d, 1H), 8.13 (s, 1H), 8.38 (d, 1H)

- 10 MS APCI+ m/z 372 $[\text{MH}]^+$

Preparation 38

[5-Dimethylamino-1-(2-ethoxyethyl)-7-(pyrimidin-4-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-3-yl]methanol




15


The title product was prepared by a method similar to that described for preparation 36 using the chloro compound of preparation 1.

^1H NMR (CD_3OD , 400MHz) δ : 1.21 (t, 3H), 3.30 (s, 6H), 3.66 (q, 2H), 3.92 (t, 2H), 4.69 (t, 2H), 4.83 (s, 2H), 8.39 (d, 1H), 8.58 (d, 1H), 8.79 (s, 1H)

- 20 MS APCI+ m/z 359 $[\text{MH}]^+$

Preparation 395-Dimethylamino-1-(2-ethoxyethyl)-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbaldehyde

- 5 The alcohol of preparation 36 (330mg, 0.89mmol) was dissolved in dichloromethane (15.5mL) and the solution cooled to 0°C and treated with 1,1,1-triacetoxy-1,1-dihydro-1,2-benziodoxol-3(1H)-one (394mg, 0.93mmol). The reaction mixture was stirred at room temperature for 2 hours and was then treated with saturated sodium thiosulphate solution (13mL), sodium
- 10 hydrogencarbonate solution (13mL) and ether (13mL). The mixture was allowed to stand for 15 minutes before being extracted into dichloromethane (3x100mL). The organics were combined, dried over magnesium sulphate and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol 100:0 to 98:2 to yield the title product,
- 15 300mg.
- ¹H NMR (CDCl₃, 400MHz) δ: 1.10 (m, 3H), 2.40 (s, 3H), 3.30 (s, 6H), 3.62 (m, 2H), 3.99 (t, 2H), 4.85 (m, 2H), 6.90 (d, 1H), 8.20 (d, 1H), 8.40 (m, 1H), 10.35 (s, 1H). MS APCI+ m/z 370 [MH]⁺

Preparation 405-Dimethylamino-1-(2-ethoxyethyl)-7-(5-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbaldehyde


- 5 The title product was prepared by a method similar to that described for preparation 39 using the alcohol of preparation 37.

^1H NMR (CD_3OD , 400MHz) δ : 1.11 (t, 3H), 2.34 (s, 3H), 3.24 (s, 6H), 3.61 (q, 2H), 3.97 (m, 2H), 4.80 (m, 2H), 7.63 (d, 1H), 8.13 (s, 1H), 8.31 (d, 1H), 10.10 (s, 1H).

- 10 MS APCI+ m/z 370 $[\text{MH}]^+$

Preparation 415-Dimethylamino-1-(2-ethoxyethyl)-7-(pyrimidin-4-ylamino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbaldehyde

15




The title product was prepared by a method similar to that described for preparation 39 using the alcohol of preparation 38.

- 20 ^1H NMR (CD_3OD , 400MHz) δ : 1.21 (t, 3H), 3.25 (s, 6H), 3.62 (q, 2H), 4.00 (t, 2H), 4.83 (t, 2H), 8.35 (d, 1H), 8.59 (d, 1H), 8.82 (s, 1H). MS APCI+ m/z 357 $[\text{MH}]^+$

Preparation 42

tert-Butyl 4-[5-dimethylamino-1-(2-ethoxyethyl)-7-(4-methylpyridin-2-ylamino)-1*H*-pyrazolo[4,3-*d*]pyrimidin-3-ylmethyl]piperazine-1-carboxylate



5

The aldehyde of preparation 39 (75mg, 0.20mmol) was dissolved in dichloromethane (5mL) and the solution treated with sodium triacetoxymethylborohydride (52mg, 0.24mmol) and piperazine-1-carboxylic acid *tert*-butyl ester (45mg, 0.24mmol). The reaction mixture was shaken in a ReactiVial™ for 2 hours at room temperature and then treated with saturated sodium bicarbonate solution (8mL). The mixture was extracted into dichloromethane (3x15mL) and the organics combined and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol 100:0 to 97.5:2.5 to yield the title product, 80mg.


15 ¹H NMR (CD₃OD, 400MHz) δ : 1.10 (t, 3H), 1.42 (s, 9H), 2.38 (s, 3H), 2.59 (m, 4H), 3.20 (s, 6H), 3.40 (m, 4H), 3.58 (q, 2H), 3.80 (s, 2H), 3.81 (t, 2H), 4.65 (m, 2H), 4.85 (d, 1H), 6.88 (d, 1H), 8.10 (d, 1H), 8.40 (s, 1H).

MS APCI+ m/z 538 [MH]⁺

20

Preparation 43

tert-Butyl (3*R*)-3-methoxypyrrolidine-1-carboxylate




(3*R*)-3-Hydroxy-pyrrolidine-1-carboxylic acid *tert*-butyl ester (12.5g, 66.70mmol) was dissolved in tetrahydrofuran (334mL), and the reaction mixture cooled to 0°C in an ice bath. The reaction mixture was treated with 80% sodium hydride in mineral oil (2.20g, 73.3mmol) and stirred until back at room temperature. The reaction mixture was then treated with methyl iodide (14.5g, 100.0mmol) and stirred at room temperature for 18 hours. The reaction mixture was diluted with water (100mL) and concentrated *in vacuo* until just the aqueous remained. The aqueous solution was extracted with ethyl acetate (750mL), the organic layer separated, dried over magnesium sulphate and concentrated *in vacuo* to yield the title product as a brown oil, 12.48g.

¹H NMR (CDCl₃, 400MHz) δ: 1.41 (s, 9H), 1.95 (m, 2H), 3.30 (s, 3H), 3.40 (m, 4H), 3.86 (m, 1H)

Preparation 44

tert-Butyl (3*S*)-3-methoxypyrrolidine-1-carboxylate




The title product was prepared by a method similar to that described for preparation 43 using (3*S*)-3-hydroxy-pyrrolidine-1-carboxylic acid *tert*-butyl ester.

¹H NMR (CDCl₃, 400MHz) δ: 1.41 (s, 9H), 1.95 (m, 2H), 3.30 (s, 3H), 3.40 (m, 4H), 3.86 (m, 1H)

Preparation 45

(3*R*)-3-Methoxypyrrolidine hydrochloride




Hydrogen chloride gas was bubbled through an ice-cooled solution of the compound from preparation 43 (6.02g, 30.0mmol) in dichloromethane (30mL),

and the reaction then allowed to warm to room temperature and stirred for 48 hours. The solution was concentrated under reduced pressure and the residue triturated with ether. The resulting crystals were filtered off and dried *in vacuo* to afford the title compound.

- 5 ^1H NMR (CD_3OD , 400MHz) δ : 2.06 (m, 1H), 2.20 (m, 1H), 3.26-3.42 (m, 7H), 4.17 (m, 1H).

Preparation 46

(3S)-3-Methoxypyrrolidine hydrochloride




10 The title compound was obtained from the compound from preparation 44, following a similar method to that described in preparation 45.

^1H NMR (CD_3OD , 400MHz) δ : 2.14 (m, 1H), 2.20 (m, 1H), 3.24-3.44 (m, 7H), 4.18 (m, 1H).

Example 1

2-Dimethylamino-N-[5-dimethylamino-1-(2-ethoxyethyl)-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-3-ylmethyl]acetamide



The chloro compound of preparation 27 (50mg, 0.11mmol) was dissolved in dimethyl sulfoxide (2mL) and the solution treated with N-ethyldiisopropylamine (22 μL , 0.12mmol) and a 33% solution of dimethylamine in ethanol (160 μL ,

- 25 1.10mmol). The reaction mixture was heated to 100°C in a ReactiVial™ for 18

hours and then partitioned between water (20mL) and ethyl acetate (20mL) and the aqueous washed with ethyl acetate (2x20mL). The organics were combined, washed with water (10mL), dried over magnesium sulphate and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:ammonium hydroxide 98:2:0.5 to yield the title product 32mg.


^1H NMR (CD_3OD , 400MHz) δ : 1.10 (t, 3H), 2.30 (s, 6H), 2.40 (s, 3H), 3.00 (s, 2H), 3.25 (s, 6H), 3.60 (q, 2H), 3.90 (t, 2H), 4.70 (m, 4H), 6.90 (d, 1H), 8.10 (d, 1H), 8.40 (s, 1H). MS APCI+ m/z 456 $[\text{MH}]^+$

10

Examples 2 - 15

The following compounds, of the general formula shown below, were prepared by a method similar to that described for example 1 using the appropriate chloro compound of preparations 18, 25, 26, 28, 29 and 30, and the appropriate HNR^3R^4 amine.


15



No.	$-\text{NR}^3\text{R}^4$	R^{15}	Data
2	$-\text{N}(\text{CH}_3)_2$	CH_3SO_2-	^1H NMR (CD_3OD , 400MHz) δ : 1.10 (t, 3H), 2.40 (s, 3H), 3.00 (s, 3H), 3.20 (s, 6H), 3.60 (q, 2H), 3.90 (t, 2H), 4.50 (s, 2H), 4.70 (t, 2H), 6.90 (d, 1H), 8.15 (d, 1H), 8.40 (s, 1H). MS APCI+ m/z 449 $[\text{MH}]^+$

3	-NHCH ₂ CH ₃	CH ₃ SO ₂ -	¹ H NMR (CD ₃ OD, 400MHz) δ: 1.10 (t, 3H), 1.30 (t, 3H), 2.40 (s, 3H), 2.90 (s, 3H), 3.50 (q, 2H), 3.60 (q, 2H), 3.90 (t, 2H), 4.50 (s, 2H), 4.70 (m, 1H), 4.85 (m, 2H), 6.90 (d, 1H), 8.10 (d, 1H). MS APCI+ m/z 449 [MH] ⁺
4	-N(CH ₃) ₂	HOCH ₂ C(O)-	¹ H NMR (CD ₃ OD, 400MHz) δ: 1.10 (t, 3H), 2.40 (s, 3H), 3.20 (s, 6H), 3.60 (q, 2H), 3.90 (t, 2H), 4.05 (s, 2H), 4.70 (m, 4H), 6.90 (m, 1H), 8.15 (d, 1H), 8.40 (s, 1H). MS APCI+ m/z 429 [MH] ⁺
5	-NHCH ₂ CH ₃	HOCH ₂ C(O)-	¹ H NMR (CD ₃ OD, 400MHz) δ: 1.10 (t, 3H), 1.30 (t, 3H), 2.40 (s, 3H), 3.50 (q, 2H), 3.60 (q, 2H), 3.85 (t, 2H), 4.00 (s, 2H), 4.60 (s, 4H), 6.90 (s, 1H), 8.15 (d, 1H), 8.45 (s, 1H). MS ES+ m/z 429 [MH] ⁺
6	-N(CH ₃) ₂	CH ₃ C(O)-	¹ H NMR (CD ₃ OD, 400MHz) δ: 1.20 (t, 3H), 2.10 (s, 3H), 2.40 (s, 3H), 3.20 (s, 6H), 3.60 (q, 2H), 3.90 (t, 2H), 4.60 (t, 2H), 4.80 (d, 2H), 6.80 (d, 1H), 7.50 (m, 1H), 8.20 (s, 1H), 8.35 (s, 1H), 9.70 (s, 1H). MS ES+ m/z 413 [MH] ⁺
7	-NHCH ₃	CH ₃ C(O)-	¹ H NMR (CD ₃ OD, 400MHz) δ: 1.20 (t, 3H), 2.10 (s, 3H), 2.40 (s, 3H), 3.10 (s, 3H), 3.60 (q, 2H), 3.90 (t, 2H), 4.60 (t, 2H), 4.70 (d, 2H), 4.90 (m, 1H), 6.80 (d, 1H), 7.30 (m, 1H), 8.18 (d, 1H), 8.30 (s, 1H), 9.75 (s, 1H). MS ES+ m/z 399.8 [MH] ⁺

8	-NHCH ₂ CH ₃	CH ₃ C(O)-	¹ H NMR (CD ₃ OD, 400MHz) δ: 1.20 (t, 3H), 1.30 (t, 3H), 2.10 (s, 3H), 2.40 (s, 3H), 3.50 (q, 2H), 3.60 (q, 2H), 3.90 (t, 2H), 4.60 (t, 2H), 4.75 (d, 2H), 4.80 (m, 1H), 6.80 (d, 1H), 8.20 (d, 1H), 8.30 (s, 1H), 9.75 (s, 1H). MS ES+ m/z 413 [MH] ⁺
9	-N(CH ₃) ₂	CH ₃ CH ₂ C(O)-	¹ H NMR (CD ₃ OD, 400MHz) δ: 1.19 (t, 3H), 1.20 (t, 3H), 2.30 (q, 2H), 2.40 (s, 3H), 3.20 (s, 6H), 3.60 (q, 2H), 3.90 (t, 2H), 4.60 (t, 2H), 4.80 (d, 2H), 6.80 (d, 1H), 7.60 (m, 1H), 8.20 (d, 1H), 8.40 (s, 1H), 9.70 (m, 1H). MS ES+ m/z 427 [MH] ⁺
10	-NHCH ₃	CH ₃ CH ₂ C(O)-	¹ H NMR (CDCl ₃ , 400MHz) δ: 1.95 (t, 3H), 2.20 (t, 3H), 2.30 (q, 2H), 2.40 (s, 3H), 3.10 (d, 3H), 3.60 (q, 2H), 3.90 (t, 2H), 4.60 (t, 2H), 4.75 (d, 2H), 4.80 (m, 1H), 6.80 (d, 1H), 7.30 (m, 1H), 8.20 (d, 1H), 8.30 (s, 1H), 9.75 (s, 1H). MS ES+ m/z 413 [MH] ⁺
11	-NHCH ₂ CH ₃	CH ₃ CH ₂ C(O)-	¹ H NMR (CDCl ₃ , 400MHz) δ: 1.03 (t, 3H), 1.20 (t, 3H), 1.30 (t, 3H), 2.30 (q, 2H), 2.40 (s, 3H), 3.50 (q, 2H), 3.60 (q, 2H), 3.90 (t, 2H), 4.60 (t, 2H), 4.75 (d, 2H), 4.80 (t, 1H), 6.80 (d, 1H), 8.15 (d, 1H), 8.25 (s, 1H), 9.70 (s, 1H). MS ES+ m/z 427 [MH] ⁺
12	-N(CH ₃) ₂	CH ₃ -	¹ H NMR (CDCl ₃ , 400MHz) δ: 1.20 (t, 3H), 2.38 (s, 3H), 2.72 (s, 3H), 3.22 (s, 6H), 3.63 (m, 2H), 3.91 (m, 2H), 4.43 (s, 2H), 4.68 (m, 2H), 6.83 (m, 1H), 8.18 (m, 1H). MS APCI+ m/z 385 [MH] ⁺




No.	-NR ³ R ⁴	Data
13	-N(CH ₃) ₂	¹ H NMR (CDCl ₃ , 400MHz) δ: Rotamers 1.20 (t, 3H), 2.15 (s, 0.5H), 2.40 (s, 3H), 2.50 (s, 2.5H), 3.00 (s, 2.5H), 3.10 (s, 0.5H), 3.20 (s, 6H), 3.60 (q, 2H), 3.90 (t, 2H), 4.60 (s, 1.5H, t, 2H), 4.80 (s, 0.5H), 6.80 (t, 1H), 8.20 (d, 1H), 8.35 (s, 1H), 9.60 (s, 1H). MS ES+ m/z 427 [MH] ⁺
14	-NHCH ₃	¹ H NMR (CDCl ₃ , 400MHz) δ: Rotamers 1.20 (t, 3H), 2.15 (s, 1H), 2.40 (s, 3H), 2.50 (s, 2H), 3.10 (s, 6H), 3.60 (q, 2H), 3.90 (t, 2H), 4.65 (t, 2H), 4.75, 4.85 (2xs, 2H), 4.90 (q, 1H), 6.80 (d, 1H), 8.15 (d, 1H), 8.25, 8.30 (2xs, 1H), 9.65, 9.70 (2xs, 1H). MS ES+ m/z 413 [MH] ⁺
15	-NHCH ₂ CH ₃	¹ H NMR (CDCl ₃ , 400MHz) δ: Rotamers 1.20 (t, 3H), 1.25 (t, 3H), 2.10, 2.45 (2xs, 3H), 2.40 (s, 3H), 3.00, 3.10 (2xs, 3H), 3.50 (q, 2H), 3.60 (q, 2H), 3.90 (t, 2H), 4.60, 4.85 (2xs, 4H), 4.80 (m, 1H), 6.80 (s, 1H), 8.20 (d, 1H), 8.25, 8.30 (2xs 1H), 9.60, 9.65 (2xs, 1H). MS ES+ m/z 427 [MH] ⁺

- Examples 3, 5, 8, 11 and 15 used a 2M solution of ethylamine in methanol as the source of the HNR³R⁴ amine
- Examples 2, 4, 6, 9, 12 and 13 used 33% solutions of dimethylamine in ethanol as the source of the HNR³R⁴ amine
- Examples 7, 10 and 14 used 2M solutions of methylamine in methanol as the HNR³R⁴ amine

Example 16

N-[5-Dimethylamino-1-(2-ethoxyethyl)-7-(pyrimidin-4-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-3-ylmethyl]-N-methylacetamide




- 5 The title product was prepared by a method similar to that described for example 1 using the chloro compound of preparation 34 and a 33% solution of dimethylamine in ethanol.

¹H NMR (CD₃OD, 400MHz) δ: Rotamers 1.22 (t, 3H), 2.15, 2.47 (2xs, 3H), 2.97, 3.16 (2xs, 3H), 3.21 (s, 3H), 3.22 (s, 3H), 3.65 (q, 2H), 3.90 (m, 2H), 4.68 (m, 2H), 4.77, 4.84 (2xs, 2H), 8.37 (d, 1H), 8.56 (d, 1H), 8.78 (d, 1H).

MS APCI+ m/z 414 [MH]⁺

Example 17

15 1-(2-ethoxyethyl)-N⁵,N⁶-dimethyl-3-(methylaminomethyl)-N⁷-(pyrazin-2-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine hydrochloride



- A mixture of the chloride from preparation 33 (109mg, 0.3mmol), dimethylamine (33% in ethanol, 0.27ml, 1.5mmol) and N,N-diisopropylethylamine (0.26ml, 1.5mmol) in 1-methyl-2-pyrrolidinone (1mL) was heated at 120°C for 18 hours in a ReactiVial™. The cooled mixture was evaporated *in vacuo* and the residue purified by column chromatography on silica gel using

dichloromethane:methanol:ammonium hydroxide (98:2:0.2) as eluant. The product was dissolved in dichloromethane, 2M hydrogen chloride in ether (0.037mL, 0.074mmol) added and the solution evaporated *in vacuo* to afford the title compound, 23mg.


- 5 ^1H NMR (CD_3OD , 400MHz) δ : 1.20 (t, 3H), 2.62 (s, 3H), 3.23 (s, 6H), 3.66 (q, 2H), 3.92 (t, 2H), 4.19 (s, 2H), 4.73 (t, 2H), 7.04 (s, 1H), 8.24 (d, 1H), 8.38 (d, 1H)

MS APCI+ m/z 372 $[\text{MH}]^+$

10

Example 18

1-(2-Ethoxyethyl)- N^5,N^5 -dimethyl-3-[(4-methylpiperazin-1-yl)methyl]- N^7 -(4-methylpyridin-2-yl)-1*H*-pyrazolo[4,3-*d*]pyrimidine-5,7-diamine hydrochloride



- The aldehyde of preparation 39 (75mg, 0.2mmol), sodium triacetoxyborohydride (52mg, 0.24mmol) and 1-methylpiperazine (73mg, 0.73mmol) were dissolved in dichloromethane (15mL). The reaction mixture was stirred at room temperature for 2 hours and was then treated with sodium bicarbonate solution (8mL) and extracted with dichloromethane (3x15mL). The organics were combined, concentrated *in vacuo* and the residue purified by column chromatography on silica gel eluting with dichloromethane:methanol 100:0 to 90:10. The product was treated with 2M hydrogen chloride in ether (0.1mL), the mixture concentrated and the product dried *in vacuo*, to afford the title compound as a yellow crystalline solid, 29.6mg.


- 25 ^1H NMR (D_2O , 400MHz) δ : 0.80 (t, 3H), 2.30 (s, 3H), 2.50 (br m, 2H), 2.72 (s, 3H), 3.00 (br m, 4H), 3.06 (s, 6H), 3.38 (m, 4H), 3.80 (m, 4H), 4.75 (t, 2H), 7.00 (d, 1H), 7.55 (s, 1H), 7.84 (d, 1H).

MS APCI+ m/z 454 $[\text{MH}]^+$




Examples 19 - 27

The following compounds, of the general formula shown below, were prepared by a method similar to that described for example 18 using the appropriate


- 5 HNR¹⁵R¹⁶ amine and the appropriate aldehyde of preparations 39 and 40.



No.	NR ¹⁵ R ¹⁶	Data
19		¹ H NMR (D ₂ O, 400MHz) δ: 0.65 (t, 3H), 1.72 (m, 1H), 1.85 (m, 2H), 2.08 (m, 1H), 2.15 (s, 3H), 2.94 (s, 6H), 3.08 (s, 3H), 3.24 (m, 1H), 3.35 (m, 2H), 3.40 (m, 3H), 3.75 (m, 3H), 4.45 (m, 2H), 4.58 (m, 2H), 6.82 (d, 1H), 7.70 (m, 1H), 7.90 (d, 1H). MS APCI+ m/z 469 [MH] ⁺
20		¹ H NMR (D ₂ O, 400MHz) δ: 0.75 (t, 3H), 1.70-2.08 (m, 3H), 2.18 (s, 3H), 2.59 (s, 6H), 3.10 (s, 3H), 3.20-3.47 (m, 6H), 3.77 (m, 3H), 4.40-4.70 (m, 5H), 6.62 (d, 1H), 7.70 (m, 1H), 7.90 (d, 1H). MS APCI+ m/z 469 [MH] ⁺
21		¹ H NMR (D ₂ O, 400MHz) δ: 0.82 (t, 3H), 2.10 (m, 2H), 2.35 (s, 3H), 3.10 (s, 6H), 3.18 (s, 3H), 3.40-3.50 (m, 6H), 3.85 (t, 2H), 4.15 (m, 1H), 4.60 (m, 2H), 4.80 (m, 2H), 7.05 (d, 1H), 7.59 (s, 1H), 7.99 (d, 1H). MS APCI+ m/z 455 [MH] ⁺
22		¹ H NMR (D ₂ O, 400MHz) δ: 0.82 (t, 3H), 2.35 (s, 3H), 3.10 (s, 6H), 3.18 (s, 3H), 3.40-3.50 (m, 6H), 3.80 (t, 2H), 4.15 (m, 1H), 4.61 (m, 2H), 4.82 (m, 2H), 7.10 (d, 1H), 7.59 (s, 1H), 7.99 (d, 1H). MS APCI+ m/z 455 [MH] ⁺


23	$(\text{CH}_3)_2\text{CHNH}-$	$^1\text{H NMR (D}_2\text{O, 400MHz) } \delta$: 0.83 (t, 3H), 1.27 (d, 6H), 2.26 (s, 3H), 3.06 (s, 6H), 3.41 (m, 3H), 3.80 (t, 2H), 4.36 (s, 2H), 4.69 (m, 2H), 6.94 (d, 1H), 7.61 (m, 1H), 7.93 (d, 1H). MS APCI+ m/z 427 $[\text{MH}]^+$ CHECK THIS
24	$\text{CH}_3(\text{CH}_2)_2\text{NH}-$	$^1\text{H NMR (D}_2\text{O, 400MHz) } \delta$: 0.83 (m, 6H), 1.60 (m, 2H), 2.26 (s, 3H), 2.97 (t, 2H), 3.06 (s, 6H), 3.40 (q, 2H), 3.80 (t, 2H), 4.35 (s, 2H), 4.70 (m, 2H), 6.94 (d, 1H), 7.62 (m, 1H), 7.93 (d, 1H). MS APCI+ m/z 413 $[\text{MH}]^+$
25		$^1\text{H NMR (D}_2\text{O, 400MHz) } \delta$: 0.86 (t, 3H), 2.02 (m, 4H), 2.35 (s, 3H), 3.15 (s, 6H), 3.18 (m, 2H), 3.40 (q, 2H), 3.45 (m, 2H), 3.84 (t, 2H), 4.55 (s, 2H), 4.81 (t, 2H), 7.03 (d, 1H), 7.57 (s, 1H), 7.96 (d, 1H). MS APCI+ m/z 425 $[\text{MH}]^+$
		
26	$\text{CH}_3\text{CH}_2\text{NH}-$	$^1\text{H NMR (CD}_3\text{OD, 400MHz) } \delta$: 1.11 (t, 3H), 1.21 (t, 3H), 2.32 (s, 3H), 2.84 (q, 2H), 3.21 (s, 6H), 3.60 (q, 2H), 3.86 (m, 2H), 4.09 (s, 2H), 4.71 (m, 2H), 7.63 (d, 1H), 8.16 (m, 1H), 8.37 (m, 1H). MS APCI+ m/z 399 $[\text{MH}]^+$
27		$^1\text{H NMR (CD}_3\text{OD, 400MHz) } \delta$: 1.08 (t, 3H), 2.28 (s, 3H), 2.64 (m, 4H), 3.21 (s, 6H), 3.59 (q, 2H), 3.68 (m, 4H), 3.86 (s, 2H), 3.89 (m, 2H), 4.69 (m, 2H), 7.63 (d, 1H), 8.16 (s, 1H), 8.37 (d, 1H). MS APCI+ m/z 441 $[\text{MH}]^+$

- Example 21 – The product of preparation 46 was used as the $\text{HNR}^{15}\text{R}^{16}$ amine
- Example 22 - The product of preparation 45 was used as the $\text{HNR}^{15}\text{R}^{16}$ amine

Examples 28 – 31

The bromo compound of preparation 19 (76mg, 0.18mmol) was dissolved in 1-methyl-2-pyrrolidinone (150μL) and the solution treated with the appropriate HNR¹⁵R¹⁶ amine (1.78mmol). The reaction mixture was stirred at 60°C for 2 hours and then concentrated to low volume *in vacuo*. A 33% solution of dimethylamine (0.18mmol) in ethanol was added and the reaction mixture sealed in a ReactiVial™ and heated to 120°C for 18 hours. The reaction mixture was concentrated *in vacuo* and the residue partitioned between dichloromethane (1mL) and saturated sodium bicarbonate solution (1mL). The organic layer was separated and purified by column chromatography on silica gel eluting with dichloromethane:methanol:0.88 ammonia 100:0:0 to 90:10:1. The residues were treated with 2M hydrogen chloride in ether (30μL), and the mixtures evaporated *in vacuo* to afford the title compounds.

No	NR ¹⁵ R ¹⁶	Data
28	(CH ₃) ₂ N-	¹ H NMR (D ₂ O, 400MHz) δ: 0.80 (t, 3H), 2.22 (s, 3H), 2.80 (s, 6H), 3.04 (s, 6H), 3.40 (q, 2H), 3.81 (t, 2H), 4.43 (s, 2H), 4.75 (m, 2H), 6.93 (d, 1H), 7.70 (m, 1H), 7.96 (d, 1H). MS APCI+ m/z 399 [MH] ⁺
29	CH ₃ O(CH ₂) ₂ NH-	¹ H NMR (D ₂ O, 400MHz) δ: 0.85 (t, 3H), 2.32 (s, 3H), 3.11 (m, 6H), 3.23 (t, 2H), 3.27 (s, 3H), 3.43 (q, 2H), 3.63 (t, 2H), 3.85 (t, 2H), 4.43 (s, 2H), 4.79 (m, 2H), 7.02 (d, 1H), 7.59 (s, 1H), 7.96 (d, 1H). MS APCI+ m/z 429 [MH] ⁺


30		^1H NMR (D_2O , 400MHz) δ : 0.82 (t, 3H), 2.31 (s, 3H), 3.08 (m, 6H), 3.14 (m, 4H), 3.41 (q, 2H), 3.80 (m, 6H), 4.37 (m, 2H), 4.75 (m, 2H), 6.98 (d, 1H), 7.65 (s, 1H), 7.96 (d, 1H). MS APCI+ m/z 441 $[\text{MH}]^+$
31	$\text{CH}_3\text{CH}_2\text{NH}-$	^1H NMR (CD_3OD , 400MHz) δ : 1.10 (t, 3H), 1.37 (t, 3H), 2.40 (s, 3H), 3.23 (q, 2H), 3.26 (s, 6H), 3.60 (q, 2H), 3.91 (t, 2H), 4.45 (s, 2H), 4.78 (m, 2H), 6.96 (d, 1H), 8.17 (d, 1H), 8.38 (s, 1H). MS APCI+ m/z 399 $[\text{MH}]^+$

- Example 28 – Used a 33% solution of dimethylamine in ethanol as the source of the $\text{HNR}^{15}\text{R}^{16}$ amine
- Example 31 – Used a 2M solution of ethylamine in methanol as the source of the $\text{HNR}^{15}\text{R}^{16}$ amine

5

Example 32

1-(2-ethoxyethyl)-3-(ethylaminomethyl)- N^5,N^5 -dimethyl- N^7 -(pyrimidin-4-yl)-1*H*-pyrazolo[4,3-*d*]pyrimidine-5,7-diamine



10

The aldehyde of preparation 41 (50mg, 0.14mmol) was dissolved in dichloromethane (2mL) and the solution treated with ethylamine hydrochloride (13mg, 0.15mmol), sodium triacetoxyborohydride (45mg, 0.21mmol) and triethylamine (20 μ L, 0.15mmol). The mixture was stirred at room temperature for 30 minutes and was then treated with additional ethylamine hydrochloride (13mg, 0.15mmol) and triethylamine (20 μ L, 0.15mmol) and stirred for a further 30 minutes. The mixture was then treated with a 2M solution of ethylamine in ethanol (160 μ L) and tetrahydrofuran (1mL) and stirred at room temperature for 1 hour. The reaction mixture was partitioned between saturated sodium hydrogencarbonate solution (20mL) and dichloromethane (20mL) and the


20

aqueous was extracted with dichloromethane (20mL). The organics were combined, dried over magnesium sulphate and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol:0.88 ammonia 90:10:1 to yield the title product, 29mg.

^1H NMR (CD_3OD , 400MHz) δ : 1.18 (m, 6H), 2.78 (q, 2H), 3.23 (s, 6H), 3.63 (q, 2H), 3.90 (m, 2H), 4.69 (m, 2H), 4.85 (s, 2H), 8.40 (m, 1H), 8.56 (d, 1H), 8.79 (s, 1H). MS APCI+ m/z 386 $[\text{MH}]^+$


Example 33

1-(2-ethoxyethyl)-3-[(2-methoxyethylamino)methyl]- N^5,N^5 -dimethyl- N^7 -pyrimidin-4-yl-1H-pyrazolo[4,3-*d*]pyrimidine-5,7-diamine




The title product was prepared by a method similar to that described in example 32 using 2-methoxyethylamine and the aldehyde of preparation 41.

^1H NMR (CD_3OD , 400MHz) δ : 1.20 (t, 3H), 2.90 (t, 2H), 3.23 (s, 6H), 3.34 (s, 3H), 3.55 (m, 2H), 3.63 (q, 2H), 3.91 (m, 2H), 4.09 (s, 2H), 4.68 (m, 2H), 8.38 (m, 1H), 8.58 (d, 1H), 8.79 (s, 1H). MS APCI+ m/z 416 $[\text{MH}]^+$

Example 343-(Diethylaminomethyl)-1-(2-ethoxyethyl)-N⁵,N⁵-dimethyl-N⁷-(pyrimidin-4-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine


- 5 The chloro compound of preparation 21 (60mg, 0.15mmol) was dissolved in dimethyl sulphoxide (2mL) and the solution treated with N-ethyl-diisopropylamine (129μL, 0.74mmol) and a 33% solution of dimethylamine in ethanol (133μL, 0.74mmol). The reaction mixture was sealed in a ReactiVial™ and heated to 120°C for 18 hours. The reaction mixture was partitioned between ethyl acetate and water and the aqueous extracted with ethyl acetate (x3). The organics were combined and washed with water and brine, dried over magnesium sulphate and concentrated *in vacuo*. The residue was purified by column chromatography on silica gel eluting with dichloromethane:methanol 95:5 to 90:10 to yield the title product, 29mg.
- 10
- 15 ¹H NMR (CDCl₃, 400MHz) δ: 1.24 (t, 6H), 1.42 (t, 3H), 2.86 (q, 2H), 3.22 (s, 6H), 3.65 (q, 2H), 3.92 (t, 2H), 4.25 (s, 4H), 4.68 (t, 2H), 8.32 (d, 1H), 8.58 (d, 1H), 8.86 (s, 1H). MS ES+ m/z 414 [MH]⁺

Example 351-(2-ethoxyethyl)-N⁵,N⁵-dimethyl-3-(methylaminomethyl)-N⁷-pyrimidin-4-yl-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine hydrochloride

- 5 The chloro compound of preparation 32 (32mg, 0.09mmol) was added to a mixture of a 33% solution of dimethylamine in ethanol (60μL, 0.45mmol) and N-ethyldiisopropylamine (80μL, 0.45mmol) in 1-methyl-2-pyrrolidinone (1mL). The reaction mixture was heated to 120°C for 18 hours in a ReactiVial™ and was then concentrated *in vacuo*. The residue was purified by column
- 10 chromatography on silica gel eluting with dichloromethane:methanol:0.88 ammonia 90:10:1. The crude product was dissolved in dichloromethane and treated with ethereal 2M hydrogen chloride and then concentrated *in vacuo* to yield the title product, 9mg.
- 15 ¹H NMR (CD₃OD, 400MHz) δ: 1.21 (t, 3H), 2.63 (s, 3H), 3.24 (s, 6H), 3.64 (q, 2H), 3.92 (m, 2H), 4.21 (s, 2H), 4.73 (m, 2H), 8.36 (s, 1H), 8.58 (d, 1H), 8.81 (s, 1H)
- MS APCI+ m/z 372 [MH]⁺

Example 36

2-([1-(2-ethoxyethyl)-3-(methylaminomethyl)-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]methylamino)ethanol hydrochloride




- 5 The BOC protected amine of preparation 35 (66.5mg, 0.14mmol) was dissolved in dimethyl sulfoxide (1.5mL) and the solution treated with 2-(methylamino)ethanol (56μL, 0.70mmol) and N-ethyldiisopropylamine (120μL, 0.70mmol). The reaction mixture was sealed in a ReactiVial™ and heated to 120°C for 18 hours and then concentrated *in vacuo*. The residue was dissolved
- 10 in dichloromethane (5mL) and the solution treated with trifluoroacetic acid (1mL) and stirred for 1 hour at room temperature. The mixture was concentrated *in vacuo* and the residue partitioned between dichloromethane (10mL) and saturated sodium bicarbonate solution (10mL). The organic layer was separated and purified by column chromatography on silica gel eluting with
- 15 dichloromethane:methanol 100:0 to 97:3. The crude product was dissolved in dichloromethane, treated with 2M ethereal hydrogen chloride (100μL) and concentrated *in vacuo* to yield the title product, 30mg.

¹H NMR (D₂O, 400MHz) δ: 0.85 (t, 3H), 2.37 (s, 3H), 2.65 (s, 3H), 3.14 (s, 3H), 3.42 (q, 2H), 3.72 (m, 2H), 3.78 (m, 2H), 3.85 (t, 2H), 4.40 (s, 2H), 4.80 (t, 2H), 7.08 (d, 1H), 7.48 (s, 1H), 7.95 (d, 1H). MS APCI+ m/z 415 [MH]⁺

20

Example 37

1-(2-ethoxyethyl)-N⁵-(2-methoxyethyl)-N⁵-methyl-3-(methylaminomethyl)-N⁷-(4-methylpyridin-2-yl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine hydrochloride




- 5 The title product was prepared by a method similar to that described for example 36 using N-(2-methoxyethyl)methylamine and the BOC protected amine of preparation 35.

¹H NMR (D₂O, 400MHz) δ: 0.85 (t, 3H), 2.37 (s, 3H), 2.65 (s, 3H), 3.14 (s, 3H), 3.22 (s, 3H), 3.44 (q, 2H), 3.65 (t, 2H), 3.78 (t, 2H), 3.87 (t, 2H), 4.40 (s, 2H), 4.82 (t, 2H), 7.10 (d, 1H), 7.49 (s, 1H), 7.95 (d, 1H). MS APCI+ m/z 429 [MH]⁺

Example 38

2-[1-(2-ethoxyethyl)-3-(methylaminomethyl)-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-ylamino]ethanol



15


The title product was prepared by a method similar to that described for example 36 using ethanolamine and the protected amine of preparation 35.

¹H NMR (D₂O, 400MHz) δ: 0.80 (t, 3H), 2.35 (s, 3H), 2.62 (s, 3H), 3.40 (m, 4H), 3.65 (m, 2H), 3.82 (t, 2H), 4.33 (s, 2H), 4.78 (t, 2H), 7.05 (d, 1H), 7.42 (s, 1H), 7.95 (d, 1H). MS APCI+ m/z 402 [MH]⁺

20

Example 39


N-[5-Dimethylamino-1-(2-ethoxyethyl)-7-(4-methylpyridin-2-ylamino)-1*H*-pyrazolo[4,3-*d*]pyrimidin-3-ylmethyl]-*N*-propylacetamide



- 5 The product of example 24 (30mg, 0.07mmol) was added to a solution of triethylamine (10 μ L, 0.09mmol) in dichloromethane (1mL) and the mixture treated with acetyl chloride (8 μ L, 0.09mmol). The reaction mixture was stirred at room temperature for 18 hours and then concentrated *in vacuo*. The residue was dissolved in methanol (2mL) and washed with 2M sodium hydroxide solution
- 10 (10mL) and water (10mL). The solution was concentrated *in vacuo* and the residue partitioned between ethyl acetate and water, the organic phase was dried over magnesium sulphate and purified by column chromatography on silica gel eluting with dichloromethane:methanol:ammonium hydroxide 98:2:0.2 to yield the title product, 10mg.
- 15 ¹H NMR (CDCl₃, 400MHz) δ : 0.90 (t, 3H), 1.15 (t, 3H), 1.65 (m, 2H), 2.19 (s, 3H), 2.42 (s, 3H), 3.32 (s, 6H), 3.59 (q, 2H), 3.85 (t, 2H), 4.59 (s, 2H), 4.79 (s, 2H), 4.82 (t, 2H), 6.95 (d, 1H), 7.75 (s, 1H), 8.27 (d, 1H), 10.60 (s, 1H). MS APCI+ m/z 455 [MH]⁺

Example 40

1-(2-ethoxyethyl)-N⁵,N⁵-dimethyl-N⁷-(4-methylpyridin-2-yl)-3-(piperazin-1-ylmethyl)-1H-pyrazolo[4,3-d]pyrimidine-5,7-diamine hydrochloride



- 5 The protected amine of preparation 42 (80mg, 0.15mmol) was dissolved in 10% solution of trifluoroacetic acid in dichloromethane (5mL) and the reaction mixture stirred at room temperature for 1 hour. The reaction mixture was concentrated *in vacuo* and the residue purified by column chromatography on silica gel eluting with dichloromethane:methanol 100:0 to 90:10. The crude product was treated
10 with 2M hydrogen chloride in ether (100 μ L) and concentrated *in vacuo* to yield the title product, 33mg.

¹H NMR (D₂O, 400MHz) δ : 0.70 (t, 3H), 1.80 (s, 3H), 2.50 (m, 4H), 2.70 (m, 6H), 2.80 (m, 4H), 3.30 (q, 2H), 3.55 (s, 2H), 3.65 (m, 2H), 4.30 (m, 2H), 6.65 (m, 1H), 7.80 (m, 2H). MS APCI+ m/z 440 [MH]⁺

15

Assay

- The compounds of the invention are inhibitors of cyclic guanylate
20 monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE-5 inhibitors). Preferred compounds suitable for use in accordance with the present invention are potent and selective PDE5 inhibitors. *In vitro* PDE inhibitory activities against cyclic guanosine 3',5'-monophosphate (cGMP) and cyclic adenosine 3',5'-monophosphate (cAMP) phosphodiesterases can be determined by
25 measurement of their IC₅₀ values (the concentration of compound required for 50% inhibition of enzyme activity).

The required PDE enzymes can be isolated from a variety of sources, including human corpus cavernosum, human and rabbit platelets, human cardiac ventricle, human skeletal muscle and bovine retina, essentially by a modification of the method of Thompson, WJ *et al.*; Biochemistry 18(23), 5228-5237, 1979, as described by Ballard SA *et al.*; J. Urology 159(6), 2164-2171, 1998. In particular, cGMP-specific PDE5 and cGMP-inhibited cAMP PDE3 can be obtained from human corpus cavernosum tissue, human platelets or rabbit platelets; cGMP-stimulated PDE2 was obtained from human corpus cavernosum; calcium/calmodulin (Ca/CAM)-dependent PDE1 from human cardiac ventricle; cAMP-specific PDE4 from human skeletal muscle; and photoreceptor PDE6 from bovine retina. Phosphodiesterases 7-11 can be generated from full length human recombinant clones transfected into SF9 cells.


Assays can be performed either using a modification of the "batch" method of Thompson WJ and Appleman MM; Biochemistry 10(2),311-316, 1971, essentially as described by Ballard SA *et al.*; J. Urology 159(6), 2164-2171, 1998, or using a scintillation proximity assay for the direct detection of [³H]-labelled AMP/GMP using a modification of the protocol described by Amersham plc under product code TRKQ7090/7100. In summary, for the scintillation proximity assay the effect of PDE inhibitors was investigated by assaying a fixed amount of enzyme in the presence of varying inhibitor concentrations and low substrate, (cGMP or cAMP in a 3:1 ratio unlabelled to [³H]-labeled at a concentration of ~1/3 K_m or less) such that $IC_{50} \cong K_i$. The final assay volume was made up to 100µl with assay buffer [20mM Tris-HCl pH 7.4, 5mM MgCl₂, 1mg/ml bovine serum albumin]. Reactions were initiated with enzyme, incubated for 30-60min at 30°C to give <30% substrate turnover and terminated with 50µl yttrium silicate SPA beads (containing 3mM of the respective unlabelled cyclic nucleotide for PDEs 9 and 11). Plates were re-sealed and shaken for 20min, after which the beads were allowed to settle for 30min in the dark and then counted on a TopCount plate reader (Packard, Meriden, CT) Radioactivity units were converted to % activity of an uninhibited control (100%), plotted against inhibitor concentration and inhibitor IC_{50} values obtained using the 'Fit Curve' Microsoft Excel extension.

All compounds of the invention have an activity against PDE-5 of less than 10,000nM. IC₅₀ values for representative preferred compounds are listed in the table below.

Example	IC ₅₀ (nM)	Example	IC ₅₀ (nM)
1	1.12	11	0.53
2	1.25	15	0.48
4	0.77	18	2.30
6	0.39	30	1.06
8	0.59	31	3.40
9	0.33		

Claims

1. A compound of formula (I)



wherein

R^1 is a cyclic group selected from R^A , R^B , R^C and R^D , each of which is optionally substituted with one or more R^7 groups;

R^2 is hydrogen or C_1 - C_2 alkyl;

R^3 and R^4 are each independently C_1 - C_8 alkyl, C_2 - C_8 alkenyl, C_2 - C_8 alkynyl or C_3 - C_{10} cycloalkyl, each of which is optionally substituted with one or more R^8 groups, or R^E , which is optionally substituted with one or more R^9 groups, or hydrogen;

or $-NR^3R^4$ forms R^F , which is optionally substituted with one or more R^{10} groups;

R^5 is $-Y-NR^{15}R^{16}$;

R^6 , which may be attached at N^1 or N^2 , is C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl or C_2 - C_6 alkynyl, each of which is optionally substituted by C_1 - C_6 alkoxy, (C_3 - C_6 cycloalkyl)methoxy, C_1 - C_6 haloalkoxy or a cyclic group selected from R^J , R^K , R^L and R^M , or R^6 is R^N , C_3 - C_7 cycloalkyl or C_3 - C_7 halocycloalkyl, each of which is optionally substituted by C_1 - C_6 alkoxy or C_1 - C_6 haloalkoxy, or R^6 is hydrogen;

R^7 is halo, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, C_3 - C_{10} cycloalkyl, C_3 - C_{10} halocycloalkyl, phenyl, OR^{12} , $OC(O)R^{12}$, NO_2 , $NR^{12}R^{13}$, $NR^{12}C(O)R^{13}$, $NR^{12}CO_2R^{14}$, $C(O)R^{12}$, CO_2R^{12} , $CONR^{12}R^{13}$ or CN ;

R^8 is halo, phenyl, C_1 - C_6 alkoxyphenyl, OR^{12} , $OC(O)R^{12}$, NO_2 , $NR^{12}R^{13}$, $NR^{12}C(O)R^{13}$, $NR^{12}CO_2R^{14}$, $C(O)R^{12}$, CO_2R^{12} , $CONR^{12}R^{13}$, CN , C_3 - C_6 cycloalkyl, R^G or R^H , the last two of which are optionally substituted with one or more R^9 groups;

R^9 is C_1 - C_6 alkyl, C_1 - C_6 haloalkyl or CO_2R^{12} ;

R^{10} is halo, C_3 - C_{10} cycloalkyl, C_3 - C_{10} halocycloalkyl, phenyl, OR^{12} , $OC(O)R^{12}$, NO_2 , $NR^{12}R^{13}$, $NR^{12}C(O)R^{13}$, $NR^{12}CO_2R^{14}$, $C(O)R^{12}$, CO_2R^{13} , $CONR^{12}R^{13}$, CN , oxo, C_1 - C_6 alkyl or C_1 - C_6 haloalkyl, the last two of which are optionally substituted by R^{11} ;

R^{11} is phenyl, $NR^{12}R^{13}$ or $NR^{12}CO_2R^{14}$;

R^{12} and R^{13} are each independently hydrogen, C_1 - C_6 alkyl or C_1 - C_6 haloalkyl;

R^{14} is C_1 - C_6 alkyl or C_1 - C_6 haloalkyl;

R^{15} is selected from R^{17} , $R^{17}C(O)$ and $R^{18}SO_2$, and

R^{16} is selected from hydrogen, C_1 - C_6 alkyl optionally substituted with one or more R^{19} groups, C_1 - C_6 haloalkyl and C_3 - C_{10} cycloalkyl optionally substituted with one or more R^{20} groups,

or $-NR^{15}R^{16}$ constitutes a 3- to 8-membered saturated ring which may optionally include one or more further heteroatoms selected from nitrogen, oxygen and sulphur, and which may optionally be substituted with one or more groups selected from R^{21} , R^{22} and $(C_1$ - C_6 alkoxy) C_1 - C_6 alkyl;

R^{17} is hydrogen or R^{18} ;

R^{18} is selected from C_1 - C_6 alkyl optionally substituted with one or more R^{19} groups, C_1 - C_6 haloalkyl and C_3 - C_{10} cycloalkyl optionally substituted with one or more R^{20} groups;

R^{19} is selected from R^{21} , $-NR^{23}R^{24}$, $-CO_2R^{25}$, $-CONR^{26}R^{27}$, R^{28} and phenyl optionally substituted by R^{29} ;

R^{20} is selected from R^{21} , R^{22} and oxo;

R^{21} is hydroxy, C_1 - C_6 alkoxy, C_1 - C_6 (haloalkyl)oxy or C_3 - C_7 cycloalkyloxy;

R^{22} is C_1 - C_6 alkyl or C_1 - C_6 haloalkyl;

R^{23} and R^{24} are each independently selected from hydrogen and C_1 - C_6 alkyl;

or $-NR^{23}R^{24}$ constitutes an azetidine, pyrrolidine, piperidine or morpholine ring;

R^{25} is hydrogen or C_1 - C_6 alkyl;

R^{26} and R^{27} are each independently selected from hydrogen and C_1 - C_6 alkyl;

or $-NR^{26}R^{27}$ constitutes an azetidine, pyrrolidine, piperidine or morpholine ring;

R^{28} is a saturated, unsaturated or aromatic heterocycle with up to 10 ring atoms, at least one of which is selected from nitrogen, oxygen and sulphur;

R^{29} is selected from halo, R^{21} and R^{22} ,

R^A and R^J are each independently a C_3 - C_{10} cycloalkyl or C_3 - C_{10} cycloalkenyl group, each of which may be either monocyclic or, when there are an appropriate number of ring atoms, polycyclic and which may be fused to either

(a) a monocyclic aromatic ring selected from a benzene ring and a 5- or 6-membered heteroaromatic ring containing up to three heteroatoms selected from nitrogen, oxygen and sulphur, or

(b) a 5-, 6- or 7-membered heteroalicyclic ring containing up to three heteroatoms selected from nitrogen, oxygen and sulphur;

R^B and R^K are each independently a phenyl or naphthyl group, each of which may be fused to

(a) a C_5 - C_7 cycloalkyl or C_5 - C_7 cycloalkenyl ring,

(b) a 5-, 6- or 7-membered heteroalicyclic ring containing up to three heteroatoms selected from nitrogen, oxygen and sulphur, or

(c) a 5- or 6-membered heteroaromatic ring containing up to three heteroatoms selected from nitrogen, oxygen and sulphur;

R^C , R^L and R^N are each independently a monocyclic or, when there are an appropriate number of ring atoms, polycyclic saturated or partly unsaturated ring system containing between 3 and 10 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur, which ring may be fused to a C_5 - C_7 cycloalkyl or C_5 - C_7 cycloalkenyl group or a monocyclic aromatic ring selected from a benzene ring and a 5- or 6-membered heteroaromatic ring containing up to three heteroatoms selected from nitrogen, oxygen and sulphur;

R^D and R^M are each independently a 5- or 6-membered heteroaromatic ring containing up to three heteroatoms independently selected from nitrogen, oxygen and sulphur, which ring may further be fused to

(a) a second 5- or 6-membered heteroaromatic ring containing up to three heteroatoms selected from nitrogen, oxygen and sulphur;

(b) C_5 - C_7 cycloalkyl or C_5 - C_7 cycloalkenyl ring;

(c) a 5-, 6- or 7-membered heteroalicyclic ring containing up to three heteroatoms selected from nitrogen, oxygen and sulphur; or

(d) a benzene ring;

R^E , R^F and R^G are each independently a monocyclic or, when there are an appropriate number of ring atoms, polycyclic saturated ring system containing between 3 and 10 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur;

R^H is a 5- or 6-membered heteroaromatic ring containing up to three heteroatoms independently selected from nitrogen, oxygen and sulphur; and

Y is a covalent bond, C_1 - C_6 alkylenyl or C_3 - C_7 cycloalkylenyl;

a tautomer thereof or a pharmaceutically acceptable salt, solvate or polymorph of said compound or tautomer.

2. A compound according to claim 1 wherein R^1 is R^A , which is optionally substituted with one or more R^7 groups; and R^A is a C_3 - C_{10} cycloalkyl group, which may be either monocyclic or, when there are an appropriate number of ring atoms, polycyclic, which may be fused to either
 - (a) a monocyclic aromatic ring selected from a benzene ring and a 5- or 6-membered heteroaromatic ring containing up to three heteroatoms selected from nitrogen, oxygen and sulphur, or
 - (b) a 5-, 6- or 7-membered heteroalicyclic ring containing up to three heteroatoms selected from nitrogen, oxygen and sulphur.
3. A compound according to claim 2 wherein R^A is a monocyclic C_3 - C_8 cycloalkyl group.
4. A compound according to claim 3 wherein R^A is a monocyclic C_5 - C_7 cycloalkyl group.
5. A compound according to claim 4 wherein R^A is cyclopentyl or cyclohexyl.
6. A compound according to claim 1 wherein R^1 is R^B , which is optionally substituted with one or more R^7 groups.
7. A compound according to claim 6 wherein R^B is phenyl.
8. A compound according to claim 1 wherein R^1 is R^C , which is optionally substituted with one or more R^7 groups.
9. A compound according to claim 8 wherein R^C is a monocyclic saturated or partly unsaturated ring system containing between 3 and 8 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur.

10. A compound according to claim 9 wherein R^C is a monocyclic saturated or partly unsaturated ring system containing between 5 and 7 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur.
11. A compound according to claim 10 wherein R^C is a monocyclic saturated ring system containing between 5 and 7 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur.
12. A compound according to claim 1 wherein R^1 is R^D , which is optionally substituted with one or more R^7 groups.
13. A compound according to claim 12 wherein R^D is a 5- or 6-membered heteroaromatic ring containing up to three heteroatoms independently selected from nitrogen, oxygen and sulphur.
14. A compound according to claim 13 wherein R^D is a 5-membered heteroaromatic ring containing a heteroatom selected from nitrogen, oxygen and sulphur and optionally up to two further nitrogen atoms in the ring, or a 6-membered heteroaromatic ring including 1, 2 or 3 nitrogen atoms.
15. A compound according to claim 14 wherein R^D is furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isothiazolyl, thiazolyl, oxadiazolyl, pyridyl, pyridazinyl, pyrimidyl or pyrazinyl.
16. A compound according to claim 15 wherein R^D is pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, oxadiazolyl, pyridyl, pyridazinyl, pyrimidyl or pyrazinyl.
17. A compound according to any one of claims 1 to 16 wherein R^7 is halo, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, OR^{12} or $CONR^{12}R^{13}$.
18. A compound according to claim 17 wherein R^7 is halo, C_1 - C_3 alkyl, C_1 - C_3 alkoxy, hydroxy or $CONH(C_1$ - C_3 alkyl).

19. A compound according to claim 18 wherein R^7 is fluoro, methyl, ethyl, hydroxy, methoxy, propoxy or CONHMe.
20. A compound according to any one of claims 1 to 19 wherein R^2 is hydrogen or methyl.
21. A compound according to claim 20 wherein R^2 is hydrogen.
22. A compound according to any one of claims 1 to 21 wherein R^3 is hydrogen, C_1 - C_6 alkyl, which is optionally substituted with one or more R^8 groups, or R^E , which is optionally substituted with one or more R^9 groups; and wherein R^E is a monocyclic or, when there are an appropriate number of ring atoms, polycyclic saturated ring system containing between 3 and 7 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur.
23. A compound according to claim 22 wherein R^3 is hydrogen, C_1 - C_4 alkyl, which is optionally substituted with one or more R^8 groups, or R^E , which is optionally substituted with one or more R^9 groups; and wherein R^E is a monocyclic saturated ring system containing between 3 and 7 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur.
24. A compound according to claim 23 wherein R^3 is R^E , which is optionally substituted with one or more R^9 groups and wherein R^E is a monocyclic saturated ring system containing between 3 and 7 ring atoms containing one nitrogen atom.
25. A compound according to claim 24 wherein R^E is azetidiny, pyrrolidiny or piperidiny.
26. A compound according to claim 23 wherein R^3 is C_1 - C_4 alkyl, which is optionally substituted with one or more R^8 groups and wherein R^8 is halo, phenyl, C_1 - C_6 alkoxyphenyl, OR^{12} , $NR^{12}R^{13}$, $NR^{12}CO_2R^{14}$, CO_2R^{12} , $CONR^{12}R^{13}$, R^G or R^H , the last two of which are optionally substituted with one or more R^9 groups.

27. A compound according to claim 26 wherein R^8 is hydroxy, methoxy, methoxyphenyl, NH_2 , $NHMe$, NMe_2 , $NHCO_2^tBu$, $NMeCO_2^tBu$, CO_2H , $CONHMe$, R^G or R^H , the last two of which are optionally substituted with one or more R^9 groups.
28. A compound according to claim 27 wherein R^8 is R^G , which is optionally substituted with one or more R^9 groups and wherein R^G is a monocyclic saturated ring system containing between 3 and 7 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur.
29. A compound according to claim 28 wherein R^G is a monocyclic saturated ring system containing between 3 and 7 ring atoms containing one nitrogen atom and optionally one oxygen atom.
30. A compound according to claim 29 wherein R^G is pyrrolidinyl, piperidinyl or morpholinyl.
31. A compound according to claim 27 wherein R^8 is R^H , which is optionally substituted with one or more R^9 groups and wherein R^H is a 5- or 6-membered heteroaromatic ring containing up to two nitrogen atoms.
32. A compound according to claim 31 wherein R^H is pyrazolyl.
33. A compound according to any one of claims 22 to 32 wherein R^9 is methyl or CO_2^tBu .
34. A compound according to claim 23 wherein R^3 is hydrogen or C_1 - C_4 alkyl, which is optionally substituted with one or more R^8 groups, or R^3 is azetidiny, pyrrolidinyl or piperidinyl, each of which is optionally substituted with one or more R^9 groups, wherein R^8 is hydroxy, methoxy, methoxyphenyl, NH_2 , $NHMe$, NMe_2 , $NHCO_2^tBu$, $NMeCO_2^tBu$, CO_2H , $CONHMe$, pyrrolidinyl, piperidinyl, morpholinyl or pyrazolyl, the last four of which are optionally substituted with one or more R^9 groups and wherein R^9 is methyl or CO_2^tBu .

35. A compound according to any one of claims 1 to 34 wherein R^4 is hydrogen, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_2 - C_6 alkenyl or C_2 - C_6 alkynyl.
36. A compound according to claim 35 wherein R^4 is hydrogen, C_1 - C_6 alkyl or C_1 - C_6 haloalkyl.
37. A compound according to claim 36 wherein R^4 is hydrogen, methyl or ethyl.
38. A compound according to any one of claims 1 to 21 wherein $-NR^3R^4$ forms R^F , which is optionally substituted with one or more R^{10} groups and wherein R^F is a monocyclic or, when there are an appropriate number of ring atoms, polycyclic saturated ring system containing between 3 and 10 ring atoms containing at least one nitrogen atom and optionally one other atom selected from oxygen and sulphur.
39. A compound according to claim 38 wherein R^F is a monocyclic or, when there are an appropriate number of ring atoms, polycyclic saturated ring system containing between 3 and 10 ring atoms containing one or two nitrogen atoms and optionally one other atom selected from oxygen and sulphur.
40. A compound according to claim 39 wherein R^F is selected from azetidiny, pyrrolidiny, piperidiny, piperaziny, morpholiny, 3-azabicyclo[3.1.0]hex-3-yl, homopiperaziny, 2,5-diazabicyclo[4.3.0]non-2-yl, 3,8-diazabicyclo[3.2.1]oct-3-yl, 3,8-diazabicyclo[3.2.1]oct-8-yl, 2,5-diazabicyclo[2.2.1]hept-2-yl, 1,4-diazabicyclo[4.3.0]non-4-yl and 1,4-diazabicyclo[3.2.2]non-4-yl.
41. A compound according to any one of claims 38 to 40 wherein R^{10} is halo, OR^{12} , $NR^{12}R^{13}$, $NR^{12}CO_2R^{14}$, CO_2R^{13} , oxo, C_1 - C_6 alkyl or C_1 - C_6 haloalkyl, the last two of which are optionally substituted by R^{11} .
42. A compound according to claim 41 wherein R^{10} is halo, methyl, ethyl, isopropyl, hydroxy, methoxy, NH_2 , $NHMe$, NMe_2 , $NHCO_2^tBu$, CO_2H , CO_2^tBu , oxo, benzyl, $-CH_2NH_2$, $-CH_2NHMe$, CH_2NMe_2 or $-CH_2NMeCO_2^tBu$.
43. A compound according to any one of claims 1 to 42 wherein Y is C_1 - C_6 alkylenyl.

44. A compound according to claim 43 wherein Y is $-\text{CH}_2-$.
45. A compound according to any one of claims 1 to 44 wherein R^{15} is $\text{R}^{17}\text{C}(\text{O})$ or R^{18}SO_2 and R^{16} is hydrogen or $\text{C}_1\text{-C}_6$ alkyl.
46. A compound according to any one of claims 1 to 44 wherein R^{15} is R^{17} and R^{16} is hydrogen or $\text{C}_1\text{-C}_6$ alkyl.
47. A compound according to any one of claims 1 to 46 wherein R^{17} is R^{18} and R^{18} is $\text{C}_1\text{-C}_6$ alkyl optionally substituted with one R^{19} group.
48. A compound according to any one of claims 1 to 44 wherein $-\text{NR}^{15}\text{R}^{16}$ constitutes a 3- to 8-membered saturated ring which may optionally include one or more further heteroatoms selected from nitrogen, oxygen and sulphur, and which may optionally be substituted with one or more groups selected from R^{21} , R^{22} and $(\text{C}_1\text{-C}_6 \text{ alkoxy})\text{C}_1\text{-C}_6$ alkyl.
49. A compound according to claim 48 wherein $-\text{NR}^{15}\text{R}^{16}$ constitutes a 5- or 6-membered saturated ring which may optionally include one further nitrogen atom, and which may optionally be substituted with a group selected from R^{21} , R^{22} and $(\text{C}_1\text{-C}_6 \text{ alkoxy})\text{C}_1\text{-C}_6$ alkyl.
50. A compound according to claim 48 or 49 wherein R^{21} is $\text{C}_1\text{-C}_6$ alkoxy and R^{22} is $\text{C}_1\text{-C}_6$ alkyl.
51. A compound according to any one of claims 1 to 50 wherein R^6 is positioned on N^1 .
52. A compound according to any one of claims 1 to 51 wherein R^6 is $\text{C}_1\text{-C}_6$ alkyl or $\text{C}_1\text{-C}_6$ haloalkyl, each of which is optionally substituted by $\text{C}_1\text{-C}_6$ alkoxy, $\text{C}_1\text{-C}_6$ haloalkoxy or a cyclic group selected from R^J , R^L and R^M , or R^6 is R^N or hydrogen; R^J is a $\text{C}_3\text{-C}_7$ monocyclic cycloalkyl group;

R^L and R^N are each independently a monocyclic, saturated or partly unsaturated ring system containing between 4 and 7 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur; and

R^M is a 5- or 6-membered heteroaromatic ring containing up to three heteroatoms independently selected from nitrogen, oxygen and sulphur.

53. A compound according to claim 52 wherein R^6 is C_1 - C_4 alkyl or C_1 - C_4 haloalkyl, each of which is optionally substituted by C_1 - C_4 alkoxy, C_1 - C_4 haloalkoxy or a cyclic group selected from R^J , R^L and R^M , or R^6 is R^N or hydrogen;

R^J is cyclopropyl or cyclobutyl;

R^L and R^N are each independently a monocyclic saturated ring system containing either 5 or 6 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur; and

R^M is a 5- or 6-membered heteroaromatic ring containing a heteroatom selected from nitrogen, oxygen and sulphur.

54. A compound according to claim 53 wherein R^6 is C_1 - C_4 alkyl or C_1 - C_4 haloalkyl, each of which is optionally substituted by C_1 - C_4 alkoxy or a cyclic group selected from R^J , R^L and R^M , or R^6 is R^N or hydrogen;

R^J is cyclopropyl or cyclobutyl;

R^L and R^N are each independently a monocyclic saturated ring system containing either 5 or 6 ring atoms containing one heteroatom selected from nitrogen, oxygen and sulphur; and

R^M is a 5- or 6-membered heteroaromatic ring containing one nitrogen atom.

55. A compound according to claim 54 wherein R^6 is C_1 - C_4 alkyl or C_1 - C_4 haloalkyl, each of which is optionally substituted by C_1 - C_4 alkoxy, cyclopropyl, cyclobutyl, tetrahydrofuranyl, tetrahydropyranyl or pyridinyl, or R^6 is hydrogen or tetrahydropyranyl.

56. A compound according to claim 55 wherein R^6 is hydrogen, methyl, ethyl, isopropyl, isobutyl, methoxyethyl, methoxypropyl, ethoxyethyl, ethoxypropyl, propoxyethyl, 2,2,2-trifluoroethyl, tetrahydrofuranylmethyl, tetrahydropyranylmethyl, tetrahydropyranyl or pyridinylmethyl.

57. A compound according to claim 1 wherein

R^3 is hydrogen, C_1 - C_4 alkyl, which is optionally substituted with one or more R^8 groups, or R^E , which is optionally substituted with one or more R^9 groups;

R^4 is hydrogen, C_1 - C_6 alkyl or C_1 - C_6 haloalkyl;

or $-NR^3R^4$ forms R^F , which is optionally substituted with one or more R^{10} groups;

R^6 is C_1 - C_4 alkyl or C_1 - C_4 haloalkyl, each of which is optionally substituted by C_1 - C_4 alkoxy, C_1 - C_4 haloalkoxy or a cyclic group selected from R^J , R^L and R^M , or R^6 is R^N or hydrogen;

R^A is a monocyclic C_3 - C_8 cycloalkyl group;

R^B is phenyl;

R^C is a monocyclic saturated or partly unsaturated ring system containing between 3 and 8 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur;

R^D is a 5- or 6-membered heteroaromatic ring containing up to three heteroatoms independently selected from nitrogen, oxygen and sulphur;

R^E is a monocyclic saturated ring system containing between 3 and 7 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur;

R^F is a monocyclic or, when there are an appropriate number of ring atoms, polycyclic saturated ring system containing between 3 and 10 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur;

R^J is cyclopropyl or cyclobutyl;

R^L and R^N are each independently a monocyclic saturated ring system containing either 5 or 6 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur;

R^M is a 5- or 6-membered heteroaromatic ring containing a heteroatom selected from nitrogen, oxygen and sulphur; and

Y is C_1 - C_6 alkylene.

58. A compound according to claim 57 wherein R^1 is a cyclic group selected from R^A , R^B , R^C and R^D , each of which is optionally substituted with one or more R^7 groups;

R^7 is halo, C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, OR^{12} or $CONR^{12}R^{13}$;

R^8 is halo, phenyl, C_1 - C_6 alkoxyphenyl, OR^{12} , $NR^{12}R^{13}$, $NR^{12}CO_2R^{14}$, CO_2R^{12} , $CONR^{12}R^{13}$, R^G or R^H , the last two of which are optionally substituted with one or more R^9 groups;

R^A is a monocyclic C_5 - C_7 cycloalkyl group;

R^B is phenyl;

R^C is a monocyclic saturated ring system containing between 5 and 7 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur;

R^D is a 5-membered heteroaromatic ring containing a heteroatom selected from nitrogen, oxygen and sulphur and optionally up to two further nitrogen atoms in the ring, or a 6-membered heteroaromatic ring including 1, 2 or 3 nitrogen atoms;

R^E is a monocyclic saturated ring system containing between 3 and 7 ring atoms containing one nitrogen atom;

R^F is a monocyclic or, when there are an appropriate number of ring atoms, polycyclic saturated ring system containing between 3 and 10 ring atoms containing at least one nitrogen atom and optionally one other atom selected from oxygen and sulphur;

R^G is a monocyclic saturated ring system containing between 3 and 7 ring atoms, of which at least one is a heteroatom selected from nitrogen, oxygen and sulphur;

R^H is a 5- or 6-membered heteroaromatic ring containing up to two nitrogen atoms; and

Y is -CH₂-.

59. A compound according to claim 1 selected from:

2-dimethylamino-*N*-[5-dimethylamino-1-(2-ethoxyethyl)-7-(4-methylpyridin-2-ylamino)-1*H*-pyrazolo[4,3-*d*]pyrimidin-3-ylmethyl]acetamide,

N-[5-dimethylamino-1-(2-ethoxyethyl)-7-(4-methylpyridin-2-ylamino)-1*H*-pyrazolo[4,3-*d*]pyrimidin-3-ylmethyl]methanesulfonamide,

N-[5-dimethylamino-1-(2-ethoxyethyl)-7-(4-methylpyridin-2-ylamino)-1*H*-pyrazolo[4,3-*d*]pyrimidin-3-ylmethyl]-2-hydroxyacetamide,

N-[5-dimethylamino-1-(2-ethoxyethyl)-7-(4-methylpyridin-2-ylamino)-1*H*-pyrazolo[4,3-*d*]pyrimidin-3-ylmethyl]acetamide,

N-[1-(2-ethoxyethyl)-5-ethylamino-7-(4-methylpyridin-2-ylamino)-1*H*-pyrazolo[4,3-*d*]pyrimidin-3-ylmethyl]acetamide,

N-[5-dimethylamino-1-(2-ethoxyethyl)-7-(4-methylpyridin-2-ylamino)-1*H*-pyrazolo[4,3-*d*]pyrimidin-3-ylmethyl]propionamide,

N-[1-(2-ethoxyethyl)-5-ethylamino-7-(4-methylpyridin-2-ylamino)-1*H*-pyrazolo[4,3-*d*]pyrimidin-3-ylmethyl]propionamide,

N-[1-(2-ethoxyethyl)-5-ethylamino-7-(4-methylpyridin-2-ylamino)-1*H*-pyrazolo[4,3-*d*]pyrimidin-3-ylmethyl]-*N*-methylacetamide,

1-(2-ethoxyethyl)-*N*⁵,*N*⁵-dimethyl-3-[(4-methylpiperazin-1-yl)methyl]-*N*⁷-(4-methylpyridin-2-yl)-1*H*-pyrazolo[4,3-*d*]pyrimidine-5,7-diamine,

1-(2-ethoxyethyl)-*N*⁵,*N*⁵-dimethyl-3-[(4-morpholino)methyl]-*N*⁷-(4-methylpyridin-2-yl)-1*H*-pyrazolo[4,3-*d*]pyrimidine-5,7-diamine, and

1-(2-ethoxyethyl)-3-(ethylaminomethyl)-*N*⁵,*N*⁵-dimethyl-*N*⁷-(4-methylpyridin-2-yl)-1*H*-pyrazolo[4,3-*d*]pyrimidine-5,7-diamine

and tautomers thereof and pharmaceutically acceptable salts, solvates and polymorphs of said compounds or tautomers.

60. A pharmaceutical composition comprising a compound of formula (I) as claimed in any one of claims 1 to 59, or pharmaceutically acceptable salts, solvates or polymorphs thereof, and a pharmaceutically acceptable diluent or carrier.

61. A compound of formula (I) as claimed in any one of claims 1 to 59, or a pharmaceutically acceptable salt, solvate or polymorph thereof, for use as a medicament.

62. A compound of formula (I) as claimed in any one of claims 1 to 59, or a pharmaceutically acceptable salt, solvate or polymorph thereof, for use in accordance with claim 61 as a medicament for the treatment of a disease or condition where inhibition of PDE5 is known, or can be shown, to produce a beneficial effect.

63. A compound of formula (I) as claimed in any one of claims 1 to 59, or a pharmaceutically acceptable salt, solvate or polymorph thereof, for use in accordance with claim 61 or 62 as a medicament for the treatment of a disease or condition selected from hypertension (including essential hypertension, pulmonary hypertension, secondary hypertension, isolated systolic hypertension, hypertension associated with diabetes, hypertension associated with atherosclerosis, and renovascular

hypertension), congestive heart failure, angina (including stable, unstable and variant (Prinzmetal) angina), stroke, coronary artery disease, congestive heart failure, conditions of reduced blood vessel patency (such as post-percutaneous coronary angioplasty), peripheral vascular disease, atherosclerosis, nitrate-induced tolerance, nitrate tolerance, diabetes, impaired glucose tolerance, metabolic syndrome, obesity, sexual dysfunction (including male erectile disorder, impotence, female sexual arousal disorder, clitoral dysfunction, female hypoactive sexual desire disorder, female sexual pain disorder, female sexual orgasmic dysfunction and sexual dysfunction due to spinal cord injury), premature labour, pre-eclampsia, dysmenorrhea, polycystic ovary syndrome, benign prostatic hyperplasia, bladder outlet obstruction, incontinence, chronic obstructive pulmonary disease, acute respiratory failure, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, gut motility disorders (including irritable bowel syndrome), Kawasaki's syndrome, multiple sclerosis, Alzheimer's disease, psoriasis, skin necrosis, scarring, fibrosis, pain (particularly neuropathic pain), cancer, metastasis, baldness, nutcracker oesophagus, anal fissure and haemorrhoids.

64. A method of treatment of a disorder or condition where inhibition of PDE5 is known, or can be shown, to produce a beneficial effect, in a mammal, comprising administering to said mammal a therapeutically effective amount of a compound of formula (I) as claimed in any one of claims 1 to 59, or a pharmaceutically acceptable salt, solvate or polymorph thereof.

65. The method according to claim 64, wherein the disorder or condition is selected from hypertension (including essential hypertension, pulmonary hypertension, secondary hypertension, isolated systolic hypertension, hypertension associated with diabetes, hypertension associated with atherosclerosis, and renovascular hypertension), congestive heart failure, angina (including stable, unstable and variant (Prinzmetal) angina), stroke, coronary artery disease, congestive heart failure, conditions of reduced blood vessel patency (such as post-percutaneous coronary angioplasty), peripheral vascular disease, atherosclerosis, nitrate-induced tolerance, nitrate tolerance, diabetes, impaired glucose tolerance, metabolic syndrome, obesity, sexual dysfunction (including male erectile disorder, impotence, female sexual arousal disorder, clitoral dysfunction, female hypoactive sexual desire disorder, female sexual pain disorder, female sexual orgasmic dysfunction and sexual dysfunction due to spinal

cord injury), premature labour, pre-eclampsia, dysmenorrhea, polycystic ovary syndrome, benign prostatic hyperplasia, bladder outlet obstruction, incontinence, chronic obstructive pulmonary disease, acute respiratory failure, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, gut motility disorders (including irritable bowel syndrome), Kawasaki's syndrome, multiple sclerosis, Alzheimer's disease, psoriasis, skin necrosis, scarring, fibrosis, pain (particularly neuropathic pain), cancer, metastasis, baldness, nutcracker oesophagus, anal fissure and haemorrhoids.

66. Use of a compound of formula (I) as claimed in any one of claims 1 to 59, or a pharmaceutically acceptable salt, solvate or polymorph thereof, in the preparation of a medicament for the treatment of a disorder or condition where inhibition of PDE5 is known, or can be shown, to produce a beneficial effect.

67. Use according to claim 66, wherein the disorder or condition is selected from hypertension (including essential hypertension, pulmonary hypertension, secondary hypertension, isolated systolic hypertension, hypertension associated with diabetes, hypertension associated with atherosclerosis, and renovascular hypertension), congestive heart failure, angina (including stable, unstable and variant (Prinzmetal) angina), stroke, coronary artery disease, congestive heart failure, conditions of reduced blood vessel patency (such as post-percutaneous coronary angioplasty), peripheral vascular disease, atherosclerosis, nitrate-induced tolerance, nitrate tolerance, diabetes, impaired glucose tolerance, metabolic syndrome, obesity, sexual dysfunction (including male erectile disorder, impotence, female sexual arousal disorder, clitoral dysfunction, female hypoactive sexual desire disorder, female sexual pain disorder, female sexual orgasmic dysfunction and sexual dysfunction due to spinal cord injury), premature labour, pre-eclampsia, dysmenorrhea, polycystic ovary syndrome, benign prostatic hyperplasia, bladder outlet obstruction, incontinence, chronic obstructive pulmonary disease, acute respiratory failure, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, gut motility disorders (including irritable bowel syndrome), Kawasaki's syndrome, multiple sclerosis, Alzheimer's disease, psoriasis, skin necrosis, scarring, fibrosis, pain (particularly neuropathic pain), cancer, metastasis, baldness, nutcracker oesophagus, anal fissure and haemorrhoids.

68. Use according to claim 67 wherein the disorder or condition is hypertension.

69. Use according to claim 68 wherein the disorder or condition is selected from essential hypertension, pulmonary hypertension, secondary hypertension, isolated systolic hypertension, hypertension associated with diabetes, hypertension associated with atherosclerosis, and renovascular hypertension.
70. Use according to claim 67 wherein the disorder or condition is diabetes.
71. A pharmaceutical composition comprising a compound of formula (I) as claimed in any one of claims 1 to 59, or pharmaceutically acceptable salts, solvates or polymorphs thereof, and a second pharmaceutically active agent selected from aspirin, angiotensin II receptor antagonists (such as losartan, candesartan, telmisartan, valsartan, irbesartan and eprosartan), calcium channel blockers (such as amlodipine), beta-blockers (i.e. beta-adrenergic receptor antagonists such as sotalol, propranolol, timolol, atenolol, carvedilol and metoprolol), C11027, CCR5 receptor antagonists, imidazolines, sGCα's (soluble guanylate cyclase activators) antihypertensive agents, diuretics (such as hydrochlorothiazide, torsemide, chlorothiazide, chlorthalidone and amiloride), alpha adrenergic antagonists (such as doxazosin), ACE (angiotensin converting enzyme) inhibitors (such as quinapril, enalapril, ramipril and lisinopril), aldosterone receptor antagonists (such as eplerenone and spironolactone), neutral endopeptidase inhibitors, antidiabetic agents (such as insulin, sulfonylureas (such as glyburide, glipizide and glimepiride), glitazones (such as rosiglitazone and pioglitazone) and metformin), cholesterol lowering agents (such as atorvastatin, pravastatin, lovastatin, simvastatin, clofibrate and rosuvastatin), and alpha-2-delta ligands (such as gabapentin, pregabalin, [(1R,5R,6S)-6-(aminomethyl)bicyclo[3.2.0]hept-6-yl]acetic acid, 3-(1-aminomethyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one, C-[1-(1H-tetrazol-5-ylmethyl)-cycloheptyl]-methylamine, (3S,4S)-(1-aminomethyl-3,4-dimethyl-cyclopentyl)-acetic acid, (1α,3α,5α)-(3-amino-methyl-bicyclo[3.2.0]hept-3-yl)-acetic acid, (3S,5R)-3-aminomethyl-5-methyl-octanoic acid, (3S,5R)-3-amino-5-methyl-heptanoic acid, (3S,5R)-3-amino-5-methyl-nonanoic acid. and (3S,5R)-3-amino-5-methyl-octanoic acid).
72. Use of a compound of formula (I) as claimed in any one of claims 1 to 59, or a pharmaceutically acceptable salt, solvate or polymorph thereof, in the preparation of a


medicament combined with a second pharmaceutically active agent selected from aspirin, angiotensin II receptor antagonists (such as losartan, candesartan, telmisartan, valsartan, irbesartan and eprosartan), calcium channel blockers (such as amlodipine), beta-blockers (i.e. beta-adrenergic receptor antagonists such as sotalol, propranolol, timolol, atenolol, carvedilol and metoprolol), C11027, CCR5 receptor antagonists, imidazolines, sGCa's (soluble guanylate cyclase activators) antihypertensive agents, diuretics (such as hydrochlorothiazide, torsemide, chlorothiazide, chlorthalidone and amiloride), alpha adrenergic antagonists (such as doxazosin), ACE (angiotensin converting enzyme) inhibitors (such as quinapril, enalapril, ramipril and lisinopril), aldosterone receptor antagonists (such as eplerenone and spironolactone), neutral endopeptidase inhibitors, antidiabetic agents (such as insulin, sulfonylureas (such as glyburide, glipizide and glimepiride), glitazones (such as rosiglitazone and pioglitazone) and metformin), cholesterol lowering agents (such as atorvastatin, pravastatin, lovastatin, simvastatin, clofibrate and rosuvastatin), and alpha-2-delta ligands (such as gabapentin, pregabalin, [(1R,5R,6S)-6-(aminomethyl)bicyclo[3.2.0]hept-6-yl]acetic acid, 3-(1-aminomethyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one, C-[1-(1H-tetrazol-5-ylmethyl)-cycloheptyl]-methylamine, (3S,4S)-(1-aminomethyl-3,4-dimethyl-cyclopentyl)-acetic acid, (1 α ,3 α ,5 α)-(3-amino-methyl-bicyclo[3.2.0]hept-3-yl)-acetic acid, (3S,5R)-3-aminomethyl-5-methyl-octanoic acid, (3S,5R)-3-amino-5-methyl-heptanoic acid, (3S,5R)-3-amino-5-methyl-nonanoic acid and (3S,5R)-3-amino-5-methyl-octanoic acid), for the treatment of a disease or condition where inhibition of PDE5 is known, or can be shown, to produce a beneficial effect.

73. Use according to claim 72 of a compound of formula (I) as claimed in any one of claims 1 to 59, or a pharmaceutically acceptable salt, solvate or polymorph thereof, in the preparation of a medicament combined with a second pharmaceutically active agent selected from aspirin, angiotensin II receptor antagonists (such as losartan, candesartan, telmisartan, valsartan, irbesartan and eprosartan), calcium channel blockers (such as amlodipine), beta-blockers (i.e. beta-adrenergic receptor antagonists such as sotalol, propranolol, timolol, atenolol, carvedilol and metoprolol), C11027, CCR5 receptor antagonists, imidazolines, sGCa's (soluble guanylate cyclase activators) antihypertensive agents, diuretics (such as hydrochlorothiazide, torsemide, chlorothiazide, chlorthalidone and amiloride), alpha adrenergic antagonists (such as doxazosin), ACE (angiotensin converting enzyme) inhibitors (such as quinapril,

enalapril, ramipril and lisinopril), aldosterone receptor antagonists (such as eplerenone and spironolactone), neutral endopeptidase inhibitors, antidiabetic agents (such as insulin, sulfonylureas (such as glyburide, glipizide and glimepiride), glitazones (such as rosiglitazone and pioglitazone) and metformin), cholesterol lowering agents (such as atorvastatin, pravastatin, lovastatin, simvastatin, clofibrate and rosuvastatin), and alpha-2-delta ligands (such as gabapentin, pregabalin, [(1R,5R,6S)-6-(aminomethyl)bicyclo[3.2.0]hept-6-yl]acetic acid, 3-(1-aminomethyl-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one, C-[1-(1H-tetrazol-5-ylmethyl)-cycloheptyl]-methylamine, (3S,4S)-(1-aminomethyl-3,4-dimethyl-cyclopentyl)-acetic acid, (1 α ,3 α ,5 α)-(3-amino-methyl-bicyclo[3.2.0]hept-3-yl)-acetic acid, (3S,5R)-3-aminomethyl-5-methyl-octanoic acid, (3S,5R)-3-amino-5-methyl-heptanoic acid, (3S,5R)-3-amino-5-methyl-nonanoic acid and (3S,5R)-3-amino-5-methyl-octanoic acid), for the treatment of a disease or condition is selected from hypertension (including essential hypertension, pulmonary hypertension, secondary hypertension, isolated systolic hypertension, hypertension associated with diabetes, hypertension associated with atherosclerosis, and renovascular hypertension), congestive heart failure, angina (including stable, unstable and variant (Prinzmetal) angina), stroke, coronary artery disease, congestive heart failure, conditions of reduced blood vessel patency (such as post-percutaneous coronary angioplasty), peripheral vascular disease, atherosclerosis, nitrate-induced tolerance, nitrate tolerance, diabetes, impaired glucose tolerance, metabolic syndrome, obesity, sexual dysfunction (including male erectile disorder, impotence, female sexual arousal disorder, clitoral dysfunction, female hypoactive sexual desire disorder, female sexual pain disorder, female sexual orgasmic dysfunction and sexual dysfunction due to spinal cord injury), premature labour, pre-eclampsia, dysmenorrhea, polycystic ovary syndrome, benign prostatic hyperplasia, bladder outlet obstruction, incontinence, chronic obstructive pulmonary disease, acute respiratory failure, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, gut motility disorders (including irritable bowel syndrome), Kawasaki's syndrome, multiple sclerosis, Alzheimer's disease, psoriasis, skin necrosis, scarring, fibrosis, pain (particularly neuropathic pain), cancer, metastasis, baldness, nutcracker oesophagus, anal fissure and haemorrhoids.

74. A compound of formula (II^A)

-141-


(II^A)

wherein R¹, R², R³, R⁴, R⁶ and Y are as defined in claim 1.

75. A compound according to claim 74 wherein R⁶ is attached at N¹.

76. A compound according to claim 74 or 75 wherein Y is -CH₂-.

77. A compound of formula (II^B)

(II^B)


wherein R¹, R², R³, R⁴ and R⁶ are as defined above and W is a covalent bond or a C₁-C₅ alkylene group.

78. A compound according to claim 77 wherein R⁶ is attached at N¹.

79. A compound according to claim 77 or 78 wherein W is a covalent bond.

80. A compound of formula (XVI)

-142-



(XVI)


wherein R^1 , R^2 , R^5 and R^6 are as defined above.

81. A compound according to claim 80 wherein R^6 is attached at N^1 .

Abstract

Novel Pharmaceuticals

This invention relates to compounds of formula (I)



2005-17
1048480

1.12.03

PCT/IB2005/000891

